A study on the epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis by Frey, Noel
   
 
A Study on the Epidemiology of Stevens-Johnson 
Syndrome and Toxic Epidermal Necrolysis 
 
 
Inauguraldissertation 
 
zur 
Erlangung der Würde eines Doktors der Philosophie 
vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät 
der Universität Basel 
 
 
 
 
von 
Noel Frey 
aus Erlinsbach (SO) 
 
 
Basel, 2018 
Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel 
edoc.unibas.ch 
   
 
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät  
auf Antrag von 
 
Prof. Dr. Christoph Meier 
Prof. Dr. Stephan Krähenbühl 
 
 
Basel, den 27. März 2018 
 
         Prof. Dr. Martin Spiess 
         Dekan 
 
 
 
 
 
 
 
 
   
Acknowledgements 
The work presented in this thesis was conducted between August 2014 and March 2018 
at the Basel Pharmacoepidemiology Unit at the Institute for Clinical Pharmacy and 
Epidemiology of the University of Basel. The support and assistance of the people 
mentioned in this chapter was of immeasurable value for the successful outcome of this 
project and fills me with immense gratitude. 
My special gratitude goes to my supervisor Dr. Julia Spöndlin, who has been a 
wonderful mentor and a great source of support throughout the past three and a half 
years. Aside from making this project financially possible, I want to thank you Julia for 
your support and trust, and for sharing your tremendous knowledge of and passion for 
epidemiologic research. It has been an incredible pleasure working with you and getting 
to know you.  
I would also like to express my special gratitude to Prof. Dr. Christoph Meier for his 
unlimited trust and patience, as well as for sharing his brilliant expertise of 
pharmacoepidemiology with me. Working under your supervision was everything I 
could hope for. 
Further thank goes to PD Dr. Michael Bodmer for his large interest in this thesis. Your 
vast contributions to my work and your profound clinical knowledge, combined with 
your capacity for enthusiasm have been of invaluable worth for this project. 
Many thanks also to PD Dr. Andreas Bircher for standing at my side with brilliant 
expertise in Stevens-Johnson syndrome and toxic epidermal necrolysis, as well as 
general clinical knowledge. I am infinitely grateful for your uninterrupted support and 
enthusiasm despite my many requests and questions. I am very much looking forward 
to working with you upon completion of this thesis. 
I also want to give many thanks to Prof. Susan Jick from the Boston Collaborative Drug 
Surveillance Program for co-authoring and proof-reading all manuscripts, and for kindly 
hosting me for three months in Lexington.  
   
I furthermore thank PD Dr. Stephan Rüegg for his willingness to help and his 
contributions to this research project. 
Furthermore I would like to thank all my dear colleagues from the Basel 
Pharmacoepidemiology Unit and Hospital Pharmacy, namely Pascal Egger (for his 
excellent IT-support, for providing the soundtrack to my PhD, and for letting me swim 
in his pool), Dr. Fabienne Biétry and Dr. Cornelia Schneider (for joyful coffee breaks 
and discussions), and Dr. Marlene Blöchliger, Dr. Claudia Becker, Nadja Stohler, Delia 
Bornard, Dr. Daphne Reinau, and Dr. Saskia Bruderer (for welcoming me into the group 
so dearly and for lending me a hand whenever needed), Dr. Patrick Imfeld (for being a 
great roommate in Boston and a great guy in general), Janine Jossi (for your 
contributions to my research during your master thesis), and Alexandra Müller, Rahel 
Schneider, Luis Velez, Stephan Gut, Sarah Charlier, Theresa Burkhard, and Angela 
Filippi (for being such great colleagues and friends).  
Finally, I would like to thank my family and friends for all their support during the past 
three and a half years. Thank you Fränzi, Beat, Annina, Etienne, Rosmarie, and Ernst 
for your unconditional love and support. Thank you Dave, Sandro, Tobi, Dani, Priska, 
Melanie, Mia, Philip, Lukas, Stefan, Christoph, Michael, Kade, Katrin, Leander, Julia, 
and Tobias for your friendship and for all the beautiful moments I got to share with you 
over the past years. A special thank goes to you Stefan for proofreading my thesis. 
Above all I would like to thank you Kerstin for your unconditional love and for sharing 
your life with me. You have been an unbelievable source of strength and support over 
the past years. And thank you particularly for practicing presentations with me over and 
over again. 
 
 
 
 
   
Table of Contents 
Summary .................................................................................................................................................. i 
Abbreviations .......................................................................................................................................... v 
1 Introduction .......................................................................................................................................... 3 
1.1 Pharmacoepidemiology ................................................................................................................. 3 
1.1.1 Rise of a new science ............................................................................................................. 3 
1.1.2 Observational research and particularities of pharmacoepidemiology ................................... 5 
1.1.3 Causality ................................................................................................................................. 8 
1.1.4 Study designs, bias, and confounding .................................................................................... 9 
1.1.5 Data sources in Pharmacoepidemiology............................................................................... 14 
1.2 Stevens-Johnson syndrome and toxic epidermal necrolysis ........................................................ 17 
1.2.1 History .................................................................................................................................. 17 
1.2.2 Epidemiology of SJS/TEN ................................................................................................... 18 
1.2.3 Clinical manifestation ........................................................................................................... 19 
1.2.4 Diagnosis .............................................................................................................................. 23 
1.2.5 Etiology ................................................................................................................................ 24 
1.2.6 Pathomechanism ................................................................................................................... 28 
1.2.7 Management ......................................................................................................................... 30 
2 Aims of the thesis ............................................................................................................................... 36 
3 Stevens-Johnson syndrome and toxic epidermal necrolysis project................................................... 40 
3.1 Validation of Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis Diagnoses in the 
Clinical Practice Research Datalink (Study 3.1) ............................................................................... 40 
3.1.1 Abstract ................................................................................................................................ 41 
3.1.2 Introduction .......................................................................................................................... 42 
3.1.3 Patients and Methods ............................................................................................................ 43 
3.1.4 Results .................................................................................................................................. 47 
3.1.5 Discussion ............................................................................................................................ 48 
3.2 The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK 
(Study 3.2) ......................................................................................................................................... 60 
3.2.1 Abstract ................................................................................................................................ 61 
3.2.2 Introduction .......................................................................................................................... 62 
3.2.3 Patients and Methods ............................................................................................................ 63 
3.2.4 Results .................................................................................................................................. 66 
3.2.5 Discussion ............................................................................................................................ 67 
3.3 The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of 
antiepileptic drugs (Study 3.3) .......................................................................................................... 76 
   
3.3.1 Abstract ................................................................................................................................ 77 
3.3.2 Introduction .......................................................................................................................... 78 
3.3.3 Patients and Methods ............................................................................................................ 79 
3.3.4 Results .................................................................................................................................. 81 
3.3.5 Discussion ............................................................................................................................ 83 
3.4 Antibiotic drug use and the risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis 
(Study 3.4) ......................................................................................................................................... 96 
3.4.1 Abstract ................................................................................................................................ 97 
3.4.2 Letter .................................................................................................................................... 98 
3.5 Stevens-Johnson syndrome and toxic epidermal necrolysis in association with commonly used 
drugs other than antiepileptics and antibiotics ................................................................................ 108 
3.5.1 Abstract .............................................................................................................................. 109 
3.5.2 Introduction ........................................................................................................................ 110 
3.5.3 Patients and Methods .......................................................................................................... 110 
3.5.4 Results ................................................................................................................................ 113 
3.5.5 Discussion .......................................................................................................................... 116 
4 Discussion and Outlook .................................................................................................................... 134 
4.1 Discussion ................................................................................................................................. 134 
4.1.1 Study 3.1 ............................................................................................................................. 137 
4.1.2 Study 3.2 ............................................................................................................................. 138 
4.1.3 Study 3.3 ............................................................................................................................. 139 
4.1.4 Study 3.4 ............................................................................................................................. 140 
4.1.5 Study 3.5 ............................................................................................................................. 141 
4.2 Limitations of this project ......................................................................................................... 144 
4.2.1 Case misclassification ........................................................................................................ 144 
4.2.2 Stevens-Johnson syndrome vs. toxic epidermal necrolysis ................................................ 145 
4.2.3 Missing information on drug exposures ............................................................................. 145 
4.2.4 ALDEN score ..................................................................................................................... 146 
4.2.5 Further limitations .............................................................................................................. 146 
4.3 Outlook ...................................................................................................................................... 148 
5 References ........................................................................................................................................ 152 
6 Index of tables .................................................................................................................................. 168 
 
Summary   
i 
 
Summary 
Pharmacoepidemiology is the science of the use and the effects of drugs in large human 
populations. Although originally confined to post-marketing drug surveillance of rare 
or long-latency adverse drug events, the science is gaining increased importance and is 
regularly applied to assess drug utilization patterns and cost-effectiveness, to 
characterize target populations of drugs in development, to evaluate undiscovered 
beneficial or detrimental drug effects, or to provide evidence of effectiveness when 
randomized controlled trials face ethical or practical barriers. 
Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare but life-
threatening mucocutaneous diseases that predominantly occur as adverse reactions to 
newly administered drugs. The current knowledge of SJS/TEN is sparse, mainly due to 
the rare nature of SJS/TEN and the long-time unclear classification of the disease. As a 
consequence many aspects of SJS/TEN remain unclear despite the severe impact of 
SJS/TEN on affected patients.  
The aim of this comprehensive SJS/TEN project presented within this thesis was to 
contribute to the general understanding of SJS/TEN, thereby focusing on the 
epidemiology and potential culprit drugs. The project comprises five individual 
observational studies using data from the Clinical Practice Research Datalink (CPRD). 
This United Kingdom (UK)-based database contains longitudinal primary-care records 
of millions of patients, representative of the UK population. Information is recorded by 
general practitioners and includes demographics, lifestyle factors, medical diagnoses, 
referrals to secondary care, laboratory and diagnostic results, and a complete history of 
drug prescriptions. 
In Study 3.1 we comprehensively validated incident SJS/TEN diagnoses recorded in the 
CPRD between 1995 and 2013. The aim of this study was to assess whether SJS/TEN 
can be studied using CPRD data, and to establish a large and valid SJS/TEN case 
population. Using diagnoses from secondary care as a gold standard, we managed to 
compose a case population consisting of 551 SJS/TEN patients with a positive predictive 
value of 90% in cooperation with two specialised clinicians. 
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In Study 3.2 we calculated an overall incidence rate in the UK of 5.76 SJS/TEN 
cases/1’000’000 person-years, whereby incidence rates were highest in patients aged 
<10 or ≥80 years. In a case-control analysis, we further found that patients of black, 
Asian, or mixed ethnicity were at increased risk of SJS/TEN when compared to 
Caucasians, and observed associations between SJS/TEN and pre-existing depression, 
lupus erythematosus, chronic kidney disease, recent pneumonia, and active cancer. 
In the Studies 3.3, 3.4, and 3.5, we conducted case-control analyses to assess 
associations between SJS/TEN and drugs which have previously been associated with 
SJS/TEN. We furthermore calculated cumulative incidences of SJS/TEN for each of 
these drugs to assess the absolute risk of SJS/TEN among drug users.  
Study 3.3 confirms associations between SJS/TEN and the aromatic antiepileptics 
carbamazepine, phenytoin, and lamotrigine, with absolute risks of 20-46 SJS/TEN 
cases/100’000 new users. Conversely to previous reports we did not find any exposed 
cases for valproate, gabapentin and pregabalin despite high number of new users 
(>40’000).  
While previous case-control studies reported a strong association between SJS/TEN and 
cotrimoxazole (sulfamethoxazole+trimethoprim), Study 3.4 was the first to show an 
association between SJS/TEN and trimethoprim as a single agent with an absolute risk 
of 1 SJS/TEN case/100’000 users. Only few patients were exposed to sulfonamide 
antibiotics in the CPRD which is why we were not able to study associations for 
sulfamethoxazole and other anti-infective sulfonamides. This study further corroborates 
previously reported associations between SJS/TEN and use of penicillins, quinolones, 
cephalosporins, and macrolides (0.3-1.0 SJS/TEN cases/100’000 users).  
Study 3.5 confirms the previously reported association between SJS/TEN and 
allopurinol with an absolute risk of 6 SJS/TEN cases/100’000 new users. Further drugs 
identified as possible triggers of SJS/TEN were coxibs (1.9 cases/100’000 new users), 
sulfasalazine (4.3 cases/100’000 new users), mesalamine (3.8 cases/100’000 new users), 
mirtazapine (1.6 cases/100’000 new users), and fluoxetine (0.2 cases/100’000 new 
users). We further observed an association between SJS/TEN and proton pump 
inhibitors (0.5-1.3 cases/100’000 new users). However, proton pumps are often used in 
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combination with other drugs (e.g nonsteroidal anti-inflammatory drugs) which could 
potentially confound such an association. Only little evidence previously suggested 
associations between SJS/TEN and these drugs. For various other drugs which have 
been suggested as culprit drugs of SJS/TEN in case reports (oxicam analgesics, 
benzodiazepines, citalopram, sertraline, paroxetine, venlafaxine, and 
phosphodiesterase-5 inhibitors), we did not find any exposed SJS/TEN cases despite a 
high number of new users (>100’000) in the CPRD. Our results suggest that these drugs 
appear to be at least relatively safe in terms of SJS/TEN. 
In summary, the population-based observational studies presented in this thesis 
contribute to the understanding of the epidemiology of SJS/TEN yielding the first 
calculated incidence rates of SJS/TEN in the UK and information on patients at higher 
risk of SJS/TEN. They further include comprehensive analyses of culprit drugs of 
SJS/TEN, which provide important evidence for the successful treatment of SJS/TEN 
patients, as early discontinuation of the culprit drug is crucial and often decisive for the 
outcome of SJS/TEN. 
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1 Introduction 
1.1 Pharmacoepidemiology 
1.1.1 Rise of a new science 
Pharmacoepidemiology is the study of the use of and the effects of drugs in large 
numbers of people. It is a combination of clinical pharmacology, the study of the effects 
of drugs in humans, and epidemiology, the study of the distribution and determinants of 
diseases in populations. Pharmacoepidemiology emerged in the mid 1960’s when the 
fast growth of the pharmaceutical armoury, along with increasing possibilities for 
combating diseases and improving the overall health of our population, has brought 
about various medical risks in the form of adverse drug reactions (ADRs). In 1961 a 
public controversy over ADRs was sparked off after ‘in-utero’ exposure with 
thalidomide, a mild hypnotic marketed despite no obvious advantages over other similar 
drugs, was discovered to cause phocomelia in new-borns.1 The growing impact and 
awareness of such ADRs, the rising number of product liability suits against drug 
manufacturers, and the realization that many ADRs are unlikely to be detected in pre-
marketing randomized controlled trials (RCT; Table 1.1-1) called for new methods of 
post-marketing drug surveillance in large populations.2–4  
Table 1.1-1: Adverse drug reactions that are unlikely to be detected in randomized controlled trials. 
Undetected 
ADRs in RCTs 
Advantages of pharmacoepidemiology 
over RCTs 
Example 
   
Rare ADRs Due to restricted patient numbers of RCTs 
(500-3000 patients), rare ADRs often 
remain undetected. 
With an incidence of 20 SJS cases/100’000 
patients exposed to carbamazepine, SJS 
(adverse reaction to carbamazepine) likely 
remains undetected during RCTs.5 
   
Long-latency 
ADRs 
ADRs with a long latency-period only 
manifest after a prolonged period of drug 
exposure and are therefore unlikely to 
occur during RCTs. 
Sclerosing peritonitis caused by practolol 
occurred on average 4 years after initiation 
of drug therapy.6 
   
ADRs that 
mainly occur in 
specific patient 
groups 
Although drug effects can vary with sex, 
ethnicity, age, and genetic differences, 
RCTs are often conducted in homogenous 
patient groups often excluding children, 
older patients, or pregnant women. 
The incidence of major haemorrhage after 
exposure to warfarin is higher in patients 
aged ≥80 years compared to younger 
patients.7 However, elderly patients are often 
excluded from premarketing studies.8  
   
ARD=Adverse drug reaction; RCT=Randomized controlled trial; SJS=Stevens-Johnson syndrome. 
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The first steps towards a better understanding and prevention of ADRs were taken in 
1952, when the first monograph of ADRs called ‘Side Effects of Drugs’ was published 
by L. Meyler,9 and the first official registry of ADRs was established to collect cases of 
drug-induced blood dyscrasia (a morbid general state resulting from the presence of 
abnormal material in the blood).10 In 1960, the Food and Drug Administration (FDA) 
began to collect reports of ADRs and sponsored new hospital-based drug monitoring 
programs.2 Although spontaneous reports of ADRs have led to market withdrawal of 
several drugs (e.g. flosequinan due to increased mortality in 1993) the spontaneous 
reporting system has a number of shortcomings that are listed in Table 1.1-2.11,12 
Table 1.1-2: Shortcomings of spontaneous ADR reporting systems. 
Problem Implication 
  
Under-reporting Reporting varies with the reporter’s skill and experience to detect ADRs, as 
well as with the character of ADRs (see bias), and some ADRs might therefore 
remain unreported. 
  
Bias Trivial ADRs (e.g. mild headaches), ADRs perceived to already be well-
known, and ADRs with a long latency period are less likely to be reported, and 
might therefore be overlooked. 
  
Unknown 
population-at-risk 
The risk associated with a drug cannot be quantified accurately because 
information on the underlying population that is exposed to the drug is lacking. 
  
No control group Patients who are exposed to a drug are often not comparable to patients who 
were not exposed to the same drug. 
  
ADR=Adverse drug reaction. 
These limitations prompted the demand for a more systematic and effective approach 
for post-marketing drug surveillance in large human populations, and thus led to the 
emergence of the science of pharmacoepidemiology in the mid 1960’s. In the following 
years, the first pharmacoepidemiologic studies were conducted by the Boston 
Collaborative Drug Surveillance Program (BCDSP) and the Johns Hopkins Hospital 
after they started monitoring in-hospital drug use.2 
The significance of pharmacoepidemiology for the assessment of ADRs that are difficult 
to detect in pre-marketing RCTs are well recognized today. But besides identifying 
adverse or unexpected effects of drugs, pharmacoepidemiology has further proven to be 
valuable for assessing benefit-to-risk relationships and cost-effectiveness of drug 
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therapies, which are issues of growing importance within the health-care system due to 
the increasing costs of medications. As a consequence the relatively young discipline 
has become an integral part of the drug development process over the past decades and 
is frequently used in academia, by health care providers, drug regulatory agencies, and 
the pharmaceutical industry to study patterns of drug use, drug safety, effectiveness of 
drugs, and economic evaluations of drug use.2,3  
 
1.1.2 Observational research and particularities of pharmacoepidemiology 
Clinical observational research is an area of non-experimental research in which a 
researcher observes usual clinical practice. Contrary to experimental clinical research 
(i.e. randomized or non-randomized clinical trials), the independent variable (e.g. 
patient’s exposure status) is not actively assigned to in observational studies. 
Observational research can further be divided into two categories; descriptive studies 
(i.e. case reports and case series) and analytical studies (i.e. case-control studies, cohort 
studies, and cross-sectional studies; Figure 1.1-1). The main difference between the two 
categories is that while the latter only describes clinical observations in patients affected 
with an exposure or outcome of interest, analytical studies feature a control group 
allowing quantification of associations between an exposure and an outcome. 
Pharmacoepidemiology is comprised of analytical observational studies.2 
 
Figure 1.1-1: Classification of clinical research study designs. 
Introduction  Pharmacoepidemiology
  
6 
 
Evidence-based medicine categorizes different types of clinical evidence and rates or 
grades them according to the strength of their absence of the various biases that beset 
medical research. In terms of evidence-based medicine, the classification presented in 
Table 1.1-3 has been suggested for clinical research studies regarding the quality of 
evidence (irrespective of internal validity).13 
Table 1.1-3: Classification of clinical evidence according to the US Preventive Services Task Force.14 
Grade of quality Source of evidence 
  
Level I 
Evidence obtained from at least one properly designed randomized controlled 
trial. 
Level II-1 Evidence obtained from well-designed controlled trials without randomization. 
Level II-2 
Evidence obtained from well-designed cohort studies or case-control studies, 
preferably from more than one centre or research group. 
Level II-3 
Evidence obtained from multiple time series designs with or without the 
intervention. Dramatic results in uncontrolled trials might also be regarded as 
this type of evidence. 
Level III 
Opinions of respected authorities, based on clinical experience, descriptive 
studies, or reports of expert committees. 
  
 
The role of observational research in medicine 
The existence of bias and confounding in observational studies due to the lack of 
randomization, previous examples of poorly designed observational studies (partly due 
to the lack of methodologic possibilities in the past), as well as the fact that causal 
inference cannot be drawn from observational studies due to their empirical nature have 
long undermined the significance of observational studies in medical research.2,13,15 
However, more recently studies have demonstrated that results from observational 
studies were congruent with results from RCTs if the study designs were aligned and 
data analysis was performed similarly.16,17  
With growing data availability and advancements in the methodology, observational 
studies have become an invaluable tool in medical research and the method of choice 
whenever RCTs are not applicable due to practical or ethical restraints. Under the 
following conditions observational studies are of particular significance. Firstly, under 
circumstances where severe and potentially fatal outcomes are to be expected, 
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deliberately bringing patients into these circumstances is unethical (e.g.: exposing 
patients with a genetic predisposition for carbamazepine-induced SJS/TEN to 
carbamazepine; testing the effects of benzodiazepines on the ability to drive a car). 
Second, results from observational studies are more representative for the general 
population due to the restrictive eligibility criteria in RCTs (Table 1.1-1). Third, 
studying outcomes with a long latency-period or rare outcomes is impractical in RCTs 
(Table 1.1-1). Fourth, besides descriptive studies (e.g. case reports) observational 
studies are often the first to generate or assess hypotheses for previously unknown drug 
effects (e.g. the discovery that aspirin prevents myocardial infarction), which are only 
later analysed in RCTs. Finally, observational studies can be conducted in a more cost 
and time efficient manner.2,3,18 
 
Particularities of drugs as an exposure variable 
In epidemiology, an exposure variable can roughly be defined as a factor that may be 
associated with an outcome of interest. Researchers often rely on readily available 
(existing) data elements to identify a patient’s exposure status, and the definition of the 
exposure variable is a key factor in observational studies. In pharmacoepidemiologic 
studies, the definition and assessment of exposure status requires unique methodologic 
considerations, as exposures to drugs, which depict the exposures of interest in 
pharmacoepidemiology, imply specific challenges.18 First, comparisons between 
patients exposed and patients unexposed to a certain drug are often prone to confounding 
by indication and selection bias due to the underlying indication of the respective drug 
that is only present in the exposed patients or for contraindication for the respective drug 
that is only present in unexposed patients. Second, a patient’s drug use and therefore 
exposure status may change over time in terms of changes in dosages, intermittent drug 
use, non-compliance, or limited duration of drug use. Third, knowledge of the 
pharmacokinetic and pharmacodynamic properties of drugs as well as the relationship 
between a potential culprit drug and the outcome of interest (e.g. dose-response 
relationship, relevant time period between exposure and outcome) have to be taken into 
consideration when defining drug exposure. Finally, poor drug compliance (i.e. patients 
do not follow medical instructions) might lead to differences between the assessed and 
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actual exposure status. To assure the internal validity of a pharmacoepidemiologic study 
(i.e. avoiding or minimising confounding and biases), the features listed above should 
be addressed with meticulous attention during the collection of data and the choice of a 
study design and methodology (see Chapter 1.1.4).4,18 
 
1.1.3 Causality 
Pharmacoepidemiology is an empirical science which mainly aims to identify the causes 
of certain outcomes in association with drug exposure. While the study designs and 
statistical methods used in pharmacoepidemiology allow determining the existence of 
associations between exposures and outcomes as well as measuring their strength, 
determining whether these associations are a consequence of a causal relationship is 
more complex. Besides complex study designs and statistical analyses, checklists with 
criteria that might infer causality, such as the ‘Hill criteria’ (Table 1.1-4), have been 
proposed as useful tools for assessing causality in epidemiologic research.19 Checklists 
have furthermore been designed to assess causality between an exposure and a specific 
outcome only, such as the algorithm of drug causality in epidermal necrolysis (ALDEN), 
which is a clinical score used to assess causality between drug exposure and SJS/TEN.20 
However, due to its empirical nature pharmacoepidemiologic research will always fail 
to deliver a clear verdict for a proposed causal association irrespective of 
methodological approaches. Despite these limitations, observations from 
pharmacoepidemiologic research are nevertheless of great importance, if the available 
tools used to evaluate causal inference are used as effectively as possible, and resulting 
observations are analysed and interpreted with adequate critical scrutiny.15 
 
 
 
 
Table 1.1-4: ‘Hill criteria’ on causal inference in medical research and their limitations. 
Criterion Reasoning Problem 
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Strength of association A strong association is more likely to 
have a causal component than a modest 
association. 
 Strength can depend on 
confounders/other causes 
 Absence of a strong association does not 
rule out a causal effect 
   
Consistency Associations that are observed 
repeatedly in different populations, 
places etc. are more likely to be causal. 
Shared flaws in different studies would 
tend to replicate the same wrong 
conclusion. 
   
Specificity An association observed specifically 
for a particular outcome or in a 
particular population is more likely to 
be causal. 
A factor might be the cause for several 
outcomes. 
   
Temporal relationship The outcome has to occur after the 
alleged cause. 
Temporality might be difficult to establish 
(e.g.: diseases that develop slowly). 
   
Biological gradient Evidence of a dose-response 
relationship indicates causality. 
 Prone to confounding 
 Dose-response thresholds exist for some 
associations 
   
Plausibility A plausible mechanism underlying an 
association between a proposed cause 
and effect increases the likelihood of 
causality. 
Novel observations might be wrongfully 
dismissed. 
   
Coherence A causal conclusion should not 
fundamentally contradict present 
substantive knowledge. 
See consistency and plausibility. 
   
Experiment Causation is more likely if evidence is 
based on randomised experiments. 
Not always available and applicable. 
   
Analogy If an association for analogous 
exposures and outcomes has already 
been shown, causality is more likely. 
False analogies may be considered and 
mislead. 
   
 
1.1.4 Study designs, bias, and confounding 
Aside from estimating epidemiologic measures such as incidence rates (IRs), cumulative 
incidences, or prevalences (i.e. absolute risk measures), methodologically more 
elaborate pharmacoepidemiologic studies aim to compare such measures with the aim 
of predicting certain events, learning about the causes of these events, or evaluating the 
impact of these events on a population by calculating relative risk measures. The 
continuous advancements in data availability, as well as statistical methods and software 
have increased the methodological possibilities in pharmacoepidemiology. Some of the 
most important study designs and methodologic aspects are described below. 
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Case-control studies 
In a case-control study patients are selected on the basis of whether they do (cases) or 
do not (controls) have a particular outcome (e.g. disease) of interest. The proportion of 
cases and controls which have experienced a certain exposure before this particular 
outcome of interest are then compared. This approach allows the calculation of an odds 
ratio (OR), which is a relative measure of effect size used to describe the strength of an 
association between two binary variables. An OR greater than 1 for example indicates 
that having an exposure of interest is associated with having an outcome of interest. 
Case-control studies are especially effective for the study of diseases with a long latency 
period, rare diseases, and multiple exposures of interest. However, because both the 
exposure and outcome have already occurred at the time the patients enter into a case-
control study, this design is particularly prone to bias and confounding. Two major 
methodological measures to prevent such bias or confounding are ensuring 
comparability between cases and controls (i.e. despite not having the outcome of interest 
they should represent the population at risk of becoming cases as closely as possible), 
and ensuring that exposure information is reported/recorded similarly in cases and 
controls.21  
 
Cohort studies 
In a cohort study two groups of patients are defined on the basis of whether or not they 
are exposed to a particular factor of interest (e.g. antidiabetic drug treatment). Both 
groups are then followed over a period of time to assess and compare the occurrence or 
incidence of an outcome of interest in the two groups. All potential subjects must be free 
from the outcome of interest at the time that the exposure status is defined. Relative risk 
estimates in cohort studies are risk ratios, incidence rate ratios, and hazard ratios. Based 
on the point of time of data collection, cohort studies can be separated in prospective or 
retrospective studies. A prospective cohort study is initiated before the outcome of 
interest occurred and participants are followed into the future to assess the incidence of 
the outcomes of interest. In a retrospective cohort study all relevant events (i.e. exposure, 
outcomes of interest) have already occurred at the time the study is initiated. Advantages 
of cohort studies are that they allow analysing rare exposures as well as multiple effects 
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of a single exposure. Major sources of bias which have to be considered in cohort studies 
are differential losses to follow-up between exposed and unexposed subjects or potential 
changes in exposure status in subjects over time (e.g. a previously unexposed patient 
starts therapy with a drug under study during the study period).21 
 
Nested case-control studies 
Nested case-control studies are case-control studies embedded within a cohort. 
Analogously to a cohort study, a cohort of study participants is assembled and followed 
forward in time to assess the occurrence of an outcome of interest. However, the analysis 
of data is conducted as a case-control study, whereby subjects from the initial cohort 
who developed an outcome of interest are defined as cases and a number of subjects 
from the initial cohort who did not developed an outcome of interest are defined as 
controls (usually 4-10 controls for each case). If risk set sampling is applied, a future 
case is eligible to be a control for a prior case and that subject might be selected as a 
control more than once to prevent the occurrence of bias. The method of analysis is 
identical to that of a conventional matched case-control study. Nested case-control 
studies are often used when the exposure of interest is difficult or expensive to obtain 
and when the outcome is rare. Because data previously collected from a large cohort 
study can be used, the time and cost of initiating a new case-control study is avoided. 
Nested-case control studies furthermore allow calculating IRs of the outcome of interest 
and controlling for potential bias from time-dependent changes of risks for an event or 
of drug exposure through matching on the date of the outcome.21 
 
 
 
Bias 
Biases are systematic errors in epidemiologic studies that result in an incorrect estimate 
of the true association between an exposure and an outcome of interest.22 Some 
examples of common types of biases in epidemiology are listed below. 
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Selection bias 
Selection bias occurs when a systematic difference is present between subjects in the 
case and control or exposed and unexposed population, respectively. Common examples 
for selection bias are the ‘healthy worker bias’ which may occur when a subgroup of 
study participants are recruited in a specific occupational setting, or the ‘health care 
access bias’ which occurs when a subgroup of patients with access to health care is 
compared to patients without access to health care. Besides cautious selection of the 
study population, appropriate matching in the study population is an important measure 
to prevent selection bias.22 
Information bias 
Information bias arises from systematic errors that occur during the collection of data. 
Misclassification, where study subjects are assigned to the wrong category, is a common 
source of information bias. Misclassification is divided into differential 
misclassification (i.e. misclassification differs in the groups being compared), and non-
differential misclassification (i.e. misclassification is similar across the groups being 
compared). Differential misclassification can result in both an exaggeration and 
underestimation of an effect, whereas non-differential misclassification of a 
dichotomous exposure always biases an effect towards the null. Common causes of 
misclassification are recall bias (i.e. differences in the accuracy or completeness of 
retrieved recollections of past events), detection bias (i.e. an event/variable is more 
likely to be observed for a particular set of study subjects), observer bias (i.e. researcher 
subconsciously influences the experiment), or reporting bias (i.e. observations of a 
certain kind are more likely to be reported).22  
Protopathic bias 
Protopathic bias is another type of information bias that is relevant in 
pharmacoepidemiology. It occurs when a drug is inadvertently administered for an early 
symptom of an outcome that has yet not been detected or recorded. When the outcome 
is later detected or recorded a causal association between the drug and the outcome may 
be incorrectly inferred.23  
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Confounding 
Confounding occurs when a third variable influences both the dependent variable 
(outcome) and independent variable (exposure), without being an intermediate step in 
the causal pathway and without being a collider (i.e. a consequence of the exposure and 
the outcome; Figure 1.1-2).24 Confounding can substantially distort risk estimates, and 
is a major issue in analytical observational studies. In observational studies, confounding 
can be controlled or prevented at the design stage of a study by matching or restriction 
of the study population. At the stage of data analysis confounding can be controlled by 
conditioning on potential confounders, given that sufficient and accurate information on 
potential confounders has been measured or assembled.25  
 
Figure 1.1-2: Schematic depiction of confounding. 
Confounding by indication 
A special type of confounding, which frequently has to be taken into consideration in 
pharmacoepidemiologic studies, is ‘confounding by indication’. This type of 
confounding bias arises if the indication for the prescription of a drug of interest is 
related to the outcome of interest. Confounding by indication could for example underlie 
an observed association between antidepressant drug use and infertility, because 
depression itself (and therefore the indication for antidepressant drugs) is associated 
with infertility and is therefore a confounder. Confounding by indication may lead to 
false assumptions regarding the effectiveness of a drug under study, if exposed patients 
reveal a higher/lower incidence of the outcome of interest which should be prevented 
by the drug under study than unexposed patients. In other cases, a direct association 
between the drug under study and an outcome of interest might wrongfully be assumed. 
Introduction  Pharmacoepidemiology
  
14 
 
Confounding by indication is often difficult to control, and is best prevented by 
implementing appropriate eligibility restrictions at the design stage of a study.25
 
Propensity scores in pharmacoepidemiology 
In observational studies, systematic differences in covariate distributions between 
treated and untreated subjects remain a major challenge due to the lack of 
randomization. This may distort the estimates of measured treatment effects unless 
adequate statistical adjustments are made. Propensity scores are a meanwhile established 
method used to correct for such confounding by balancing the probability to receive a 
certain drug between patients in different treatment groups based on prognostic patient 
characteristics. Using logistic regression a single variable representing the likelihood of 
each patient to receive a treatment is calculated based on several patient characteristics. 
Study subjects are then matched, stratified, or weighted on their propensity scores, or 
scores can be integrated into a multivariate regression analysis. Propensity scores are 
particularly useful for studies conducted in smaller study populations that do not allow 
conventional matching or adjusting. However, propensity scores cannot rule out 
unmeasured confounding and further potential limitations arise from errors made during 
the selection of propensity score variables.26  
 
1.1.5 Data sources in Pharmacoepidemiology 
Before the 1980’s, the data used for pharmacoepidemiologic studies was mainly 
hospital-based. While the validity of diagnoses is easily assessable, most information on 
exposures is retrieved by patient interviews and therefore specific information is only 
available if included in the questionnaire. Furthermore, this approach is prone to recall 
bias and only allows recruiting a limited number of patients for a study.27 Other sources 
of data were multipurpose cohorts in which a defined population is followed over time. 
A famous example is the US Nurses’ Health Study, in which questionnaires inquiring 
about different exposures, life-style factors, and chronic conditions are periodically sent 
to female nurses across the US. With the emergence of large health-care databases over 
the past decades the possibilities of conducting pharmacoepidemiologic observational 
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studies have substantially increased. However, in order to conduct high-quality 
pharmacoepidemiologic studies, researchers have to consider the strengths and 
weaknesses of such databases for observational research (Table 1.1-5).27 
Table 1.1-5: Strengths and weaknesses of health-care databases for pharmacoepidemiologic studies. 
Strengths of health-care databases for 
pharmacoepidemiologic studies 
Weaknesses of health-care databases for 
pharmacoepidemiologic studies 
  
 Potential for large sample sizes 
 Relatively inexpensive to use (by-product of 
existing administrative systems) 
 Data can be representative of a population 
 Include a broad range of medical 
information 
 Missing information can potentially be 
collected via linkages to other data sources 
 No recall or interviewer bias 
 Data is collected longitudinally 
 Uncertainty regarding the validity of 
recorded information 
 Databases do not included all health-related 
information (e.g. inpatient information in 
primary-care databases; diagnoses in some 
claims databases) 
 Instability of the population (disenrollment 
of patients from the database) 
 Mainly include information about illnesses 
severe enough to come to medical attention 
 A database population may not 
representative for a general population 
  
 
Claims or administrative databases  
Claims data arises from a patient’s use of the health-care system and consists of claims 
codes for medical billing events such as dispenses of drugs, medical procedures, or 
hospitalizations. Claims of medical expenses are subject to various controls and claims 
data is generally of very high quality. However, diagnoses are recorded with less 
reliability, because the ICD-9-CM codes used for diagnoses are not always of high 
accuracy and because reimbursement does not usually depend on the actual diagnosis.27  
 
 
Medical record databases 
Over the past decades, medical record databases started to emerge when informatics 
gained currency in the health care system and electronic patient records replaced paper 
patient records. Examples for such databases are the UK-based Clinical Practice 
Research Datalink (CPRD),28 and ‘The Health Improvement Network’ (THIN), which 
primarily include primary-care outpatient data. Medical record databases have 
advantages over claims databases mainly regarding the validity of recorded diagnoses. 
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However, medical records often lack information about a patient’s medical history 
depending on the source of the data (inpatient or outpatient databases).27 
 
Clinical Practice Research Datalink 
The CPRD is a UK-based primary care database which was established in 1987 as the 
small Value Added Medical Products (VAMP), then became the GPRD in 1993 and the 
CPRD in 2012. Participating general practitioners (GPs), who act as the first point of 
contact for any non-emergency health-related issues in the UK (i.e. GPs are the 
gatekeepers of the UK health-care system), were requested to record health-related 
information about their patients in anonymized electronic patient files. Secondary care 
teams also forward information to GPs about their patients, including key diagnoses. A 
subset of secondary practices has further consented to participate in the CPRD linkage 
scheme including for example Hospital Episode Statistics (HES data) or the Office for 
National Statistics (mortality data including causes of death). With 13 million 
participating patients, the CPRD is one of the largest databases of longitudinal medical 
records from primary care in the world, and patients are broadly representative of the 
UK general population in terms of age, sex and ethnicity. Data are collected on 
demographic information, drug prescriptions, symptoms, diagnoses, preventive care, 
tests, vaccinations, specialist and hospital referrals, and details relating to death. Until 
2015, additional information for certain events was furthermore accessible in the form 
of free texts (GP notes).28 The data in the CPRD have been repeatedly demonstrated to 
be of high quality, and the database has been used for numerous epidemiological studies 
published in peer-reviewed journals.29 Studies require approval by the Independent 
Scientific Advisory Committee (ISAC) for Medicines and Healthcare products 
Regulatory Agency (MHRA) database research.
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1.2 Stevens-Johnson syndrome and toxic epidermal necrolysis 
1.2.1 History 
The first report of SJS dates back to the year 1922, when the American paediatricians 
Albert Mason Stevens and Frank Chambliss Johnson described two patients with 
‘unusual conditions, entirely unlike anything previously observed’.30 The condition, 
which was later named after the authors of this first case report, was therein 
characterized as ‘generalized eruption with continued fever, inflamed buccal mucosa 
and severe purulent conjunctivitis’ (Figure 1.2-1).  
 
 
Figure 1.2-1: Extract from the first case report of SJS published in 1922.30 
 
The term ‘toxic epidermal necrolysis (TEN)’ first appeared in 1956, when the Scottish 
dermatologist Alan Lyell described a severe skin disease which was later also referred 
to as Lyell’s syndrome.31 In his report, Lyell reported four cases of acute onset of a skin 
eruption with widespread areas of epidermal detachment, which he believed to be a 
consequence of a systemic upset caused by a toxin or an infection. As more patients 
with TEN were reported in the following years, it became clear that TEN is a 
consequence of exposure to a variety of drugs, of which sulphonamides and antiepileptic 
drugs (AEDs) were the most frequently alleged triggers. 
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Today, SJS and TEN are considered to be distinct disease entities within the same 
mucocutaneous disease spectrum, differing only by the severity of the disease.32 
Affected patients are classified into three groups according to the proportion of body 
surface area (BSA) affected by skin detachment: <10% defined as SJS, 10–30% defined 
as SJS/TEN overlap, and >30% defined as TEN.33 However, before this classification 
was reached there has long been discordance regarding the terminology and 
classification of SJS/TEN and erythema multiforme majus (EMM), another cutaneous 
reaction with mucosal involvement. Although different in clinical pattern, prognosis, 
and etiology, EMM was widely considered to be part of the SJS/TEN spectrum, until a 
consensus definition suggesting the differentiation of EMM and SJS/TEN was reached 
in the mid 1990’s.33,34 This consensus classification has since been used in numerous 
observational studies. 
 
1.2.2 Epidemiology of SJS/TEN 
The epidemiology of SJS/TEN is under-investigated, primarily because many health-
care databases, which are an important tool in epidemiologic research, have been shown 
to be ineligible for the study of SJS/TEN for different reasons. First, most databases are 
too small to allow the assembly of a sufficient number of SJS/TEN patients due to the 
rare nature of the disease. Second, studies have reported a rather low validity for 
SJS/TEN diagnoses in some databases, which they attributed to the complexity of 
correctly diagnosing SJS/TEN as well as to the long unclear differentiation from 
EMM.35–37 Finally, up until 2008, the ICD-9 coding system which is used in many 
databases did not differentiate between erythema multiforme (EM) and SJS/TEN.38  
Due to this absence of previous database studies, existing evidence on SJS/TEN is 
mainly based on hospital-based studies, which lack information on the underlying 
population at risk since only patients who develop the disease are captures. 
Consequently reported IRs of SJS/TEN vary greatly and range from 1.0 to 12.7 cases 
per million person-years (py).39–42 Schöpf et al. conducted one of the earliest 
epidemiologic studies on SJS/TEN in West Germany between 1981 and 1985, and 
reported an annual risk of 1.1 cases and 0.93 cases per million patients for SJS and TEN, 
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respectively. The 574 SJS/TEN patients included in the study were recruited by sending 
questionnaires to all medical centres that were considered likely to treat severe skin 
reactions.39 A more recent Europe-based study conducted in a Spanish primary care 
database between 2001 and 2011 reported an IR of 3.21 SJS/TEN cases/million py.40 
One large cross-sectional study including 3657 SJS/TEN patients investigated the 
epidemiology of SJS/TEN in the United States (US) between 2009 and 2012, using data 
from the Nationwide Inpatient Sample, and observed an overall IR of 12.7 SJS/TEN 
cases/million py (adults only), which is higher than most previously reported IRs for 
SJS/TEN.42 Another large observational study (n=1167 SJS/TEN patients) based on 
insurance claims data from Korea with a coverage of 97% of the population calculated 
an IR of 5.9 SJS/TEN cases/million py between 2010 and 2013.41 
 
1.2.3 Clinical manifestation 
Acute phase 
Initial symptoms of SJS/TEN usually present within 4 weeks after drug intake and 
include unspecific, flu-like symptoms such as fever, stinging eyes, rhinitis, and 
dysphagia. Mucocutaneous and cutaneous lesions typically develop 1-3 days after the 
onset of these prodromal symptoms. Lesions of mucous membranes occur in more than 
80% of cases, predominantly involving the buccal, genital and/or ocular mucosa (by 
definition at least 2 sites are involved), and are characterized by erythema, hemorrhagic 
erosions, and painful bullae.32 Ocular involvement is frequent (50-90% of SJS/TEN 
cases), and mainly affects the conjunctivas. Symptoms include acute conjunctivitis as 
well as conjunctival and corneal ulceration.43 
Cutaneous lesions predominantly affect the trunk and face, and involve erythematous 
and purpuric macules, which manifest as atypical targets. The macules have a tendency 
to coalescence and evolve to the formation of tense bullae. In a second phase, large areas 
of epidermal detachment develop. In the absence of spontaneous epidermal detachment, 
checking for a positive Nikolsky sign can help asserting a SJS/TEN diagnosis.32 A 
positive Nikolsky sign is present if tangential pressure induces epidermal detachment, 
but is not specific for SJS/TEN, as it can also be present in some other bullous skin 
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diseases.32,44 The BSA of necrotic and detachable skin is a major prognostic factor for 
the outcome of SJS/TEN.45  
In some cases of SJS/TEN the respiratory and gastrointestinal tracts are also affected. 
Pulmonary dysfunctions affect approximately 40% of SJS/TEN patients and include 
breathing difficulties, cough, pulmonary oedema, and bronchial obstruction,46 whereas 
gastrointestinal involvement includes diarrhoea, bloating of the abdomen, and rarely 
bowel perforation.47 Renal disturbances (e.g. acute renal failure, acute tubular necrosis, 
haematuria) have also been observed in the acute stage of SJS/TEN.48 
 
Long term sequelae 
Cutaneous sequelae 
Cutaneous sequelae are the most commonly observed long-term complications of 
SJS/TEN. Case series have suggested that 44-81% of SJS/TEN survivors suffer from 
dermatological complications after SJS/TEN,49–51 and reported a signiﬁcantly decreased 
Dermatology Life Quality Index in affected patients.52 The most common 
dermatological complications are hyper-/hypopigmentation, hypertrophic and keloid 
scars, eruptive naevi, chronic pruritus, hyperhidrosis, photosensitivity, and heterotopic 
ossiﬁcation.49,50,52–54 Furthermore, nail changes, such as onychomadesis (shedding of the 
nails) or permanent nail loss, have been observed to occur in approximately 50% of 
SJS/TEN survivors.50,52,53 
Ocular sequelae 
Chronic ocular complications affect 20–75% of SJS/TEN survivors and are associated 
with a substantially lower overall health-related quality of life.49–53,55,56 Chronic 
ophthalmic complications result from multiple pathogenic processes during the acute 
phase of SJS/TEN.56,57 Impaired tear production due to obstructed lacrimal glands lead 
to chronic dryness of the eyes.57,58 Symblepharon or ankyloblepharon can cause 
inadequate blinking/closure of eyes and limited ocular mobility in SJS/TEN patients.59 
While cicatricial changes in both the conjunctiva and lid margins perpetuate ongoing 
damage,59 the loss of limbal corneal stem cells further impairs reparative processes in 
the eye.60 On the exterior of the eye, scarring of the lid margins leads to ectropion, 
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entropion and trichiasis/districhiasis.60 The combination of these processes eventually 
results in recurrent corneal erosions, ulcerations, neovascularization, stromal scarring, 
and conjunctivalization of the corneal surface, and ultimately in decline of vision or 
even blindness.61  
Oral sequelae 
Although lesions of oral mucous membranes occur in most SJS/TEN patients during the 
acute phase, complete oral mucosal healing within 1 year has been reported in the 
majority of SJS/TEN patients.55,62 However, studies have found that 10–20% of 
SJS/TEN survivors suffer from chronic oronasopharyngeal mucosal lesions, whereby 
the severity of acute oral mucosal involvement seems to be a predictor for such chronic 
complications.49 Long-term oral complications include adhesions on lips, gingiva, and 
under the tongue, oral ulcers, depapillation of the tongue, Sjögren-like sicca syndrome, 
and reduced or acidic saliva production.49,55,63 Such changes can affect mouth mobility,64 
and promote caries, gingival inﬂammation and periodontitis by encouraging the growth 
of bacteria.65 Dental growth abnormalities as a consequence of disordered root 
development have been reported in children who suffered from SJS/TEN, and may cause 
eating difficulties.66 
Pulmonary sequelae 
Reported late pulmonary complications of SJS/TEN are interstitial lung disease, 
respiratory tract obstruction, bronchiectasis, bronchitis and bronchiolitis obliterans.61 
Bronchiolitis obliterans is a consequence of airway epithelial injury/scarring resulting 
in ciliary dysfunction, which predisposes to infections of the lungs, dyspnoea, and 
airway obstruction.67 Bronchiolitis obliterans after SJS/TEN has predominantly been 
observed in paediatric SJS/TEN cases and has frequently been linked with concomitant 
mycoplasma infections, and it is not entirely clear if bronchiolitis obliterans is a direct 
consequence of pulmonary complications in SJS/TEN or the high incidence of 
mycoplasma infections in SJS/TEN patients.61 Duong et al. observed that 18 out of 32 
SJS/TEN survivors had abnormal pulmonary function tests two months after SJS/TEN, 
and that severity of SJS/TEN seems to correlate with decreased pulmonary function.68 
Urogenital/gynaecological sequelae 
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Chronic gynaecological sequelae are observed in approximately 28% of patients,69 and 
mainly involve adhesions. Female SJS/TEN survivors have been reported to suffer from 
vaginal adenosis, vulvovaginal endometriosis, persistent genital ulcerations, 
dyspareunia, haematocolpos due to complete fusion of the vulvar vestibule, and birth 
canal stenosis which may require delivery by caesarean section.69–75 Vaginal adhesions 
and stenosis might be treated by nymphoplasty, (vulvo-) perineotomy, dissection with 
subsequent insertion of vaginal moulds, and menstrual suppression.69 During the acute 
phase of SJS/TEN possible preventive measures for vulvovaginal sequelae include 
insertion of a mould into the vagina and using topical corticosteroids to prevent vaginal 
adhesion/stenosis, or postponing menstruation to prevent vaginal adenosis and 
endometriosis.69,76 In men, chronic urogenital sequelae after SJS/TEN has to date not 
been described in detail. 
Gastrointestinal and hepatic sequelae  
Reported chronic gastrointestinal complications are oesophageal strictures, 
hypopharyngeal stenosis causing dysphagia and recurrent aspiration, inﬂammatory 
pancolitis with ulceration and persistent discharge, and intestinal ulceration causing 
diarrhoea and malabsorption.47,77,78 Patients with chronic small intestinal complications 
may require parenteral nutrition or even ileal resection.79 Few patients with SJS/TEN 
have also been reported to suffer from a chronic cholestasis known as vanishing bile 
duct syndrome after the acute stage of SJS/TEN.80  
Renal sequelae 
Although renal involvement in SJS/TEN is rather rare in the acute phase (20% of 
cases),48 follow-up studies of SJS/TEN survivors showed that approximately 23% of 
SJS/TEN survivors developed renal issues including chronic renal insufﬁciency, and 
that 5% of SJS/TEN patients with renal complications during the acute phase of 
SJS/TEN require long-term dialysis.49  
Psychiatric and psychosocial sequelae 
The long-term psychiatric morbidity in SJS/TEN survivors has not been studied 
sufficiently as of to date. A study by Dodiuk-Gad et al. including 17 SJS/TEN survivors 
reported that 65% of the survivors showed symptoms of post-traumatic stress, 71% 
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suffered from significant psychological distress, and that only 29% were employed 
following SJS/TEN.81  
Mortality 
A longitudinal analysis in 460 SJS/TEN patients reported mortality rates after SJS/TEN 
of 23% at 42 days, 28% at 90 days, and 34% at 1 year, which suggests that the risk of 
death continues to be increased after the acute phase of SJS/TEN. The study further 
showed that risk of dying within 42 days after SJS/TEN was 7.7-times higher for patients 
with TEN when compared to patients with SJS, and 2.6-times higher for patients with 
SJS/TEN overlap when compared to SJS.82 Old age, delayed admission to a specialist, 
and presence of comorbidities are other reported risk factors for death after 
SJS/TEN.42,49,82  
 
1.2.4 Diagnosis 
The tentative diagnosis of SJS/TEN is typically based on clinical signs, as to date no 
specific laboratory parameters which would allow diagnostic tests have been identified. 
Typical clinical signs of SJS/TEN are initial unspecific systemic symptoms with fever, 
flat targetoid skin lesions (i.e. circular, concentric lesions) with central necrosis mainly 
on the trunk and face, and mucosal involvement in at least 2 sites (mostly eyes and 
mouth).83 Erythema multiforme can also present with mucocutaneous involvement, but 
the presence of typical target lesions and lesions on extremities suggests EM rather than 
SJS/TEN.84 Further important indications to the diagnosis of SJS/TEN are non-
blanchable (i.e. lesions do not lose redness upon application of pressure), non-transient, 
and often painful skin lesions, as well as a positive Nikolsky sign (i.e. affected skin 
exfoliates upon tangential pressure).85 Aside from clinical signs, histological workup of 
a skin biopsy are used to rule out differential diagnoses such as generalized fixed drug 
eruption, acute generalized exanthematous pustulosis, drug-induced linear IgA bullous 
dermatosis, paraneoplastic pemphigus, disseminated fixed bullous drug eruption, and 
staphylococcal scalded skin syndrome. 
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1.2.5 Etiology  
SJS/TEN is mostly triggered by drugs. SJS/TEN typically occurs 4-28 days after 
initiation of a new drug therapy, but cases with a latency period of up to 8 weeks have 
been observed. Current knowledge of the pathogenesis of SJS/TEN suggests that, aside 
from exposure to certain drugs, a patient’s genetic predisposition (alleles of the human 
leukocyte antigen [HLA], drug metabolism by cytochrome P450 [CYP], and T-cell 
clonotypes) may play a role in a patient’s susceptibility to SJS/TEN (Figure 1.2-2). 
Proposed triggers of SJS/TEN other than drugs are infections (e.g. mycoplasma 
pneumoniae, herpes virus) and radiotherapy.86 
 
 
Figure 1.2-2: Etiologic factors involved in the pathomechanism of SJS/TEN. 
CYP=Cytochrome P450, HLA=Human leukocyte antigen. 
 
Culprit drugs 
In the absence of effective pharmacotherapy for acute SJS/TEN, early identification and 
discontinuation of the culprit drug is essential to minimize complications of SJS/TEN. 
Despite the importance of knowledge of culprit drugs of SJS/TEN, Haddad et al. 
reported in a study where they assessed the accuracy and completeness of SJS/TEN 
warnings in drug dictionaries that the quality of information on the risk of SJS/TEN is 
rather low and needs improvement.87 The lack of knowledge of culprit drugs can mainly 
be attributed to the rare nature of SJS/TEN, which requires a huge data source to identify 
a sufficiently large study population, previous issues with SJS/TEN diagnoses in 
healthcare databases (see Chapter 1.2.2.; multi-diagnostic coding of ICD-9 codes), and 
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the impracticability of conducting clinical studies on this subject due to ethical and 
practical considerations. Two previous multi-national case-control studies based in 
Europe have identified sulphonamide antibiotics, allopurinol, carbamazepine, 
phenobarbital, phenytoin, lamotrigine, nevirapine, and oxicam analgesics as the main 
culprit drugs of SJS/TEN.88,89 Various other drugs have been linked to SJS/TEN albeit 
based on weak evidence from observational studies,89,90 or from case reports (Table 1.2-
1).91–139 
Potential tests for the identification of the causative agents in SJS/TEN (e.g. patch 
testing, pin prick, intradermal injection, lymphocyte transformation test, basophil 
activation test) have not been proven to be reliable in predicting SJS/TEN and lack 
sensitivity.140 
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Table 1.2-1: Drug previously associated with SJS/TEN in observational studies or case reports. 
 
 
Suspected culprit drugs 
for SJS/TEN with strong 
evidence from observational 
studies88,89 
Suspected culprit drugs 
for SJS/TEN with conflicting or 
few evidence from observational 
studies88,89 
Suspected culprit drugs for SJS/TEN suggested in case reports only91–139 
     
Carbamazepine Valproate Coxibs Itraconazole Amlodipine 
Phenobarbital Penicillins Nimesulide Fluconazole Losartan 
Phenytoin Quinolones Tetracepam Voriconazole Indapamide 
Lamotrigine Cephalosporins Clobazam Terbinafine Dipyridamole 
Allopurinol Tetracyclines Gabapentin Metronidazole Hydralazine 
Oxicam-analgesics Macrolides Zonisamide Vancomycin Acetazolamide 
Cotrimoxazole Acetic-acid NSAIDs Fluoxetine Rifaximin Methotrimeprazine 
Sulfasalazine Ibuprofen Fluvoxamine Oseltamivir Bezafibrate 
Nevirapine Diclofenac Paroxetine Adefovir Strontium ranelate 
 Acetaminophen Mirtazapine Abacavir Danazol 
 Pyrazolones Duloxetine Efavirenz Mesalamine 
 Corticosteroids Venlafaxine Afatinib Bendamustine 
 Imidazole antimycotics Bupropion Sorafenib Febuxostat 
 Pantoprazole Paliperidone Etanercept Hydroxychloroquine 
 Sertraline Omeprazole Methotrexate Ethambutol 
  Esomeprazole Metolazone Modafinil 
  Lansoprazole Furosemide Phosphodiesterease-5 inhibitors 
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Genetic predispositions of SJS/TEN 
First reports of potential genetic susceptibility to SJS/TEN emerged in 1987, when 
associations between the presence of certain HLA alleles and sulphonamide-induced 
TEN (HLA-B*12, HLA-A*29, and HLA-DR*7), and oxicam-induced TEN (HLA-
B*12 and HLA-A*2) were observed in Europeans.141 Over the course of the following 
years many other associations between genetic predispositions and SJS/TEN have been 
discovered (Table 1.2-2). 
Table 1.2-2: Drug previously associated with SJS/TEN in observational studies or case reports. 
HLA allele or CYP Culprit drug Ethnicity References 
    
HLA alleles    
HLA-B*15:02 Carbamazepine 
Oxcarbazepine 
Lamotrigine 
Phenytoin 
Asian 142–145 
HLA-B*15:11 Carbamazepine Asian 146,147 
HLA-B*59:01 Carbamazepine Asian 148 
HLA-A*31:01 Carbamazepine Asian, European 149,150 
HLA-B*38 Sulfamethoxazole European 151 
HLA-C*04:01 Nevirapine African 152 
HLA-B*73 Oxicam European 151 
HLA-B*58:01 Allopurinol Asian, European 151,153,154 
    
CYP alleles    
CYP2C9*3 Phenytoin Asian 155 
CYP2B6 Nevirapine African 156 
    
CYP=Cytochrome P450; HLA=Human leukocyte antigen. 
An association between the presence of HLA-B*15:02 and carbamazepine-induced 
SJS/TEN has been reported in Asians but so far not in Europeans, in whom the HLA-
B*15:02 allele has a low prevalence (<1%).142–145,157 The same association was also 
observed in Europeans with Asian ancestry.157 This observation suggests that the risk of 
SJS/TEN might vary by ethnicity. Chen et al. reported a significant reduction of 
SJS/TEN-incidence in patients from Taiwan who were screened for HLA-B*15:02 prior 
to onset of carbamazepine treatment.158 The results of this study suggested that routine 
screenings for the presence of a HLA-B*15:02 allele should be considered in Asian 
patients before starting carbamazepine treatment. The association between HLA-
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B*58:01 and allopurinol-induced SJS/TEN on the other hand has been found in both 
Asian and European patients.151,153 
Besides HLA alleles, altered drug metabolism or clearance may also play a role in the 
pathogenesis of SJS/TEN.32 Two studies reported associations between phenytoin-
related SJS/TEN and genetic variants of CYP2C, namely CYP2C9*3.155,159 CYP2C9*3 
has a reduced catalytic activity compared to wild-type CYP2C*1, resulting in delayed 
clearance of plasma phenytoin and increased phenytoin toxicity in patients carrying this 
CYP2C variant.160 The results from a further study suggest that polymorphisms of 
CYP2B6 may influence the risk of developing SJS/TEN after exposure to nevirapine.156  
 
1.2.6 Pathomechanism 
Mechanism of Cell Death  
The current understanding of the pathogenesis of SJS/TEN is mainly based on studies 
that found increased numbers of CD8 T-lymphocytes and Natural Killer (NK) cells in 
the blister fluid of patients with SJS/TEN.161,162 These findings implicate, that the 
widespread keratinocyte cell death seen in SJS/TEN can be attributed to apoptosis 
(programmed cell death) rather than to necrosis (cell death triggered by external factors 
or diseases). The activated CD8 T-cells and NK cells in SJS/TEN induce keratinocyte 
death in a drug-specific, major histocompatibility complex-I (MHC-I)-restricted 
manner.163 
Aside from drug-specific cytotoxic T-cells and NK cells multiple other cell-death 
mediators, as well as altered anti-apoptotic pathways, and altered or defective regulation 
of drug-specific immune reactions are suggested to play a role in the apoptosis of 
keratinocytes.164 Granulysin, Fas–Fas ligand interaction, tumour necrosis factor-α 
(TNF-α), TNF-related apoptosis-inducing ligand, and perforin-granzyme B have all 
been implicated as mediators of apoptosis in SJS/TEN.32,165 
Chung et al. identified granulysin, a cytolytic protein produced and secreted by cytotoxic 
T-lymphocytes and NK cells, as a key cell death mediator in SJS/TEN.166 The study 
identified granulysin as the most highly expressed cytotoxic molecule in five patients 
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with SJS/TEN, and found that the concentration of granulysin in blister fluid of 
SJS/TEN patients correlated with clinical severity of the reaction. Dose-dependent 
blistering and cell death was further observed when injecting granulysin from SJS/TEN 
patient blisters into mice skin.166  
The Fas–Fas ligand pathway is another proposed pathway for the widespread apoptosis 
of keratinocytes in SJS/TEN. Viard et al. found that TEN patients had elevated levels of 
soluble Fas ligands (sFasL) in keratinocytes which activate apoptosis by binding to Fas 
receptors.167 However, a subsequent study by Abe et al. could only find elevated levels 
of sFasL in the serum, but not in keratinocytes.168 They concluded that the elevated 
levels of sFasL stem from peripheral blood mononuclear cells rather than keratinocytes 
and that sFasL may thus not be the primary mediators of apoptosis. In a further study 
conducted in 35 SJS/TEN patients, they found that sFasL levels were significantly 
increased in the serum of affected patients before development of skin detachment or 
mucosal lesions, and proposed that sFasL may play a role as a marker of disease at initial 
presentation.169  
Other ‘death receptors’ such as TNF-receptor 1, death receptors 4 and 5, and their 
ligands TNF-α and TNF-related apoptosis-inducing ligand may also be involved in the 
pathogenesis of SJS/TEN.32,165  
 
Initiation of Apoptosis  
The exact mechanism of cytotoxic T-cell activation in SJS/TEN is an issue that has not 
yet been sufficiently clarified. One proposed concept is that metabolites of culprit drugs 
interact with the T-cell receptors (TCR) after covalently binding to a peptide (hapten-
concept). Another proposed concept is that culprit drugs non-covalently bind directly to 
MHC-I and TCR without being metabolized first (pharmacologic interaction concept).32 
The results of a study by Wei et al. support this proposed mechanism for carbamazepine-
induced SJS/TEN, by showing that carbamazepine is able to directly bind to HLA-
B*15:02 and activate T-cells.170 However, the results of a further study suggest that the 
hapten-concept is more likely to underlie cytotoxic T-cell activation in SJS/TEN 
induced by abacavir.171 
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1.2.7 Management 
Supportive care 
If SJS/TEN is suspected, the culprit drug should be identified and discontinued as soon 
as possible. Early discontinuation of the culprit drug is crucial and often decisive for the 
outcome of SJS/TEN. Patients should then be referred to specialised clinicians or, in 
case of TEN, a burn intensive care unit to receive further supportive care, which mainly 
involves wound care with focus on preventing infections, and management of airways, 
renal function, fluid and electrolyte balance, nutrition, ocular complications, and pain.172 
The different analgesic regimens for pain management in SJS/TEN have to date not been 
investigated in studies. Existing guidelines suggest that patients with mild pain should 
be treated with acetaminophen and if required with oral codeine or tramadol. Because 
of the potential for renal and gastric injury, NSAIDs should be avoided. Patients with 
moderate or severe pain should receive opiate-based analgesia (e.g. morphine, fentanyl) 
enterally or via infusion.172 Systemic antibiotics should only be administered if there are 
clinical signs of infections and not preventively.172 When evaluating therapeutic actions 
caretakers should also consider assessing SCORTEN (severity-of-illness score for 
TEN), which is a score that was designed to predict the severity and risk of death in 
SJS/TEN patients based on age, affected BSA, presence of malignancy, heart rate, serum 
urea, serum bicarbonate, and serum glucose.45  
Ophthalmologists play an important role in the management of SJS/TEN and should be 
consulted as soon as possible to prevent long-term ocular complications. Preventive 
measures include lubrication, use of topical antibiotics and corticosteroids, lysis of 
adhesion, and amniotic membrane transplantation. In patients with urogenital 
complications during the acute phase of SJS/TEN consultation with an urologist or 
gynaecologist is recommended to prevent urogenital sequelae.172 
Pharmacological therapy 
The pharmacologic treatment of SJS/TEN is a subject of discussion and evidence on 
various potentially effective drugs is conflicting and based on low patient numbers. To 
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date systemic corticosteroids, intravenous immunoglobulin (IVIG), TNF inhibitors, and 
cyclosporine A are discussed as potential adjunctive acute therapy options. 
Systemic corticosteroids are regularly used to treat SJS/TEN despite conflicting 
evidence on their effectiveness. Previous observational studies reported that systemic 
corticosteroids successfully alleviate symptoms in SJS/TEN patients during the acute 
phase.173,174 However, previous reports on the effects of systemic corticosteroids on 
mortality are contradictory. While some early studies found an increased risk for 
infections and death in patients treated with systemic corticosteroids,175 more recent 
studies suggested a similar or a slightly better chance of survival when compared to 
supportive therapy alone.82,176,177 Due to equivocal evidence and the lack of controlled 
clinical trials, guidelines do not give specific recommendations regarding the use of 
systemic corticosteroids in SJS/TEN.172 
Intravenous immunoglobulins are commonly used in SJS/TEN. Although positive 
effects of IVIG in SJS/TEN patients have been described in case reports and series,140 
the results of a systematic review and meta-analysis including 221 SJS/TEN patients 
treated with IVIG suggested no significant advantage of IVIG over supportive care only 
regarding patient survival.178 Due to the conflicting results on the efficacy of IVIG for 
the treatment of SJS/TEN and potential side effects, the use of IVIG should be carefully 
considered in SJS/TEN patients.140,172  
Studies observed increased serum TNF-alpha levels in SJS/TEN patients suggesting that 
TNF-alpha inhibitors might be effective in the treatment of SJS/TEN.179 However, to 
date only little evidence exists on the effectiveness of TNF inhibitors in SJS/TEN. 
Several case reports found that infliximab and etanercept impede skin detachment, 
promote re-epithelialization, and increase survival probability in SJS/TEN.180–182  
An increased mortality in patients with TEN was observed in association with 
thalidomide in the only existing randomized placebo-controlled trial conducted to assess 
the effectiveness of adjunctive therapy in SJS/TEN. The study was terminated after 10 
out of 12 TEN patients treated with thalidomide died, while only 3 deaths were observed 
in 10 TEN patients in the placebo group.183 
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Cyclosporine A has also been reported to slow progression of SJS/TEN in the acute 
phase in various case reports.184 A retrospective analysis conducted in a cohort of 44 
SJS/TEN patients further reported that cyclosporine A successfully decreased the 
number of deaths in 24 SJS/TEN patients when compared to the number of deaths 
predicted by SCORTEN.185  
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2 Aims of the thesis 
The aim of this thesis was to contribute to the understanding of the epidemiology and 
culprit drugs of SJS/TEN by conducting comprehensive observational studies using data 
from the CPRD, a large, UK-based primary-care database. Despite the severe impact of 
SJS/TEN on affected patients, the current scientific understanding of SJS/TEN is 
insufficient, particularly regarding its epidemiology, aetiology, pathophysiology, 
treatment, and long-term sequelae. 
SJS/TEN has not been studied in the CPRD before, and numerous previous attempts of 
studying these reactions in medical claims databases have failed due to issues with the 
multi-diagnostic coding of the ICD-9 coding system.35–38 Study 3.1 is the basis of the 
project and aims to evaluate the eligibility of studying SJS/TEN in the CPRD by 
assessing the validity of SJS/TEN diagnoses recorded in the CPRD, and to establish a 
valid population of SJS/TEN patients from the CPRD for observational studies (i.e. 
Studies 3.2 to 3.5). 
Study 3.2 aimed at comprehensively analysing the epidemiology of SJS/TEN by 
calculating IRs of SJS/TEN in the UK for the first time. We further aimed to identify 
risk groups of SJS/TEN by assessing associations between SJS/TEN and demographic 
factors, life-style characteristics, ethnicity, and pre-existing comorbidities.  
Studies 3.3 to 3.5 analyse associations between SJS/TEN and potential culprit drugs as 
well as absolute risks of SJS/TEN in association with each of the drugs to provide a 
better understanding of the safety/risk of these drugs regarding SJS/TEN. Absolute risks 
of SJS/TEN have previously only been reported for some AEDs. Study 3.3 encompasses 
all AEDs in clinical use in the UK of which some have previously been associated with 
SJS/TEN with strong evidence (e.g. carbamazepine, lamotrigine, phenytoin, 
phenobarbital) or little evidence (e.g. valproate, gabapentin). Study 3.4 encompasses 
various antibiotic drugs among which cotrimoxazole in particular has repeatedly been 
linked to SJS/TEN. Numerous other drugs which have been associated with SJS/TEN 
in observational studies (e.g. allopurinol) or case reports (e.g. coxibs) as well as drugs 
of common use are included in Study 3.5. 
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3 Stevens-Johnson syndrome and toxic epidermal necrolysis 
project 
 
3.1 Validation of Stevens-Johnson Syndrome or Toxic Epidermal 
Necrolysis Diagnoses in the Clinical Practice Research Datalink (Study 
3.1) 
 
 
Noel Frey1,2, MSc, Andreas Bircher3, MD, Michael Bodmer4, MD, Susan S. Jick5, DSc, 
Christoph R. Meier1,2,5, PhD, MSc, Julia Spoendlin1,2, PhD 
 
 
 
 
 
1 Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of 
Pharmaceutical Sciences, University of Basel, Basel, Switzerland; 
2 Hospital Pharmacy, University Hospital Basel, Basel, Switzerland; 
3 Allergology, University Hospital Basel, Basel, Switzerland; 
4 Internal Medicine, Zuger Kantonsspital, Switzerland; 
5 Boston Collaborative Drug Surveillance Program, Boston University School of Public Health, 
Lexington MA, United States. 
 
 
 
 
 
 
Pharmacoepidemiology and Drug Safety 2017, 26(3):429-436. 
SJS/TEN project  Study 3.1 
41 
 
3.1.1 Abstract 
Purpose: To evaluate the validity of recorded diagnoses of Stevens–Johnson syndrome 
(SJS) and TEN in the CPRD. 
Methods: We identified patients with a diagnosis of SJS or TEN between 1995 and 2013 
in the CPRD. We reviewed information from patient records, free text, and HES data, 
and excluded patients with no indication of a secondary care referral. Remaining patients 
were classified as probable, possible, or unlikely cases of SJS/TEN by two specialised 
clinicians or based on pre-defined classification criteria. We quantified positive 
predictive values (PPV) for all SJS/TEN patients and for patients categorised as 
‘probable/possible’ cases of SJS/TEN, based on a representative subsample of 118 
patients for whom we had unequivocal information (original discharge letters or HES 
data). 
Results: We identified 1324 patients with a diagnosis of SJS/TEN, among whom 638 
had a secondary care referral recorded. Of those, 565 were classified as probable or 
possible cases after expert review. We calculated a PPV of 0.79 (95% CI, 0.71–0.86) 
for all SJS/TEN patients with a recorded secondary care referral, and a PPV of 0.87 
(95% CI, 0.81–0.93) for probable/possible cases. After excluding 14 false positive 
patients, our study population consisted of 551 SJS/TEN patients. 
Conclusions: Diagnoses of SJS/TEN are recorded with moderate diagnostic accuracy in 
the CPRD, which was substantially improved by additional expert review of all available 
information. We established a large population-based SJS/TEN study population of high 
diagnostic validity from the CPRD. 
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3.1.2 Introduction 
SJS/TEN are life-threatening skin reactions, which predominantly occur as a 
complication of newly administered drug therapy. These reactions are rare, with 
estimated IRs of SJS/TEN ranging from 1 to 12.7 per million py.40,42,186,187 Current 
evidence suggests that SJS and TEN are one disease entity, which differ by the 
proportion of BSA affected by skin detachment.83,86,188 Epidemiologic data on SJS/TEN 
is limited; previous studies have focused primarily on identifying drugs that cause these 
skin reactions using hospital based case–control studies.88,89,189 Large electronic 
databases are an important tool in epidemiologic research and can be particularly useful 
in conducting population-based studies on rare outcomes. However, studies on SJS/TEN 
using these data sources are scarce for several reasons. Some databases are too small to 
quantify such a rare disease, and up until 2008, data from large databases that used the 
ICD-9 coding system were not ideal for research because of the non-specific coding of 
the outcome, which did not differentiate between EM and SJS/TEN.36,37,190 Thus, more 
evidence on IRs of SJS/TEN and characteristics of patients with the outcome from 
population-based data are needed. Previously reported IRs of SJS/TEN vary greatly 
presumably because of difficulties in defining the population at risk. Lack of 
longitudinal follow-up studies on SJS/TEN patients also limits knowledge about long-
term complications in SJS/TEN survivors.165,187,189,191  
The Clinical Practice Research Datalink is a large UK-based primary care database, and 
a potentially suitable resource to study the epidemiology of SJS/TEN, because its Read-
coding system allows differentiation between EM, SJS, and TEN. Furthermore, 
anonymised original secondary care documentation is available. Moreover, the large 
size, the virtually complete drug prescription history, the long mean patient follow-up 
(9.4 years for currently enrolled patients), and the population-based nature of the 
database make it an attractive resource for studying rare diseases using a longitudinal 
approach. Diagnostic accuracy in the CPRD has been demonstrated to be high for many 
diseases, but the validity of recorded SJS or TEN diagnoses has not yet been evaluated. 
We therefore sought to (i) assess the feasibility of studying SJS/TEN in the CPRD, and 
to (ii) assemble a study population of validated incident SJS/TEN cases. 
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3.1.3 Patients and Methods 
Data sources 
CPRD  
This study was conducted in the CPRD, a large (around 11 million patients) 
computerised primary care database that is representative of the UK population with 
regard to age and sex. Since 1987, participating GPs have recorded patient 
characteristics, symptoms, diagnoses, laboratory test results, drug prescriptions, and 
referrals, including the primary diagnoses made in secondary care (defined as 
hospitalisations and visits to outpatient consultants).28 The data in the CPRD have been 
repeatedly demonstrated to be of high quality,29 and the database has been used for 
numerous epidemiological studies published in peer-reviewed journals. This study was 
approved by the ISAC for MHRA database research (ISAC protocol 14_009R). 
 
Free text  
Free text can be added to the coded patient records by the GP and can contain important 
details of medical encounters, and often contains relevant information regarding 
diagnoses from secondary care, procedures, symptoms, referrals, or any other 
information the GP considered important.190,192 Of note, free text is only available up to 
June 2013 because of new regulations of privacy protection within the UK. 
 
Hospital episode statistics data  
HES data are computerised details of hospitalisations in NHS hospitals in England (a 
subset of CPRD patients) available since 1989. These linked data include information 
on primary and secondary discharge diagnoses, procedures performed during a hospital 
stay, length of stay, and methods of admission and discharge. 
 
Original discharge letters 
We further ordered discharge letters for 50 randomly selected patients with an incident 
SJS/TEN diagnosis who were referred to a secondary care institution (hospital or 
dermatology/ophthalmology unit). Discharge letters were available from participating 
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GPs who copy and send, in anonymised manner, clinical records to the CPRD for 
validation purposes. 
 
Study population 
We identified all patients of any age in the CPRD who had a READ-code for SJS or 
TEN between January 1995 and December 2013 (Table 3.1-1). We then requested all 
available free text and HES data for these patients. Using all available information, we 
identified patients who had some indication, from one of the data sources, that they had 
been seen in secondary care within 30 days before or after the first SJS/TEN diagnosis 
code. We defined referrals to secondary care as a Read-code for a referral to a secondary 
care institution or a specialist (dermatologist or ophthalmologist), a hospitalisation 
recorded in HES data, receipt of letters from a specialist, or a recorded entry for a 
hospital discharge (or receipt of a discharge letter). Those with no information to suggest 
a secondary care visit were excluded from further study, because patients with true 
SJS/TEN inevitably require hospitalisation or consultation with a specialist. 
 
Validation of SJS and TEN diagnoses 
Researchers reviewed and abstracted all relevant information from CPRD electronic 
patient records (not including drug prescriptions), free text, and HES data of SJS/TEN 
patients with an identified secondary care referral. All information from free text or HES 
data with regard to drug prescriptions or any information that confirmed or refuted an 
SJS/TEN diagnosis (SJS/TEN diagnoses and differential diagnoses) was manually 
blinded before it was linked to the respective patient, because this information was later 
used to evaluate the PPV of the recorded SJS/TEN diagnoses. Patients were then 
allocated to either group A or group B. Group A included patients whose electronic 
record contained sufficient clinical information (≥3 different codes for symptoms, 
diagnoses, or patient management for skin disease or had free text with clinical 
information from secondary care or the GP). These were then evaluated by two 
clinicians, a dermatologist who is specialised in allergology, and an internist with 
specialisation in emergency and intensive care medicine. Based on their clinical 
knowledge, the two clinicians independently classified each potential SJS/TEN case as 
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probable, possible, or unlikely. We considered expert review the most accurate way to 
classify patients, because SJS/TEN is usually diagnosed in secondary care based on 
clinical presentation. Because there are no accepted universal clinical guidelines for 
SJS/TEN, implementation of an unequivocal pre-specified clinical validation algorithm 
was not feasible. Group B contained patients with an evident secondary care referral but 
whose records did not contain sufficient clinical information to be allocated in group A. 
Because we could not classify these patients based on clinical information, patients in 
group B were categorised as probable, possible, or unlikely strictly according to pre-
specified criteria (Table 3.1-2), which were previously developed by two 
epidemiologists based on the number of SJS/TEN codes and other supporting codes such 
as procedures and patient management codes, recorded differential diagnoses, and 
hospital and emergency visits. 
 
True diagnoses  
We considered patients who had diagnoses of SJS/TEN found in secondary care 
discharge letters, HES data, or free text to be true cases of SJS/TEN if the letter explicitly 
confirmed the SJS/TEN diagnosis. We determined that when another differential skin 
diagnosis was present the SJS/TEN was not a true case. When there was ambiguity, 
letters were reviewed by an allergist (n=5; 3 considered true cases, and in 2 instances 
we were not able to confirm or refute the recorded SJS/TEN diagnosis based on the 
content of the letter). We accepted diagnoses recorded in free text as valid if they 
referred to a discharge letter and to the recorded diagnosis of interest, or to a diagnosis 
which was made by a specialist. Diagnoses from HES data were considered to validate 
cases if the primary discharge diagnosis explicitly confirmed the SJS/TEN diagnosis 
(bullous EM [ICD-10 L51.1]) or to refute the SJS/TEN diagnosis (another explicit 
differential diagnosis of SJS/TEN involving the skin or mucous membranes was 
recorded). 
 
 
 
Statistical analysis 
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We calculated PPVs with 95% confidence intervals (CI) for (i) all SJS/TEN patients 
with a secondary care referral prior to expert classification (n=638), and for (ii) patients 
classified as possible or probable SJS/TEN patients after expert classification (n=565), 
based on a representative sample of SJS/TEN patients for whom true diagnoses from 
secondary care discharge letters, HES data, or free text were available. The PPV was 
calculated based on a representative subset of the 118 patients for whom information 
from HES data, free text, or discharge letters unequivocally confirmed or refuted the 
SJS/TEN diagnosis (93 cases confirmed and 25 refuted). Because the likelihood of 
having unequivocal information available was independent of the validity of the 
diagnosis, this proportion was then extrapolated to (i) the full set of all 638 SJS/TEN 
cases with secondary care referrals and separately to (ii) all 565 SJS/TEN patients 
classified as ‘probable/possible’ SJS/TEN cases to estimate the proportion of true cases 
in the study population.  
To evaluate whether ‘true’ cases and unconfirmed ‘probable/possible’ SJS/TEN cases 
differed in specific characteristics from patients classified as unlikely (confirmed or 
unconfirmed) SJS/TEN cases, we compared the 2 groups with respect to sex and age 
distribution, the year of the first recorded SJS/TEN diagnosis, and whether or not 
patients had recorded diagnoses for EM within 2 weeks before or after the first SJS/TEN 
diagnosis. All analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC, USA). 
 
Incidence rate 
We calculated a population-based overall IR of SJS/TEN for the years 1995 through 
2013, by dividing 551 probable/possible SJS/TEN cases by the total number of py at 
risk in patients without a previous diagnosis for SJS/TEN in the CPRD population. We 
adjusted the overall IR for type I error (false positive cases) and for type II error (false 
negative cases) by multiplying the numerator by the overall PPV (i.e. 0.87) and by the 
proportion of patients that was erroneously excluded because of a non-evident but true 
hospitalisation (proportion based on HES data 1.24). 
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3.1.4 Results  
We identified 1324 patients with a recorded SJS/TEN diagnosis in the CPRD during the 
study period, of whom 638 had an ascertainable secondary care referral within 30 days 
before or after the first SJS/TEN diagnosis. 
Based on the initial review, we allocated 284 patients into group A (for review by 
clinicians) and 354 patients into group B (for review by epidemiologists). In group A, 
81 patients with SJS/TEN diagnoses were classified as probable, 151 as possible, and 
52 as unlikely cases of SJS/TEN. Patients in group B were classified according to the 
criteria listed in Table 3.1-2, which resulted in 172 patients being classified as probable, 
161 as possible, and 21 as unlikely SJS/TEN patients (Figure 3.1-1).  
Of 959 patients with a recorded SJS/TEN diagnosis during the study period and an 
existing flag for available free text in the patient profile around the time of diagnosis, 
we received free text for 474 patients (49.4%; Table 3.1-5). Free text of 39 potential 
SJS/TEN patients contained extracts of discharge letters which explicitly confirmed 
(n=36) or refuted (n=3) the SJS/TEN diagnosis (Table 3.1-3).  
A total of 176 patients had HES data recorded between 1995 and December 2013, of 
whom 70 patients had a hospitalisation recorded in HES data within one month prior to 
or after the first CPRD SJS/TEN diagnosis. Seventeen (24.3%) of those 70 secondary 
care referrals indicated in HES data were not otherwise coded as referrals in the CPRD 
patient profiles. The HES data confirmed the SJS/TEN diagnosis recorded in the CPRD 
patient profile in 39 patients. An additional 10 cases were refuted based on the 
information in the HES data (Table 3.1-3).  
We received 35 of 50 requested discharge letters (70%; Table 3.1-5). Of these, 16 
confirmed and 12 refuted the SJS/TEN diagnosis recorded in the CPRD patient profile. 
The remaining 7 discharge letters (14.0%) were not helpful as they either were not 
legible, contained too little information, or they referred to a diagnosis/symptom other 
than the SJS/TEN diagnosis (Table 3.1-3).  
We identified 118 patients for whom we had unequivocal (true) diagnoses from HES 
data, free text, or discharge letters. Of these, 93 confirmed and 25 refuted the SJS/TEN 
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diagnoses. We estimated PPV based on the 118 cases for whom we had unequivocal 
diagnostic information, and applied the results to all SJS/TEN patients with a secondary 
care referral and to all SJS/TEN patients classified as probable/possible, respectively.  
Among the 638 patients who had an incident SJS/TEN diagnosis in the CPRD between 
January 1995 and December 2013 accompanied by a coded secondary care referral we 
estimated, based on the sample, a PPV of 0.79 (95% CI, 0.71–0.86, Table 3.1-4). The 
565 SJS/TEN cases who were classified as probable or possible yielded an overall PPV 
of 0.87 (95% CI, 0.81–0.93). The PPV in group A (53 true cases) was 0.89 (95% CI, 
0.80–0.97), and the PPV in group B (54 true cases) was 0.85 (95% CI, 0.76–0.95, Table 
3.1-4). Of these, 13.6% of patients were explicitly diagnosed with TEN. We combined 
patients classified as probable and possible into one group, because we observed no 
statistically significant differences between the PPVs (p-value =0.699, Pearson chi-
square test) calculated separately in patients classified as probable versus unlikely 
(PPV=0.88) and possible versus unlikely (PPV=0.86; Table 3.1-4).  
Based on the 551 probable/possible cases, we calculated an overall SJS/TEN IR of 6.52 
cases/million py in the CPRD population between 1995 and 2013. Furthermore, cases 
of SJS/TEN classified as unlikely cases were more likely to have had a diagnosis of EM 
recorded within 2 weeks before or after the first SJS/TEN diagnosis (Table 3.1-6). 
Patient demographics were comparable across all groups. 
 
3.1.5 Discussion 
Our findings suggest that SJS and TEN diagnoses accompanied by secondary care 
referrals are recorded with moderate reliability in the CPRD (PPV 0.79, 95% CI, 0.71–
0.86, i.e. 116 false positives out of 638 potential cases). However, additional evaluation 
of the available information by clinicians/epidemiologists improved the PPV (0.87, 95% 
CI 0.81–0.93) within our final SJS/TEN study population (i.e. 72 false positives out of 
551 validated cases).  
We restricted this study to SJS/TEN diagnoses with known secondary care referrals 
because most patients with SJS/TEN require inpatient or even intensive care treatment. 
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A recent study by Davis et al. validated SJS/TEN diagnoses recorded in US-based HMO 
data after the specific ICD-9-CM coding was introduced in 2008, and reported a PPV of 
15% among ‘not-hospitalised’ patients with a specific SJS/TEN or EMM diagnosis.193 
Note that we did not look at EMM in our study so these results are not strictly 
comparable. The authors further quantified a PPV of 50% among hospitalised patients 
overall, which however was only based on secondary care record review of 10 potential 
SJS/TEN cases, including an unknown number of patients diagnosed with EMM. 
Because the final diagnosis is typically based on clinical presentation to a dermatologist 
in specialised secondary care, we used a large and representative sample of 
approximately 20% of all diagnoses documented in secondary care records to establish 
true cases. Consequently, we have no information on the validity of SJS/TEN diagnoses 
in the CPRD among patients for whom no secondary care referral was identified. Based 
on hospitalisations recorded in HES data, we estimated that approximately 24% of all 
patients with a recorded SJS/TEN diagnosis that were excluded because of absence of a 
secondary care referral, were actually hospitalised. We therefore adjusted the overall IR 
calculated from this study population accordingly. On the other hand, given the large 
size of the CPRD and the low rate of SJS/TEN, we can assume an overall high specificity 
of SJS/TEN diagnoses in the CPRD, and relative risk estimates derived from our study 
population will thus be of high precision.28  
We were not able to assess the negative predictive value (NPV) of SJS/TEN diagnoses 
in the CPRD because we only evaluated patients with a recorded SJS/TEN diagnosis. 
While we were able to estimate the number of SJS/TEN cases missed because no 
hospitalisation was recorded, it was not feasible to evaluate whether some SJS/TEN 
cases were missed because the patient did not receive a SJS/TEN code at all or the 
patient for some reason had no contact with a primary care institution. However, because 
symptoms of SJS/TEN are serious and generally compel patients to seek medical 
attention (usually from a secondary care specialist), and because GPs participating in 
the CPRD are obliged to add all secondary care diagnoses to the patient’s medical 
history,28 the proportion of missed SJS/TEN episodes in the CPRD is likely to be small.  
Of 25 patients determined not to have SJS/TEN based on HES data, free text, or 
discharge letters, 14 were incorrectly classified as possible or probable cases based on 
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electronic record review; 8 of these were in group B. Of the 11 patients correctly 
classified as unlikely cases (the final diagnosis refuted SJS/TEN diagnosis), 3 were in 
group B. However, because the resulting PPVs were similarly high in groups A and B, 
we plan to include cases from both in future research. Furthermore, clinically 
unequivocal SJS/TEN cases may not have as much clinical information recorded as 
compared to patients where the physician is insecure about the diagnosis.  
Our calculated overall IR of 6.52 cases/million py is consistent with previously reported 
IRs for SJS/TEN, which ranged between 1 and 12.7 cases/million py.40,42,186 This further 
corroborates the validity of our final study population, although the range of previously 
reported IRs is wide, likely because of difficulties in defining patients at risk, different 
case definition, or because of absence of certain triggering drugs on the market during 
earlier study periods.  
There are several additional points that should be considered when interpreting the 
results of this validation study. First, we cannot guarantee the accuracy of all diagnoses, 
which were made in secondary care. Besides skin biopsy, which is routinely performed 
but is not diagnostic or specific, there are no diagnostic tests for SJS/TEN, and 
differential diagnoses, such as EM major, linear IgA dermatosis, generalised bullous 
fixed drug eruption, and exfoliative dermatitis can lead to misdiagnosis or diagnostic 
uncertainty even in specialised secondary care.83,194 Second, although preferable, we 
were not able to order all available discharge letters, as this would have been too costly. 
However, in combination with information from HES data and free text, we were able 
to calculate the final PPV based on a relatively large and representative sample of 118 
patients (approx. 20% of all patients) for whom we had unequivocal clinical information 
to validate the case of interest (likelihood of available secondary care referral was 
independent of the validity of the diagnosis in question). Third, we were not able to 
differentiate between SJS and TEN unless explicitly diagnosed. In our study population, 
only around 15% of patients had a specific TEN diagnosis recorded within 2 months 
after the index date (four of these were after a SJS diagnosis). We identified the most 
serious diagnosis recorded to capture the most severe form of disease to occur at any 
point in the disease progression. Previous estimates of the ratio of SJS and TEN are 
sparse, but have been reported to be between approximately 3:1 and 5:1.86 In our study 
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the ratio of SJS to TEN was approximately 7:1, which may indicate that some TEN cases 
were mistakenly recorded as SJS, but it is also possible that previous studies 
overestimated the proportion of TEN events relative to SJS. We were further not able to 
capture SJS/TEN overlap syndrome (defined by the degree of affected BSA of 10–
30%).83 Finally, we cannot rule out the possibility that some patients had an episode of 
SJS/TEN prior to entering the CPRD.  
Free text as well as original discharge letters was essential for the validation of these 
SJS/TEN cases, as a source of additional clinical information. Free text ceased to be 
available to CPRD researchers in July 2013 because of concerns about patient 
confidentiality. For the same reason, original discharge letters are no longer available to 
researchers. While it is important to safeguard patient confidentiality in observational 
research, the increasing constraints on data availability may severely hamper the 
conduct of observational studies, especially of rare diseases such as SJS/TEN, where the 
diagnosis is difficult to make and clinical details are critical to the case validation 
process, and where there will always be relatively few cases. While this limitation does 
not apply to the presented study, it will be a major impediment for future research.  
In conclusion, the CPRD provides a valuable resource to perform population-based 
longitudinal epidemiologic research on SJS/TEN. However, exert validation of potential 
SJS/TEN cases is highly recommended. Because of the specific Read-coding system 
used in the CPRD and the ability to validate a large proportion of cases, we were able 
to establish the first well-validated SJS/TEN study population from a large electronic 
database. This large SJS/TEN study population (n=551) will allow population-based and 
longitudinal studies into SJS/TEN, which remains an under-investigated but clinically 
important disease. 
Table 3.1-1: Distribution of index READ-codes based on which patients were identified. 
Diagnosis READ code 
All identified patients 
(n=1324) 
   
Stevens-Johnson syndrome RM151700 1152 (87.0%) 
   
Toxic epidermal necrolysis RM151.12 134 (10.1%) 
 RM151800 14 (1.1%) 
   
Lyell's syndrome  RM151812 19 (1.4%) 
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 RM151.11 5 (0.4%) 
   
Dermonecrolysis  RM151811 - 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1-2: Classification criteria used by epidemiologists to evaluate patients. 
  
Probable: No recorded differential diagnosis ≤30 days after the diagnosis  and ≥1 of the following:  
 Recorded discharge from secondary care ≤7 days prior to the first SJS/TEN diagnosis. 
 >1 recorded SJS/TEN diagnoses (≥2 days between diagnoses). 
 Recorded (emergency) hospitalisation or dermatology referral ≤7 days prior to the first 
SJS/TEN diagnosis. 
 Mentioning of ventilation, tracheostomy, parenteral nutrition, septicaemia, or intensive care 
treatment ≤7 days prior to or after the first SJS/TEN diagnosis. 
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Possible:  No relevant information (differential diagnoses, treatment, additional SJS/TEN diagnoses, 
etc.) recorded besides the SJS/TEN diagnosis. 
 Recorded (emergency) hospitalisation or dermatology referral ≤14days after the first 
SJS/TEN diagnosis, and no recorded differential diagnosis ≤30 days after the first SJS/TEN 
diagnosis. 
 >1 recorded SJS/TEN diagnosis with a differential diagnosis recorded ≤30 days after the first 
SJS/TEN diagnosis. 
 Recorded discharge together with a recorded SJS/TEN and a recorded differential diagnosis 
(≤7 days prior to the index date). 
  
  
Unlikely:  A record for a discharge letter ≤2 days prior to or after a recorded differential diagnosis. No 
evident discharge recorded ≤2 days prior to or after the first recorded SJS/TEN diagnosis. 
 Multiple records for differential diagnoses with ≥1 differential diagnosis recorded ≤30 days 
after the first recorded SJS/TEN diagnosis. No additional information for SJS/TEN besides 
the recorded diagnosis. 
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Table 3.1-3: Response rates and information extracted from free text, HES data, and discharge letters. 
 
Available for N 
patients 
Unequivocally 
confirmed/refuted 
diagnoses‡ 
Unequivocally 
confirmed SJS/TEN 
cases┼ 
Unequivocally 
refuted SJS/TEN 
cases┼ 
     
Free text 474 
39 
(4.4%) 
36 
(92.3%) 
3 
(7.7%) 
     
HES data 176 
51 
(29.0%) 
41 
(80.4%) 
10 
(19.6%) 
     
Discharge 
letters 
35 
28 
(80.0%) 
16 
(57.1%) 
12 
(42.9%) 
     
‡Diagnoses from secondary care used to confirm/refute SJS/TEN diagnoses. 
┼Percentages apply to the number of unequivocally confirmed/refuted diagnoses available from each data source. 
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Figure 3.1-1: Patient selection and evaluation process. 
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Table 3.1-4: PPV for SJS/TEN with a secondary care referral on the CPRD before and after expert review. 
 
Sample 
size 
   True diagnoses 
  
PPV 95% CIs 
        
  Confirmed Refuted Total     
SJS/TEN diagnosis with 
secondary care referral 
638 93 25 118  0.79 (0.71-0.86) 
        
Total of patients classified as 
possible/probable cases of 
SJS/TEN  
565 93 14 107 
 
0.87 (0.81-0.93) 
Total of patients classified as 
probable cases of SJS/TEN 
253 45 6 51 
 
0.88 (0.79-0.97) 
Total of patients classified as 
possible cases of SJS/TEN 
312 48 8 56 
 
0.86 (0.77-0.95) 
        
Classified as probable/possible 
according to predefined criteria 
(Table 2) 
333 46 8 54 
 
0.85 (0.76-0.95) 
Classified as probable according to 
predefined criteria (Table 2) 
172 26 4 30  0.87 (0.68-0.98) 
Classified as possible according to 
predefined criteria (Table 2) 
161 20 4 24  0.83 (0.75-0.99) 
        
Classified as probable/possible by 
clinicians 
232 47 6 53  0.89 (0.80-0.97) 
Classified as probable by clinicians 81 19 2 21  0.91 (0.78-1.00) 
Classified as possible by clinicians 151 28 4 32  0.88 (0.76-0.99) 
        
Final study population  551 93 0 93  N/A  
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Table 3.1-5: Response rates for ordered free text, HES data, and discharge letters. 
 Requested for N patients Received for N patients 
   
Free text 959* 
474 
(49.4%) 
   
HES data 176♦ 
176 
(100%) 
   
Discharge letters 50 
35 
(70%) 
   
*FT were ordered for all patients with a recorded SJS/TEN diagnosis and an indication for available free text at 
any time during the study period (indicated in CPRD patient profiles). 
♦HES data was ordered for all patients with a recorded SJS/TEN diagnosis who have a HES linkage (indicated in 
CPRD patient profiles). 
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Table 3.1-6: Comparison of characteristics between confirmed true, unconfirmed positively classified, 
confirmed false, and unconfirmed unlikely classified cases of SJS/TEN. 
 
Confirmed true  
cases of SJS/TEN  
(n=93) 
Unconfirmed cases of 
SJS/TEN classified 
possible/probable  
(n=458*) 
Confirmed false  
cases of SJS/TEN  
(n=25) 
Unconfirmed cases 
of SJS/TEN 
classified  
unlikely (n=62†) 
     
Mean age 
(years) 
34.4 38.2 43.5 34.2 
≤10 years 18.3% 17.7% 16.0% 23.3% 
     
Gender  
(% male) 
55.9% 48.9% 56.0% 42.5% 
     
Year of first recorded SJS/TEN diagnosis   
1995-1999 13 (14.0%) 105 (22.9%) 4 (16.0%) 9 (14.5%) 
2000-2004 32 (34.4%) 108 (23.6%) 9 (36.0%) 26 (41.9%) 
2005-2009 28 (30.1%) 152 (33.2%) 7 (28.0%) 21 (33.9%) 
After 2009 20 (21.5%) 93 (20.3%) 5 (20.0%) 6 (9.8%) 
     
Diagnosis of EM recorded within 2 weeks before or after the first SJS/TEN diagnosis  
Total 3 (3.2%) 20 (4.4%) 4 (16.0%) 7 (11.3%) 
1995-1999 - 5 (4.8%) - 2 (22.2%) 
2000-2004 2 (6.3%) 6 (5.6%) 1 (11.1%) 1 (3.9%) 
2005-2009 1 (3.6%) 8 (5.3%) 1 (14.2%) 3 (14.3%) 
2010 and after - 1 (1.1%) 2 (40.0%) 1 (16.7%) 
     
*N=All 565 patients classified as probable or possible minus 93 confirmed true and 14 confirmed false cases of 
SJS/TEN. 
†N=All 73 patients classified as unlikely minus 11 confirmed false cases of SJS/TEN. 
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3.2.1 Abstract 
SJS/TEN are rare but life-threatening mucocutaneous diseases. SJS/TEN mostly 
manifest as a reaction to new drug use, but little is known about their incidence and 
epidemiology. We conducted a large observational study on the epidemiology of 
SJS/TEN using data from the UK-based CPRD. Among 551 validated SJS/TEN 
patients, we calculated an IR of 5.76 SJS/TEN cases per million py between 1995 and 
2013, which was consistent throughout the study period and was highest in patients aged 
1-10 years and 80 years or older. Within a 1:4 matched case-control analysis, black and 
Asian patients were at a 2-fold risk of SJS/TEN when compared with white patients. 
Among patients with epilepsy and gout, ORs for SJS/TEN were significantly increased 
only in the presence of recent new drug treatment with AEDs or allopurinol, 
respectively. We observed statistically significant associations between SJS/TEN and 
pre-existing depression, lupus erythematosus, recent pneumonia, chronic kidney disease 
(CKD), and active cancer, but confounding by drug use needs to be followed up. This 
large and longitudinal observational study on the epidemiology of SJS/TEN contributes 
to the understanding of this still underinvestigated severe skin disease in a European and 
largely white study population. 
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3.2.2 Introduction 
SJS/TEN are rare but life-threatening mucocutaneous diseases that predominantly occur 
as adverse reactions to newly administered drugs. Several previous observational studies 
identified AEDs, allopurinol, and certain antibiotics (mostly sulphonamide antibiotics) 
as those drugs with the highest risk of SJS/TEN, although other drugs have been 
associated with less evidence (e.g., oxicam analgesics, sertraline [a selective serotonin 
reuptake inhibitor, or SSRI], coxibs).88,89 SJS and TEN manifest with epidermal and 
mucosal necrosis and differ by the proportion of relative skin detachment.83,86 Previously 
reported IRs of SJS/TEN range from 1.4 to 12.7 cases per million py.42,186,195  
Large electronic databases are an important tool in epidemiologic research of rare 
diseases, but evidence on SJS/TEN from large observational databases is scarce. One 
large cross-sectional study investigated the epidemiology of SJS/TEN in the US between 
2009 and 2012, using data from the Nationwide Inpatient Sample, focusing on inpatient 
cost, short-term mortality, and comorbidities.42 The authors observed an overall IR of 
12.7 cases/million py (adults only), which is higher than most previously reported IRs 
for SJS/TEN,42 as well as increased ORs for SJS/TEN in association with non-white 
ethnicity, systemic lupus, epilepsy, cancer (mainly hematologic cancer), infections, and 
renal failure.42 However, the non-longitudinal nature of the data precluded assessment 
of disease temporality and the role of outpatient drug therapies. Another large 
observational study based on insurance claims data from Korea (coverage of 97% of the 
population) calculated an IR of 5.9 SJS/TEN cases/million py between 2010 and 2013.41  
We conducted a large longitudinal observational study to quantify IRs of SJS/TEN in a 
largely white European population (from the UK) using data from the population-based 
CPRD. In a case-control analysis we assessed the association of SJS/TEN with 
demographic and lifestyle factors, as well as with previously associated comorbidities, 
accounting for the temporality of disease occurrence and the role of recently initiated 
drug therapy wherever possible. 
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3.2.3 Patients and Methods 
Data sources 
This study was conducted using data from the CPRD, a large (13.3 million patients) 
primary care database that is representative of the UK population with regard to age and 
sex. Since 1987, participating GPs have recorded patient characteristics, symptoms, 
diagnoses, drug prescriptions, and referrals, including primary diagnoses made in 
secondary care.28 High data quality has repeatedly been demonstrated, and the database 
has been used for numerous epidemiological studies.29 This study was approved by the 
ISAC for Medicines and Healthcare products Regulatory Agency database research 
(ISAC protocol 14_009R). We previously validated diagnoses of SJS/TEN recorded in 
the CPRD that led to secondary care referral between 1995 and 2013. In short, two 
specialized clinicians classified all potential SJS/TEN patients with a recorded 
secondary care referral for which we had recorded clinical information into 
probable/possible or unlikely cases of SJS/TEN. Patients without recorded clinical 
information were classified according to pre-specified criteria. We then compared our 
classification against a representative subgroup of patients for whom we had 
unequivocal diagnoses from secondary care extracted from hospital discharge letters and 
HES data. We established a case population of 551 validated SJS/TEN patients, for 
which we calculated a PPV of 0.87. The validation and composition of our case 
population is described in detail elsewhere.196  
 
Incidence rates  
Incidence rates were calculated by dividing the number of new SJS/ TEN cases by the 
total number of py at risk. Person-years at risk were quantified by adding up person-
time of SJS/TEN free patients in the CPRD (excluding those with non-validated 
SJS/TEN diagnoses) between January 1995 and the end of follow-up, which was the 
earliest of an SJS/TEN diagnosis (with or without subsequent secondary care referral, 
only counting validated cases into the numerator), death, disenrollment, or December 
2013. Person time in the CPRD is representative of the UK population with regard to 
age and sex and reflects the demographic distribution of the population over time (Office 
for National Statistics UK, 2014). We further calculated IRs in categories of sex, age 
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(<1, 1-3, 4-6, 7-9 years, and in decades of age if ≥10 years), year of diagnosis, and 
season (spring ([March-May], summer [June-August], autumn [September-November], 
winter [December-February]).  
We adjusted all IRs for false positive cases by multiplying the numerator by the 
previously calculated PPV (0.87) and for patients erroneously excluded because of a 
non-evident but true hospitalization by multiplying all patients in the numerator who did 
not have recorded HES data by 1.24. Based on such HES data (available for approx. 
30% of CPRD patients), we previously estimated that 24% of patients with a recorded 
SJS/TEN diagnosis in the CPRD and no available HES data were hospitalized, although 
the hospitalization was not recorded. 
 
Case-control study 
For the case-control analysis, we included only those 480 validated SJS/TEN patients 
with at least 180 days of recorded active history in the CPRD before the index date. We 
randomly matched four SJS/ TEN-free control participants to each patient based on year 
of birth, sex, and years of active history in the CPRD.  
 
Demographics, lifestyle factors, and comorbidities 
We captured patients’ age (0-19, 20-39, 40-59, 60-79, and ≥80 years), sex, body mass 
index (12-18.4, 18.5-24.9, 25.0-29.9, and 30.0-60.0 kg/m2, or unknown), smoking status 
(non-smoker, current smoker, ex-smoker, or unknown), alcohol consumption (in units 
per week: none, 1-9, 10-19, ≥20, or unknown), ethnicity (white, black, Asian, mixed, or 
unknown), and records for alcohol or other substance abuse. We further captured 
whether patients had a recorded Read code for the following comorbidities before the 
index date: allergies (hay fever/rhinoconjunctivitis, asthma), autoimmune diseases 
(psoriasis, polymyalgia rheumatica, rheumatoid arthritis), diseases previously 
associated with SJS/TEN (lupus erythematosus, other collagen vascular diseases, 
pneumonia <120 days before the index date, CKD [Read code for CKD or ≥two 
recorded glomerular filtration rate values <60 ml/minute within 365 days, >90 days 
apart], and acute renal disease (last Read code <365 days before the index date). We 
assessed whether patients had previously been diagnosed with cancer and 
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subcategorized them by type of cancer (i.e., hematologic, central nervous system, breast, 
ovarian, bone, prostate, colon, respiratory tract, skin, uterus, pancreatic). We also 
subdivided all cancer patients into those with active cancer (a recorded cancer diagnosis 
or a record for radiotherapy, chemotherapy, or consultation with an oncologist <365 
days before the index date) and those with presumably cured cancer. We further 
captured whether patients had a recorded Read code for diseases that are usually treated 
with one of the drugs associated with increased risk of SJS/TEN (i.e., epilepsy, gout, 
depression, or other affective disorders), and categorized patients into those with or 
without new drug therapy with the suspected drug within 84 days before index date (i.e., 
AEDs [carbamazepine, phenobarbital, phenytoin, lamotrigine, valproate], allopurinol, 
SSRIs). As a negative control, we identified patients who had previously been diagnosed 
with other common diseases not previously associated with SJS/TEN (i.e., chronic 
obstructive pulmonary disease, type 2 diabetes mellitus, hypertension, hyperlipidaemia, 
myocardial infarction).  
 
Statistical analysis  
We conducted conditional logistic regression analyses using SAS 9.4 (SAS Institute, 
Cary, NC) to calculate ORs with 95% CIs for the association between SJS/TEN and 
potential risk factors. 
For all risk factors significantly associated with SJS/TEN (a-level of 0.05, i.e., lupus 
erythematosus, recent pneumonia, CKD, hematologic cancer), we reviewed the 
electronic CPRD patient records to capture patterns of clinical information or specific 
events that may have led to unrecorded drug intake (e.g., hospitalizations) before the 
index date. Small sample size precluded systematic analysis within subgroups of 
comorbidities. Because of confidentiality regulations, however, we are not able to share 
detailed patient information, and we therefore summarized some key findings observed 
during record review in the Results and Discussion sections. 
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3.2.4 Results 
Among 551 previously validated SJS/TEN patients, 50.1% were male, and the mean age 
was 37.5 years. We calculated an overall IR of 5.76 cases/million py (95% CI = 5.31-
6.30), with comparable IRs in men and women. The IRs were highest in children aged 
1-10 years (7.63-8.97 cases/million py) and in elderly patients aged 80 years or older 
(8.75 cases/million py, 95% CI = 6.29-12.17). Although IRs remained stable across the 
entire duration of the study period, we observed higher IRs in winter months (7.21 
cases/million py, 95% CI = 6.18-8.41; Table 3.2-1). 
 
Lifestyle factors 
We did not observe an association between SJS/TEN and smoking status, alcohol 
consumption, or body mass index. Black or Asian patients had 2-fold increased ORs for 
SJS/TEN when compared with white patients, but sample size was small because of 
missing information on race for 59.5% of patients and a largely white study population 
(93.4% of those with known ethnicity, Table 3.2-2). 
 
Comorbidities 
ORs for SJS/TEN were significantly increased in patients with epilepsy and new AED 
treatment for 84 days or fewer before the index date (date of the first recorded SJS/TEN 
diagnosis) (OR = 4.65, 95% CI = 2.67-8.10). The same was true for patients with gout 
and new allopurinol treatment (OR = 20.48, 95% CI = 2.39-175.19). ORs remained 
around unity for patients with either of those diseases in the absence of such new drug 
treatment. In contrast, ORs were increased in patients with depression or other affective 
disorders overall (OR = 1.48, 95% CI = 1.10-1.99) but not in those who initiated 
treatment with SSRIs 84 days or fewer before the index date (OR = 0.88, 95% CI = 0.10-
7.53). We further observed significantly increased ORs for SJS/TEN in association with 
lupus erythematosus (cutaneous or systemic, OR = 16.00, 95% CI = 1.79-143.15), 
pneumonia within 120 days before the index date (OR = 1.80, 95% CI = 1.06-3.04), 
CKD (OR = 2.12, 95% CI = 1.14-3.96), and active cancer (OR = 2.01, 95% CI = 1.27-
3.18). Subcategorization of cancer patients showed that the increased ORs were mainly 
driven by hematologic cancer (Table 3.3-3). 
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3.2.5 Discussion 
In this UK-based observational study, we calculated an overall IR of 5.76 SJS/TEN 
cases/million py in the UK between 1995 and 2013, which is substantially lower than 
the IR of 12.7 SJS/TEN cases/million py among adults reported in a previous US-based 
observational study.42 This discrepancy may be ascribed to greater overall drug use in 
the US compared with the UK.197 A greater proportion of black or Asian patients in the 
US (16.8% reported) compared with the UK (4.9% in our study population) may further 
account for some of the observed difference. Both studies observed a 2-fold increased 
risk of SJS/TEN among black and Asian patients compared with white patients. Genetic 
variations, for instance of the allele HLA-B*1502, may explain the different 
susceptibility to SJS/TEN by ethnicity.142 We recalculated our IRs (among adults only), 
applying the ethnic distribution observed in the US study, and observed an IR of 6.4 
cases/million py. On the other hand, IRs of SJS/TEN from the prior Korea-based 
observational study (5.9 cases/million py, largely Asian patients) were very similar to 
those observed in our study.41 Two hospital-based European observational studies 
previously reported IRs of 1.53 SJS/TEN cases/million py in Germany between 1990 
and 1992,186 and of 1.4 cases/million py in Italy between 2009 and 2014.195 
Methodologic, geographic, and temporal heterogeneity of the previous studies preclude 
an exact comparison with our results. Rigorous clinical case validation was a strength 
of the two hospital-based studies, whereas the strength of our CPRD-based study is that 
SJS/TEN cases and person-time at risk were captured from the same base population. 
This was not possible in hospital-based studies, where person-time at risk was 
extrapolated from national census statistics. Furthermore, with 76 SJS/TEN patients, the 
sample size in the Italian study was small.195  
Incidence rates in our study were increased during winter months, which may be due to 
increased use of antibiotics in winter,198 or to higher rates of viral infections, which has 
previously been discussed as an independent risk factor for SJS/TEN, although based 
on a small body of evidence.42 Although IRs did not vary by sex, we observed slightly 
higher IRs in patients aged 1-10 years and in patients aged 80 years or older, which was 
also reported in the Korean study.41 The higher incidence of epilepsy and subsequent 
new use of AEDs in children and elderly patients may partly explain these 
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observations.199,200 Furthermore, first-time contact with antibiotics or certain viral 
infections is more frequent in early life, whereas polypharmacy may increase 
susceptibility to SJS/TEN among the elderly.201 The IRs in children younger than 1 year 
have to be interpreted cautiously, because person-time was extrapolated from patients 
aged 1 year, because of a 30% proportion of missing person-time in this subgroup. New-
borns likely do not register with a GP until after they are discharged from the care of the 
hospital paediatrician. GPs are generally advised to record such major disease events 
once a patient registers, but we cannot rule out that some SJS/TEN patients may have 
been missed.  
Similar to other previous studies, we did not observe an association between SJS/TEN 
and alcohol consumption, smoking status, or body mass index. We observed increased 
ORs for SJS/TEN among patients with pre-existing gout or epilepsy and those who had 
recent new drug therapy with allopurinol or AEDs (carbamazepine, phenobarbital, 
phenytoin, lamotrigine, valproate), but not in the absence of such new drug treatment. 
These results are consistent with prior findings,88,89 and indicate a rather complete 
capture of drug prescriptions among patients with epilepsy and gout in the CPRD. The 
observed small increase in risk of SJS/TEN in patients with a recorded diagnosis of 
depression or affective disorder was not present in the subset of patients with newly 
initiated SSRI treatment. Sertraline was previously associated with SJS/TEN,89 but it 
was used by one patient out of four who were newly exposed to SSRIs 84 days or fewer 
before the index date among SJS/TEN patients in our study population. Sertraline was 
the fourth most frequently used SSRI in the UK in 2003 after fluoxetine, citalopram, 
and paroxetine,202 and this study is likely underpowered to detect a potential association 
of SJS/TEN with sertraline. The observed association between SJS/TEN and 
depression/affective disorder in the absence of new-onset SSRI treatment may reflect 
confounding by polymorbidity or increased use of certain drugs that have not previously 
been strongly associated with SJS/TEN.  
Patients with a pneumonia diagnosis within 120 days before the index date had an 
increased risk of SJS/TEN, which most likely reflects exposure to antibiotics.88,89 All 
patients with recent pneumonia either had a recorded outpatient prescription for an 
antibiotic or a recorded hospitalization, which likely involved intravenous antibiotic 
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treatment. However, pneumonia might also be associated with SJS/TEN via viral 
infections.42 Furthermore, a previous systematic review including 202 SJS/TEN patients 
with pneumonia suggested that Mycoplasma pneumoniae-associated mucocutaneous 
disease may be misdiagnosed as SJS/TEN in some patients.203  
We observed a 16-fold increased risk of SJS/TEN among patients with lupus 
erythematosus, an association which has been reported repeatedly.204 However, lupus 
erythematosus can manifest with bullous exanthema and epidermal necrosis, and we 
cannot rule out misclassification of SJS/TEN in some patients.205 All SJS/TEN patients 
with lupus erythematosus were female, and 50% of patients initiated therapy with a drug 
known to increase the risk of SJS/TEN within 3 months before the index date 
(carbamazepine, sulphonamide antibiotics). Furthermore, all patients received their first 
lupus diagnosis at least 1 year before the index date and were receiving ongoing oral 
prednisolone treatment, which they had initiated between 5 months and 37 years before 
the index date. Corticosteroids have previously been considered as potential triggers of 
SJS/TEN, but given the previous duration of prednisolone treatment they were likely 
not the cause of SJS/TEN in this subgroup of lupus patients.88,89 No association was 
found between other collagen vascular diseases and SJS/TEN.  
The increased risk of SJS/TEN in patients with CKD was also reported in the US-based 
study.42 A review of patient records from our study population showed that 11 of 17 
SJS/TEN patients with CKD also had a recorded first-time prescription for a high-risk 
drug within 3 months before SJS/TEN diagnosis (allopurinol, coxibs, SSRI, penicillin, 
sulphonamide antibiotic), which suggests that CKD is a proxy for polymorbidity and 
polypharmacy rather than an independent risk factor of SJS/TEN.  
The significantly increased risk of SJS/TEN among patients with active cancer is 
consistent with results from the US-based study and was mainly driven by patients with 
hematologic malignancies in both studies.42 Numerous case reports have suggested 
different chemotherapeutic agents as causes of SJS/TEN,135–137,206–208 but actual 
causation has not been established. Like CKD patients, cancer patients are usually 
exposed to a broad range of drugs, often including AEDs for pain management,209 and 
allopurinol for the prevention of tumor lysis syndrome after a cycle of chemotherapy.210 
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However, in contrast to CKD patients, cancer patients are usually treated at specialized 
oncology clinics and see their GPs less frequently. Electronic record review showed 
little clinical information, except that almost all patients had recorded referrals to 
oncology clinics or hospital stays.  
Despite several strengths of this large population-based observational study, some 
limitations must be considered. First, although we extensively validated our case 
population and adjusted IRs for type 1 error, some misclassification among SJS/TEN 
patients is more likely to be present among our study population than in previous 
hospital-based studies in which researchers had access to more clinical patient records, 
such as the EuroSCAR study.89 Differentiation between EMM and SJS/TEN is difficult, 
and we have to assume that some misclassified EMM patients are included in our study 
population, which may introduce a slight null bias and somewhat overestimated IRs.211 
Second, we observed decreased ORs for SJS/TEN among patients with missing 
information on lifestyle factors. SJS/TEN often occurs in patients who are treated with 
potential culprit drugs for an underlying chronic disease. Patients with chronic diseases 
see a GP more frequently and thus may have a more complete CPRD history 
(information bias). However, we did not observe increased ORs for patients with chronic 
diseases, which have previously not been associated with SJS/TEN (e.g., type 2 diabetes, 
hypertension). This null result among the negative control patients suggests that such 
potential information bias does not play a major role. Third, the CPRD does not record 
over-the-counter or inpatient drug use, such as chemotherapy or inpatient antibiotic use, 
which is why we were not able to assess the role of specific drugs in the observed 
association between SJS/TEN and active cancer or pneumonia. We were also not able 
to assess the association between SJS/TEN and HIV, because HIV is usually treated in 
specialized clinics in the UK. Fourth, we were not in the position to quantify valid IRs 
for SJS and TEN separately because we could not validate the two disease entities 
separately, given that neither the Read code system nor HES data coding include a code 
for SJS/TEN overlap syndrome. Fifth, given the rare occurrence of SJS/TEN, low 
statistical power is an inherent problem of studies analysing risk factors of this disease, 
even when using large data sources such as electronic databases. Therefore, results have 
to be interpreted carefully, within the context of previously published evidence and 
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biologic plausibility, and conclusions should not be drawn from one single study. 
Finally, in-depth analyses of the association between all potentially triggering drugs and 
the risk of SJS/TEN exceed the scope of this epidemiological study and will be followed 
up in future studies. We did not present adjusted ORs because the numbers of exposed 
patients were low in most categories and because of potentially unrecorded confounders 
(ethnicity, inpatient drugs). However, we accounted for potential confounders by 
performing patient record reviews and subgroup stratification wherever possible.  
In summary, in this large population-based observational study, we analysed the 
epidemiology of SJS/TEN in a European and largely white population using a large and 
longitudinal database. Our results confirm that SJS/TEN is a rare disease, with IRs being 
highest in children aged 1-10 years and in patients aged 80 years or older. We further 
observed that black or Asian patients were at increased risk of SJS/TEN and report 
associations between SJS/TEN and epilepsy or gout in the presence of new drug therapy 
with AEDs or allopurinol, respectively. Risk estimates for SJS/TEN were increased 
among patients with depression, lupus erythematosus, recent pneumonia, CKD, or 
active cancer (mainly hematologic malignancies), but the role of acute triggers, such as 
drug exposure, within these associations remains to be followed up. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2-1: Incidence rates of SJS/TEN in the CPRD. 
 
Number of person-years at 
risk 
Number of SJS/TEN 
cases 
Incidence rate* (95% confidence 
interval) 
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Overall 91,128,351 551 5.76 (5.31-6.30) 
By Sex    
Men 43,865,640 277 6.07 (5.38-6.85) 
Women 47,262,711 274 5.51 (4.88-6.22) 
By age    
<1 1,076,385† 5 4.82 (2.04-11.39) 
1-3 3,297,232 27 7.69 (5.21-11.35 
4-6 3,324,133 27 7.63 (5.17-11.26) 
7-9 3,332,842 31 8.97 (6.27-12.84) 
10-19 11,699,687 80 6.66 (5.34-8.32) 
20-29 12,061,859 61 4.82 (3.72-6.23) 
30-39 13,111,956 81 5.87 (4.69-7.34) 
40-49 12,699,991 63 4.65 (3.60-6.00) 
50-59 11,145,453 48 4.18 (3.14-5.57) 
60-69 9,041,774 49 5.25 (3.95-6.97) 
70-79 6,615,097 43 6.00 (4.40-8.20) 
≥80 4,034,375 36 8.75 (6.29-12.17) 
By year of diagnosis   
1995-1999 21,434,665 120 5.41 (4.51-6.49) 
2000-2004 25,726,652 138 5.09 (4.29-6.04) 
2005-2009 26,755,978 182 6.46 (5.57-7.50) 
2010-2013 17,236,298 111 6.21 (5.14-7.50) 
By season    
Spring  23,110,659 138 5.69 (4.80-6.75) 
Summer 23,017,075 140 5.85 (4.95-6.93) 
Autumn 22,514,328 105 4.37 (3.59-5.33) 
Winter 22,486,288 168 7.21 (6.18-8.41) 
*In SJS/TEN cases per million person-years 
†Person-time was extrapolated from patients aged 1 year due to missing values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2-2: Demographics and life-style factors of SJS/TEN cases and controls within the CPRD. 
 
Number of cases (%) 
(n=480) 
Number of controls 
(%) (n=1920) 
OR crude (95% CI) 
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Age (years)       
0-19 146 (30.4) 584 (30.4) NA  
20-39 114 (23.8) 457 (23.8) NA  
40-59 102 (21.3) 402 (21.0) NA  
60-79 87 (18.1) 354 (18.4) NA  
≥80 31 (6.5) 123 (6.4) NA  
Sex        
Male 232 (48.3) 928 (48.3) NA  
Female 248 (51.7) 992 (51.7) NA  
BMI (kg m-2)       
12.0-18.4 10 (2.1) 27 (1.4) 1.43 (0.67-3.06)  
18.5-24.9 114 (23.8) 441 (23.0) 1.00  (reference) 
25.0-29.9 102 (21.3) 390 (20.3) 1.01 (0.74-1.37) 
30.0-60.0 54 (11.3) 233 (12.1) 0.90 (0.62-1.30) 
Unknown 200 (41.7) 829 (43.2) 0.84 (0.58-1.22) 
By ethnicity       
Caucasian 211 (44.0) 697 (36.3) 1.00  (reference) 
Black 9 (1.9) 16 (0.8) 2.20  (0.89-5.44) 
Asian 8 (1.7) 15 (0.8) 2.09 (0.85-5.12) 
Mixed 6 (1.2) 10 (0.5) 2.06 (0.73-5.79) 
Unknown 246 (51.3) 1182 (61.6) 0.49 (0.37-0.65) 
Smoking status       
Non 191 (39.8) 706 (36.8) 1.00 (reference) 
Current 80 (16.7) 292 (15.2) 1.02 (0.75-1.39) 
Ex 67 (14.0) 300 (15.6) 0.83 (0.59–1.15) 
Unknown 142 (29.6) 622 (32.4) 0.66 (0.44–0.98) 
Non-abusive alcohol consumption (units per week)    
None/Ex 111 (23.1) 410 (21.4) 1.00 (reference) 
1-9 115 (24.0) 466 (24.3) 0.99 (0.74-1.34) 
10-19 29 (6.0) 117 (6.1) 1.00 (0.63-1.61) 
≥20 (but no explicit 
record of abuse) 
25 (5.2) 89 (4.6) 1.15 (0.69-1.92) 
Unknown 200 (41.7) 838 (43.7) 0.78 (0.54-1.12) 
Alcoholism or other substance abuse     
No 459 (95.6) 1853 (96.5) 1.00 (ref) 
Yes 21 (4.4) 67 (3.5) 1.29 (0.77-2.17) 
 
 
 
 
 
 
 
 
Table 3.2-3: Comorbidities of SJS/TEN cases and controls in the CPRD. 
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Number of 
cases (%) 
(n=480) 
Number of 
controls (%) 
(n=1920) 
Odds  
ratio 
Diseases previously associated with SJS/TEN  
Lupus erythematosus <5 (<1.0) <5 (<0.3) 16.00 
Other collagen vascular disease 11 (2.3) 25 (1.3) 1.83 
Pneumonia diagnosed <120 days prior <5 (<1.0) <5 (<0.3) 1.80 
Active cancer* 29 (6.0) 61 (3.2) 2.01 
Non-active cancer┼ 79 (16.5) 303 (15.8) 1.12 
Bone cancer <5 (<1.0) <5 (<0.3) 9.66 
Breast cancer 5 (1.0) 27 (1.4) 0.73 
Colon cancer <5 (<1.0) <5 (<0.3) 1.00 
Hematologic cancer 10 (2.1) 5 (0.3) 9.46 
Cancer of the nervous system 5 (1.0) 7 (0.4) 2.86 
Ovarian cancer <5 (<1.0) <5 (<0.3) 9.66 
Prostate cancer <5 (<1.0) 9 (0.5) 0.43 
Cancer of the respiratory tract <5 (<1.0) <5 (<0.3) 2.67 
Skin cancer 7 (1.5) 48 (2.5) 0.53 
Diseases usually treated with high risk drug for SJS/TEN  
Epilepsy 35 (7.3) 47 (2.5) 3.22 
New use of antiepileptic drug ≤84 days 28 (5.8) 26 (1.4) 4.65 
No new use of antiepileptic drug ≤84 days 7 (1.5) 21 (1.1) 1.44 
Gout 20 (4.2) 43 (2.2) 2.08 
New use of allopurinol ≤84 days 5 (1.0) <5 (<0.3) 20.48 
No new use of allopurinol ≤84 days 15 (3.1) 42 (2.2) 1.55 
Depression and other affective disorders 80 (16.7) 240 (12.5) 1.48 
New use of SSRI ≤84 days  <5 (<1.0) 5 (0.3) 0.88 
No new use of SSRI ≤84 days 79 (6.4) 235 (12.2) 1.49 
Allergies      
Hay fever / Allergic rhinoconjunctivitis 77 (16.0) 266 (13.9) 1.21 
Asthma 83 (17.3) 318 (16.6) 1.06 
Autoimmune diseases      
Psoriasis 12 (2.5) 62 (3.2) 0.77 
Polymyalgia rheumatic 6 (1.3) 12 (0.6) 2.11 
Rheumatoid arthritis 7 (1.5) 18 (0.9) 1.59 
Other common diseases      
COPD 9 (1.9) 31 (1.6) 1.18 
Chronic kidney disease 17 (3.5) 35 (1.8) 2.12 
Acute kidney disease (<365 days) <5 (<1.0) <5 (<0.3) 6.00 
Diabetes mellitus type 2 28 (5.8) 83 (4.3) 1.40 
Hypertension 77 (16.0) 294 (15.3) 1.09 
Hyperlipidemia 29 (6.0) 110 (5.0) 1.02 
Myocardial infarction 13 (2.7) 37 (1.9) 1.45 
      
      
 
 
COPD=chronic obstructive pulmonary disease. 
*Last cancer related record <1 year prior 
┼ Last cancer related record ≥1 year prior 
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3.3 The risk of Stevens-Johnson syndrome and toxic epidermal 
necrolysis in new users of antiepileptic drugs (Study 3.3) 
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3.3.1 Abstract 
Objective: Older AEDs are known to cause SJS/TEN. However, evidence for newer 
AED is sparse. We quantified risks of SJS/TEN in association with use of all AEDs in 
the United Kingdom (UK). 
Methods: In a matched case-control study of 480 previously validated SJS/TEN cases 
(1995–2013) we used conditional logistic regression to calculate ORs with 95% CIs, 
and calculated absolute risks of SJS/TEN within separate cohorts of new users of 28 
AEDs. We assessed causality between drugs and SJS/TEN in each exposed case, using 
an adapted version of the ALDEN score. 
Results: We observed a strong association between SJS/TEN and new use of 
carbamazepine (OR 92.57, 95% CI 19.89–∞), phenytoin (OR 49.96, 95% CI 10.13–∞), 
and lamotrigine (OR 26.90, 95% CI 4.88–∞), where causality, according to the ALDEN 
score, was very probable or probable for most exposed cases. Absolute risks for SJS/ 
TEN were highest for phenytoin (45.86 cases/100,000 exposed), lamotrigine (44.17 
cases/100,000 exposed), and carbamazepine (20.38 cases/100,000 exposed). Despite 
increased ORs for valproate (40,941 exposed), gabapentin (116,037 exposed), 
pregabalin (59,967 exposed), and clobazam (4,300 exposed), ALDEN suggested no 
causal association. There were no observed cases of SJS/TEN among new users of 
levetiracetam (n = 9677), clonazepam (n = 18,075), or topiramate (n = 11,307). 
Significance: The results of our study are consistent with those of previous studies of 
SJS/TEN, which found increased risks of SJS/TEN in new use of carbamazepine, 
phenytoin, and lamotrigine. Despite frequent use, no ALDEN-score confirmed cases 
were observed in new users of valproate, gabapentin, pregabalin, levetiracetam, 
topiramate, or clonazepam. 
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3.3.2 Introduction 
SJS/TEN are rare but life-threatening mucocutaneous diseases, characterized by 
epidermal and mucosal necrosis. The two conditions are considered one disease entity, 
which differ by the proportion of BSA affected by skin detachment, with TEN being the 
more severe. SJS/TEN is predominantly an adverse reaction to newly administered 
drugs, and is associated with 1–9% mortality in SJS and 30–50% mortality in TEN.83,86 
In the absence of a generally accepted pharmacotherapy, early identification and 
discontinuation of the culprit drug is a key measure.83,86,194 Two previous relatively large 
(n = 245 and 513 SJS/TEN cases) hospital-based case-control studies identified AEDs 
as the alleged triggers of 25% of all hospitalized SJS/TEN cases.88,89,212 Between 1989 
and 1994, Roujeau et al. and Rzany et al. reported strongly increased ORs for SJS/TEN 
in patients newly exposed (≤56 days) to carbamazepine, phenytoin, or phenobarbital in 
France, Germany, Italy, and Portugal.88,212 The more recently published EuroSCAR 
study conducted by Mockenhaupt et al. (a case-control study based in six European 
countries between 1997 and 2001) confirmed these findings and further observed a 
significantly increased risk of SJS/TEN after new exposure (≤56 days) to lamotrigine, a 
drug that became available between 1993 and 1994.89 An association between SJS/TEN 
and valproate has been reported, but causality remains unconfirmed due to small sample 
size and frequent co-medication with other potentially causal drugs.88,212,213 Case reports 
describe cases of SJS/TEN after exposure to gabapentin, clobazam, and 
zonisamide,106,121,124,214 but evidence on the potential association between SJS/TEN and 
AEDs other than carbamazepine, phenytoin, and phenobarbital is sparse, especially for 
drugs that have become available more recently. 
We analyzed the relative and absolute risk of SJS/TEN in association with new use of 
AED within one of the largest validated SJS/TEN study populations using data from the 
UK-based CPRD.196 
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3.3.3 Patients and Methods 
Data source 
The CPRD is a large (13.3 million patient) anonymized primary care database that is 
representative of the UK population with regard to age and sex. Since 1987, participating 
GPs have recorded information on patient demographics and characteristics, symptoms, 
diagnoses, laboratory test results, and referrals to consultants and secondary care. Drug 
prescriptions are issued electronically by the GP, and the CPRD thus holds a virtually 
complete outpatient drug prescription history.28 The data in the CPRD have been 
repeatedly demonstrated to be of high quality, and have been used for numerous 
epidemiologic studies published in peer-reviewed journals.29 This study was approved 
by the ISAC for MHRA database research (ISAC protocol 14_009R). 
 
Study population 
Case patients 
We previously validated diagnoses of referred SJS/TEN cases recorded in the CPRD 
between 1995 and 2013, where we established a population of 551 validated SJS/TEN 
cases. The PPV for SJS/TEN diagnoses in the CPRD was 0.87. The validation process 
is described in detail elsewhere.196 In short, two specialized clinicians classified all 
potential referred cases of SJS/TEN into probable/possible or unlikely cases according 
to prespecified criteria using available clinical details in the CPRD patient record. We 
then compared our classification against a representative sample of patients for whom 
we had unequivocal diagnoses extracted from hospital discharge letters and HES data. 
Of the validated 551 cases, we included 480 patients who had ≥180 days of recorded 
active history in the CPRD prior to the index date. The index date was defined as the 
date of the first recorded SJS/TEN diagnosis (n = 238), or the date of the first recorded 
SJS/TEN-related symptom where available (e.g., sore throat symptom, rash, pain in eye) 
prior to the first recorded SJS/TEN diagnosis (n = 242). 
 
 
 
Control patients 
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For each case, we randomly identified four control patients with no READ-code for SJS 
or TEN at any time, matched to cases on year of birth, sex, general practice, and years 
of recorded history prior to the index date. The index date for each control was the index 
date of the matched case. Control patients were required to have a recorded GP visit ≤30 
days prior to or after the index date. 
 
Exposure 
We defined drug exposure as a first recorded prescription for an AED ≤84 days prior to 
the index date. We chose ≤84 days rather than ≤56 days (EuroSCAR study),89 because 
the date of the first SJS/TEN record in the CPRD may not reflect the exact date of 
disease onset in every case (potential delay between patient presentation to emergency 
care and notification to the GP). We captured prescriptions for all AEDs that were on 
the market between 1995 and 2013 in the UK (Table 3.3-1).  
 
Statistical analysis 
Case-control 
We conducted conditional logistic regression analyses using SAS statistical software 
version 9.4 (SAS Institute, Cary, NC, U.S.A.), and calculated ORs with 95% CIs. Where 
there were no exposed cases/controls, we used exact methods to estimate the ORs and 
95% CIs.  
Because of the small number of exposed patients in each drug class, we did not perform 
multivariable adjustment, but presented concomitant new use of at least one other high-
risk drug within 84 days before the index date (Table 3.3-2). 
Due to confidentiality regulations, we were not able to report the exact number of 
patients for categories that included fewer than five patients. 
 
ALDEN 
The ALDEN score was developed in 2009 within the scope of the EuroSCAR study to 
assess drug causality for epidermal necrolysis,20 by systematically grading potential 
causality between drug exposure and adverse epidermal necrolysis (very probable, 
probable, possible, unlikely, or very unlikely) in affected patients. Because the score 
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was developed for an inpatient setting, where more clinical information is available than 
in a study based on electronic databases, we assessed an adapted version of the ALDEN 
score for each case exposed to an AED ≤84 days prior to the index date, excluding 
information that is not available in the CPRD (Table 3.3-3). 
 
Cohort studies to quantify absolute risks 
We established 28 individual cohorts of new users of 28 AED. Patients were eligible if 
they had ≥180 days of active history in the CPRD prior to the first prescription, and ≥84 
days of completed follow-up after the recorded first-time prescription in the database to 
allow for quantification of the absolute risk (cumulative incidence) in a population with 
complete follow-up. We excluded patients with any prior recorded diagnosis of 
SJS/TEN. We quantified absolute risks as the number of incident SJS/TEN diagnoses 
during follow-up, divided by the total number of new users of the same drug between 
1995 and 2013. In a sensitivity analysis, we quantified absolute risks of SJS/TEN 
restricted to those exposed cases for which we assessed a very probable or probable 
ALDEN score for the respective drug. 
 
Computer record review to assess reexposure to AED after SJS/TEN 
We reviewed patient records of all SJS/TEN cases after initiation of a high-risk AED 
(significantly associated in the case control analysis) within ≤84 days prior to disease 
onset, to anecdotally capture AED use after the SJS/TEN diagnosis. 
 
3.3.4 Results 
Our case-control study population included 480 SJS/TEN cases and 1,920 controls, of 
whom 51.7% were women. The mean age at the index date was 38.5 years (±25.2). Of 
the 480 cases, 36 (7.5%) evidently started treatment with an AED within ≤84 days prior 
to the index date. 
 
 
 
Case-control study 
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Table 3.3-2 presents the association between new use of AED and incident SJS/TEN in 
the case-control analysis. We observed substantially increased ORs for carbamazepine 
(OR 92.27, 95% CI 16.83–∞), lamotrigine (OR 49.96, 95% CI 10.13–∞), phenytoin (OR 
26.90, 95% CI 4.88–∞), and valproate (OR 10.51, 95% CI 1.25–∞). The ALDEN score 
was very probable or probable for 87.5% of cases newly exposed to carbamazepine, 
88.9% for lamotrigine, and 100% for phenytoin, whereas causality for valproate was 
possible according to ALDEN for all newly exposed cases (Figure 3.3-1; ALDEN score 
for cases newly exposed to an AED ≤84 days prior to the index date), mainly because 
the timing of first exposure was >28 or <5 days before the index date. We observed 
increased ORs for the association between SJS/ TEN and gabapentin (OR 6.35, 95% CI 
1.06–38.22), pregabalin (OR 4.00, 95% CI 0.21–∞), and clobazam (OR 4.00, 95% CI 
0.21–∞; Table 3.3-2), although statistically nonsignificant for pregabalin and clobazam; 
ALDEN-based causality was very unlikely, unlikely, or possible for all cases newly 
exposed to either of these drugs (Figure 3.3-1). This likely non-causality was due mainly 
to concomitant new exposure to other high-risk drugs and to the timing of first-time 
exposure. We did not identify any cases of SJS/TEN in association with new use of 
phenobarbital (Table 3.3-2), or with new use of primidone, ethosuximide, mesuximide, 
clonazepam, rufinamide, eslicarbazepine, oxcarbazepine, vigabatrin, tiagabine, 
sultiame, felbamate, topiramate, zonisamide, stiripentol, lacosamide, retigabine, 
perampanel, or beclamide (Table 3.3-4). 
 
Cohort study 
Within 28 individual cohorts of new AED users, we quantified the highest absolute risk 
of SJS/TEN for phenytoin (cumulative incidence of 45.86 cases/100,000 new users), 
followed by 44.17 cases/100,000 new users of lamotrigine and 20.38 cases/100,000 new 
users of carbamazepine (all cases were very probable or probable according to ALDEN; 
Table 3.3-5). We identified a total of 40,941 new users of valproate, 116,037 new users 
of gabapentin, 59,967 new users of pregabalin, and 4,300 new users of clobazam, which 
resulted in 0.27–4.89 cases/100,000 new users for valproate, gabapentin, and pregabalin. 
However, we only observed cases with very probable or probable (ALDEN scored) for 
phenytoin, lamotrigine and carbamazepine (Table 3.3-5). We did not observe any cases 
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of SJS/TEN among 18,075 new users of clonazepam, 11,307 new users of topiramate, 
or 9,677 new users of levetiracetam. We identified <5,000 new users and no cases of 
SJS/TEN in users of all other AEDs (Table 3.3-6). 
 
3.3.5 Discussion 
The results of this population-based observational study revealed a strong association 
between SJS/TEN and carbamazepine, lamotrigine, and phenytoin, with the highest 
absolute risk among new users of lamotrigine and phenytoin (both approximately 45 
cases/100,000 new users), followed by carbamazepine (20 cases/100,000 new users). 
Despite similar numbers of new users of levetiracetam, topiramate, and clonazepam 
during the study period, we did not identify any cases of SJS/TEN among new users of 
these drugs. Despite increased ORs for valproate, gabapentin, pregabalin, and clobazam, 
cases did not meet the criteria for a causal association defined in ALDEN.  
Two previous well-conducted hospital-based case-control studies reported increased 
risks of SJS/TEN in new users of aromatic AED (phenobarbital, phenytoin, and 
carbamazepine),88,89,212 whereas a strong association between SJS/TEN and new 
lamotrigine use, also an aromatic AED, was reported in only the more recent EuroSCAR 
study, given that the drug has only been available in the UK since 1993.89 Our results 
confirm these substantially increased risks of SJS/TEN among users of carbamazepine, 
phenytoin, and lamotrigine with very probable or probable ALDEN scores. 
Mockenhaupt et al. calculated a higher absolute risk of SJS/TEN in association with new 
use of phenytoin (83 cases/100,000 new users), but slightly lower in association with 
lamotrigine (25 cases/100,000 new users) and carbamazepine (14 cases/100,000 new 
users) when compared to our study.191 However, given the registry nature of the data 
source (Registry of Serious Cutaneous reactions), they had to extrapolate the number of 
new users of AEDs in Germany based on the annual growth of daily doses dispensed, 
whereas in our study, new drug use and SJS/TEN cases were identified from the same 
base population. Exposure to phenobarbital, which was identified previously as one of 
the most common triggers of SJS/TEN, was low in our study (963 new users) due to 
decline in use since the 1980s. Previous evidence of a potential association between 
SJS/TEN and the nonaromatic AED valproate is equivocal. Roujeau et al. reported a 
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strongly increased risk in 10 cases exposed to valproate, but did not assess concomitant 
drug use,88 whereas the EuroSCAR study observed no significant risk for SJS/TEN 
based on two cases newly exposed to valproate.89 We observed a tenfold increased risk 
of SJS/TEN in fewer than five cases newly exposed to valproate, all of whom scored 
only as possible causal cases in ALDEN, mainly due to the timing of the first recorded 
prescription (>56 days prior to the index date). All cases newly exposed to valproate had 
diagnoses of brain tumors recorded shortly before the index date, and were likely treated 
in secondary care, and thus may have received unrecorded drugs or 
procedures/therapies.215 Among AEDs that have not been associated with SJS/TEN in 
previous analytic studies (gabapentin, clobazam, and zonisamide were associated with 
SJS/TEN in case reports),106,121,124,214 we observed increased ORs in new users of 
gabapentin, pregabalin, and clobazam, but ALDEN did not support causal associations. 
We observed <5 cases among a relatively high number of new users of drug gabapentin 
(116,037) and pregabalin (59,967), which were likely used at lower doses for the 
treatment of neuropathic pain in most cases. The ALDEN score for the 5 cases newly 
exposed to pregabalin and gabapentin further suggested no causality based on the timing 
of first exposure (>56 days prior to the index date) in 75%, and a concomitant 
lamotrigine prescription in the remaining 25%. All cases newly exposed to clobazam 
were concomitantly prescribed another high-risk AED, resulting in a “very unlikely” 
causality score in all cases (Table1, Figure 1). 
There were no cases of SJS/TEN among new users of levetiracetam (9,677), topiramate 
(11,307), and clonazepam (18,075) where the number of new users was similar to that 
of phenytoin (10,902) and lamotrigine (18,112). For all other AEDs, we identified 
<3,000 new users during the study period, and thus information on the risk of SJS/TEN 
was limited. 
It remains to be explained why many AEDs are among the most frequently reported 
triggers of SJS/TEN. Carbamazepine, lamotrigine, phenobarbital, and phenytoin are all 
metabolized to arene oxide metabolites, which have been hypothesized to cause these 
adverse reactions.216 Valproate, gabapentin, and pregabalin are neither aromatic nor are 
they metabolized to arene oxides, which may explain a likely non-causal association 
between SJS/TEN and these drugs. 
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Computer record review revealed that cases who were newly exposed to phenytoin prior 
to the index date and who did not die or leave the practice shortly after the SJS/TEN 
diagnosis (60% of exposed cases), were exclusively treated with valproate thereafter. 
Levetiracetam was used to substitute lamotrigine in SJS/TEN survivors (44.4% of all 
exposed cases), whereas valproate, phenytoin, and carbamazepine were each prescribed 
in 11% of exposed cases, of whom none were diagnosed with a second SJS/TEN during 
the available follow-up. Of all SJS/TEN cases newly exposed to carbamazepine, 50% 
did not have a recorded diagnosis for epilepsy or seizure prior to or after the index date, 
and were likely treated for neurologic disorders, such as trigeminal neuralgia. Of the 
50% of carbamazepine users with an epilepsy diagnosis, 37.5% were treated with 
valproate after the SJS/TEN diagnosis, 25% with lamotrigine, and 12.5% with 
phenytoin. Neither of these cases had a second SJS/TEN recorded in their patient records 
after the index date. Thus our results suggest that a number of newer AEDs 
(levetiracetam, topiramate, clonazepam, and so on) are likely a safer alternative for 
antiepileptic therapy in patients with previous SJS/TEN, but further data are required to 
confirm these results. Although an aromatic AED was apparently substituted with a 
different aromatic AED in six cases, we cannot conclude from a retrospective database 
study that such an approach is safe.  
Despite several strengths of this large population-based observational study, some 
limitations must be considered. First, despite extensive validation of our case 
population, some misclassification of SJS/TEN cases cannot be ruled out. 
Misclassification was less likely to occur in the two previous hospital-based case-control 
studies due to the available in-depth clinical information.88,89 In this database study, the 
well-known risk of SJS/TEN risk in association with AED may lead physician to 
overdiagnose SJS/TEN in AED users, which may have led to the inclusion of some 
false-positive cases, and thus to slightly overestimated ORs. However, our results were 
similar to prior results, which provides confidence in the validity of our cases.217 Second, 
the proportion of cases who were recently exposed to AEDs was lower in our study 
(7.5%) than in the two previous studies (both 25%), which may partially be explained 
by the use of different AEDs over time and by the decreasing use of phenobarbital. 
However, it is also possible that we missed some AED exposures, given that over the 
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counter medication, in-hospital medication, and first-time prescriptions that are issued 
by specialists are not captured in the CPRD. In addition to underestimated ORs, this 
limitation could also have affected the assessment of concomitant use of other high-risk 
drugs for ALDEN in some cases. However, in a previous study based in the same study 
population, we observed increased risk of SJS/TEN only among patients with a 
diagnosis of epilepsy as well as a recent new prescription (≤84 days) of an AED, but not 
in epilepsy patients in the absence of such a prescription, suggesting that bias due to 
unobserved AED treatment is low in our study popyulation.217 Third, because ALDEN 
automatically grades causality higher for drugs with previous evidence for an 
association with SJS/TEN, the assessed likelihood for a causal association could 
potentially be underestimated for newer AEDs that have not previously been associated 
with SJS/TEN. However, the criterion of causal attribution (existing evidence on a 
potential association between a drug and SJS/TEN; Table 3) was not the decisive factor 
to classify probability of causality in most of the assessed cases. Finally, due to very low 
numbers of use of oxcarbazepine and eslicarbazepine in the UK, we were not able to 
assess these drugs. Especially oxcarbazepine is extensively used as monotherapy and 
add-on therapy for focal epilepsy in the US and continental Europe, most particularly in 
cases of epilepsy of frontal and temporal origin.218,219 Both compounds have been 
associated with various cutaneous adverse skin reactions.220 
In summary, this population-based case-control study observed associations between 
SJS/TEN and new use of carbamazepine, lamotrigine, and phenytoin, with the highest 
absolute risk among users of phenytoin and lamotrigine. Despite a substantial number 
of users of levetiracetam, clonazepam, and topiramate, we did not identify any cases of 
SJS/TEN exposed to one of these drugs. This provides reassurance that these newer 
AEDs are not strongly associated with SJS/TEN. 
 
 
 
Table 3.3-1: Antiepileptic drugs that were on the market between 1995 and 2013 in the UK. 
Antiepileptic drugs of interest 
    
Carbamazepines Clobazam Levetiracetam Rufinamide 
Lamotrigine Beclamide Mesuximide Stiripentol 
Phenytoin Clonazepam Oxcarbazepine Sultiame 
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Phenobarbital Eslicarbazepine Perampanel Tiagabine 
Valproate Ethosuximide Phenobarbital Topiramate 
Gabapentin Felbamate Primidone Vigabatrin 
Pregabalin Lacosamide Retigabine Zonisamide 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3-2: Relative risk for SJS/TEN in patients with new antiepileptic drug treatment. 
Antiepileptic drug 
Number of 
cases  
(%) (n=480) 
Number of controls  
(%) (n=1920) 
OR crude (95% CI) 
Cases (%) 
exposed to 
HRD 
Previously associated antiepileptics:      
Carbamazepine        
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≤84 days prior to the index date 16 (3.3) 0 (0.0) 92.57 (19.89-∞) 6.3% 
>84 days prior to the index date 16 (3.3) 27 (1.4) 2.72 (1.39-5.30)  
Lamotrigine        
≤84 days prior to the index date 9 (1.9) 0 (0.0) 49.96 (10.13-∞) 9.1% 
>84 days prior to the index date 5 (1.0) 5 (0.3) 4.00 (1.16-13.82)  
Phenytoin        
≤84 days prior to the index 
date 
5 (1.0) 0 (0.0) 26.90 (4.88-∞) 20.0% 
>84 days prior to the index 
date 
7 (1.5) 7 (0.4) 4.36 (1.45-13.07)  
Valproate        
≤84 days prior to the index 
date 
<5 (<1.0) 0 (0.0) 10.61 (1.26-∞) 0.0% 
>84 days prior to the index 
date 
9 (1.9) 21 (1.1) 1.90 (0.86-4.19)  
Phenobarbital        
≤84 days prior to the index 
date 
0 (0.0) 0 (0.0) N/A  0 
>84 days prior to the index 
date 
<5 (<1.0) <5 (<0.3) 2.00 (0.18-22.06)  
Previously not associated antiepileptics:       
Gabapentin        
≤84 days prior to the index date <5 (<1.0) <5 (<0.3) 6.35 (1.06-38.22) 33.3% 
>84 days prior to the index date 7 (1.5) 19 (1.0) 1.61 (0.65-3.98)  
Pregabalin        
≤84 days prior to the index date <5 (<1.0) 0 (0.0) 4.00 (0.21-∞) 0.0% 
>84 days prior to the index date <5 (<1.0) 10 (0.5) 0.40 (0.05-3.13)  
Clobazam        
≤84 days prior to the index date <5 (<1.0) 0 (0.0) 4.00 (0.21-∞) 100% 
>84 days prior to the index date <5 (<1.0) <5 (<0.3) 4.00 (0.56-28.40)  
OR=Odds ratio, CI=confidence interval, HRD=high-risk drugs. 
HRD include: anti-infective sulfonamides, carbamazepine, allopurinol, phenytoin, lamotrigine, phenobarbital, 
nevirapine, and oxicam analgesics. 
Due to confidentiality regulations, we were not able to report the exact number of patients for categories that 
included <5 patients. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3-3: ALDEN score adapted to the information available in the CPRD. 
Criterion Values Rules to apply  
    
Delay from initial drug component 
intake to onset of SJS/TEN (index 
date) 
Suggestive +3 5-28 days -3 to +3 
 Compatible +2 29-56 days  
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 Likely +1 1-4 days  
 Unlikely -1 >56 days  
 Excluded -3 Drug started on or after the onset of 
SJS/TEN 
 
    
    
Drug present in the body on date 
of onset of SJS/TEN (index date)* 
Likely 0 Number of prescribed tablets and dose 
instructions suggest intake of drug up 
until the date of onset of SJS/TEN 
-3 to 0 
 Doubtful -1 Number of prescribed tablets and dose 
instructions suggest intake of drug until 1-
5 days prior the date of onset of SJS/TEN 
 
 Excluded -3 Number of prescribed tablets and dose 
instructions suggest intake of drug until 
>5 days prior the date of onset of 
SJS/TEN 
 
    
    
Rechallenge┼  Positive specific for disease and drug +4 SJS/TEN after use of same drug -2 to +4 
 Positive specific for disease and drug +2 SJS/TEN after use of similar drug╪ or 
other reaction with same drug 
 
 Positive unspecific +1 Other reaction after use of similar drug╪  
 Negative -2 Re-exposure to same drug without any 
reaction 
 
    
    
Dechallenge Neutral 0 Drug stopped -2 to 0 
 Negative -2 Drug continued without harm  
    
    
Type of drug (notoriety)˥ Strongly associated +3 Drug of high-risk according to previous 
case-control studies 
-1 to +3 
 Associated +2 Drug with definite but lower risk 
according to previous case-control studies 
 
 Suspected +1 Previous case reports, ambiguous 
epidemiologic results 
 
 Unknown 0 Drugs with no reports or data from 
epidemiologic studies 
 
 Not suspected -1 No evidence of an association in previous 
epidemiologic studies with sufficient 
number of exposed patients 
 
    
    
Other cause Possible -1 Rank all drugs from highest to lowest 
intermediate score 
If at least one has an intermediate score of 
>3, subtract 1 point from the score of each 
of the other drugs taken by the patient 
(another cause is more likely) 
≤0 
    
* In the original ALDEN score, this criterion is assessed by taking into account the elimination half-life of each 
drug. Because the CPRD data does not allow determining the exact date that a patient was exposed to a tablet 
and because dose instructions are not available for all prescriptions we had to adjust this criterion.  
┼ In the original ALDEN score, potential prechallenge to the suspected drug was also determined. Because we 
only included first-time prescriptions recorded ≤84 days prior to the index to assess potential culprit drugs, we 
did not need to assess potential prechallenge. 
╪ Same ATC code up to the forth level. 
˥ Based on the EuroSCAR study, the case-control study by Roujeau et al., and previously published case reports. 
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Figure 3.3-1: ALDEN score for cases newly exposed to carbamazepine, lamotrigine, phenytoin, valproate, 
gabapentin, pregabalin, clobazam. 
<0, very unlikely; 0-1, unlikely; 2-3, possible; 4-5 probable; >5, very probable. 
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Table 3.3-4: Number of SJS/TEN cases and controls with exposure to other new antiepileptic drug treatments. 
Antiepileptic drug 
Number of cases 
(%) (n=480) 
Number of controls 
(%) (n=1920) 
OR crude (95% CI) 
Cases (%) 
exposed to 
HRD 
No newly exposed cases found:        
Barbiturates        
Primidone        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  0.0% 
>84 days prior to the index date 0 (0.0) <5 (<0.3) 4.00 (0.00-76.00)  
Succinimides        
Ethosuximide        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  0.0% 
>84 days prior to the index date 0 (0.0) <5 (<0.3) 4.00 (0.00-76.00)  
Mesuximide        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  0.0% 
>84 days prior to the index date 0 (0.0) 0 (0.0) N/A   
Benzodiazepines        
Clonazepam        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  0.0% 
>84 days prior to the index date <5 (<1.0) <5 (<0.3) 2.00 (0.37-10.92)  
Carboxamide        
Rufinamide        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  0.0% 
>84 days prior to the index date 0 (0.0) 0 (0.0) N/A   
Eslicarbazepine        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  0.0% 
>84 days prior to the index date 0 (0.0) 0 (0.0) N/A   
Oxcarbazepine        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  0.0% 
>84 days prior to the index date <5 (<1.0) 0 (0.0) 4.00 (0.21-∞)  
Fatty acid derivatives        
Vigabatrine        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  0.0% 
>84 days prior to the index date 0 (0.0) <5 (<0.3) 4.00 (0.00-76.00)  
Tiagabine        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  0.0% 
>84 days prior to the index date <5 (<1.0) 0 (0.0) 4.00 (0.21-∞)  
Other        
Sultiame        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  0.0% 
>84 days prior to the index date 0 (0.0) 0 (0.0) N/A   
Felbamate        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  0.0% 
>84 days prior to the index date 0 (0.0) 0 (0.0) N/A   
Topiramate        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  0.0% 
>84 days prior to the index date <5 (<1.0) <5 (<0.3) 4.00 (0.81-19.82)  
Zonisamide        
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≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  0.0% 
>84 days prior to the index date <5 (<1.0) 0 (0.0) 4.00 (0.21-∞)  
Stiripentol        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  0.0% 
>84 days prior to the index date 0 (0.0) 0 (0.0) N/A   
Lacosamide        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  0.0% 
>84 days prior to the index date 0 (0.0) 0 (0.0) N/A   
Retigabine        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  0.0% 
>84 days prior to the index date 0 (0.0) 0 (0.0) N/A   
Perampanel        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  0.0% 
>84 days prior to the index date 0 (0.0) 0 (0.0) N/A   
Beclamide        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  0.0% 
>84 days prior to the index date 0 (0.0) 0 (0.0) N/A   
OR=Odds ratio, CI=confidence interval, HRD=high-risk drugs. 
HRD include: anti-infective sulfonamides, carbamazepine, allopurinol, phenytoin, lamotrigine, phenobarbital, nevirapine, 
and oxicam analgesics. 
Due to confidentiality regulations, we were not able to report the exact number of patients for categories that included <5 
patients. 
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Table 3.3-5: Cumulative incidences of antiepileptic drugs associated with SJS/TEN. 
Antiepileptic drug 
Nr. of new 
users 
Total number of 
SJS/TEN cases 
Risk per 100'000 new 
users (95% CI) 
Nr. of SJS/TEN 
cases with very 
probable or 
probable causality 
Risk per 100'000 
new users (95% CI) 
Carbamazepines 68696 16 23.29 (14.27-38.02) 14 20.38 (12.07-34.41) 
Lamotrigine 18112 9 49.69 (25.85-95.50) 8 44.17 (22.09-88.32) 
Phenytoin 10902 5 45.86 (19.09-110.19) 5 45.86 (19.09-110.19) 
Phenobarbital 963 0 0 (NA) 0 0 (NA) 
Valproate 40941 <5 4.89 (1.22-19.55) 0 0 (NA) 
Gabapentin 116037 <5 0.27 (0.09-0.84) 0 0 (NA) 
Pregabalin 59967 <5 1.67 (0.24-11.86) 0 0 (NA) 
Clobazam 4300 <5 23.26 (3.28-165.13) 0 0 (NA) 
*Only cases with very probable or probable drug causality according to ALDEN. 
Due to confidentiality regulations, we were not able to report the exact number of patients for categories that 
included <5 patients. 
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Table 3.3-6: Number of users of antiepileptic drugs with no observed cases of SJS/TEN* in this study. 
Antiepileptic drug 
Nr. of new 
users 
Total number of 
SJS/TEN cases 
Risk per 100'000 
new users (95% 
CI) 
Nr. of SJS/TEN 
cases with very 
probable or 
probable causality 
Risk per 100'000 
new users (95% CI) 
Beclamide <5 0 0 (NA) 0 0 (NA) 
Clonazepam 18075 0 0 (NA) 0 0 (NA) 
Eslicarbazepine 66 0 0 (NA) 0 0 (NA) 
Ethosuximide 633 0 0 (NA) 0 0 (NA) 
Felbamate <5 0 0 (NA) 0 0 (NA) 
Lacosamide 650 0 0 (NA) 0 0 (NA) 
Levetiracetam 9677 0 0 (NA) 0 0 (NA) 
Mesuximide <5 0 0 (NA) 0 0 (NA) 
Oxcarbazepine 1105 0 0 (NA) 0 0 (NA) 
Perampanel 40 0 0 (NA) 0 0 (NA) 
Phenobarbital 963 0 0 (NA) 0 0 (NA) 
Primidone 2431 0 0 (NA) 0 0 (NA) 
Retigabine 50 0 0 (NA) 0 0 (NA) 
Rufinamide 79 0 0 (NA) 0 0 (NA) 
Stiripentol 18 0 0 (NA) 0 0 (NA) 
Sultiame 5 0 0 (NA) 0 0 (NA) 
Tiagabine 216 0 0 (NA) 0 0 (NA) 
Topiramate 11307 0 0 (NA) 0 0 (NA) 
Vigabatrin 572 0 0 (NA) 0 0 (NA) 
Zonisamide 800 0 0 (NA) 0 0 (NA) 
*Only cases with very probable or probable drug causality according to ALDEN. 
Due to confidentiality regulations, we were not able to report the exact number of patients for categories that 
included <5 patients. 
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3.4 Antibiotic drug use and the risk of Stevens-Johnson Syndrome and 
Toxic Epidermal Necrolysis (Study 3.4) 
 
A Population-Based Case-Control Study 
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3.4.1 Abstract 
SJS/TEN are rare, life-threatening mucocutaneous ADRs. Sulphonamide antibiotics are 
commonly accepted as one of the primary causes of SJS/TEN. This notion is based on 
results from two hospital-based case-control studies that identified the combined 
antibiotic cotrimoxazole (sulfamethoxazole and trimethoprim) as the cause of several 
SJS/TEN cases. Associations were also reported for penicillins, quinolones, 
cephalosporins, macrolides, tetracyclines, and metronidazole. Using data from the UK-
based CPRD, we conducted a 1:4-matched case-control study including 480 previously 
validated SJS/TEN cases (1995-2013) to quantify the association between SJS/TEN and 
antibiotics. We further quantified absolute risks of SJS/TEN within separate cohorts of 
antibiotic users and assessed causality in each exposed case using an adapted version of 
ALDEN. We observed a strong association between SJS/TEN and trimethoprim alone 
(OR=9.44, 95% CI 3.83-23.25; absolute risk: 0.98 cases/100’000 users), which suggests 
that the previously reported association between cotrimoxazole and SJS/TEN is at least 
partly attributable to the non-sulphonamide antibiotic trimethoprim, which is frequently 
prescribed as a single agent in the UK. Our study further corroborates previously 
reported associations between SJS/TEN and use of penicillins, quinolones, 
cephalosporins, and macrolides. 
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3.4.2 Letter 
Two hospital-based case-control studies found that 9% of cases with SJS/TEN had been 
exposed to sulphonamide antibiotics, of whom 59% and 69% received the combined 
antibiotic cotrimoxazole (trimethoprim/sulfamethoxazole). Other frequent exposures 
included allopurinol and AEDs. Associations were also reported for penicillins, 
quinolones, cephalosporines, tetracyclines, and macrolides.88,89 Metronidazole was 
associated with SJS/TEN in a small case-control study.134  
We conducted a population-based case-control study using data from the UK-based 
CPRD (Table 3.4-3) to quantify the association between antibiotic use and SJS/TEN.28 
The validated study population and detailed methods have been described in detail 
elsewhere.196,217 In short, we identified 480 cases with a validated SJS/TEN diagnosis 
and a secondary care referral between 1995 and 2013, and matched four, randomly 
chosen controls (≥1 visit practice visit recorded ≤30 days before or after the index date) 
to each case on age, sex, general practice, and years of recorded history in the CPRD 
prior to the index date. We calculated ORs and 95% CI for incident SJS/TEN comparing 
users of various antibiotics (Table 1) to non-users of the respective antibiotic. Antibiotic 
use was defined as a first-time recorded prescription ≤84 days before the index date 
(date of SJS/TEN diagnosis or first recorded symptom). We evaluated potential 
causality using the score to assess drug causality for epidermal necrolysis (ALDEN; 
Table 3.4-4),20 in nine cohorts of new antibiotic users to calculate absolute risks of 
SJS/TEN ≤84 days after treatment start.  
We identified 15 cases exposed to trimethoprim alone; OR=9.44 (95% CI 3.83-23.25), 
and no cases exposed to cotrimoxazole or any other sulphonamide antibiotic. Compared 
to trimethoprim (n=1’168’741 users), use of cotrimoxazole (n=11’337) and other 
sulphonamide antibiotics (n=1’655) was low. ORs were also significantly increased for 
penicillins (OR 3.63, 95% CI 2.22-5.94), quinolones (OR 4.34, 95% CI 1.40-13.50), 
cephalosporins (OR 3.73, 95% CI 1.53-9.10), and macrolides (OR 4.83, 95% CI 2.47-
9.47, Table 3.4-1). The proportion of exposed cases with very probable or probable 
ALDEN scores was 73.3% for trimethoprim, 72.7% for penicillins, 83.3% for 
quinolones, 44.4% for cephalosporins (due to timing of exposure [>56 days before the 
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index date] and exposure to other high-risk drugs), 22.2% for macrolides (due to timing 
of exposure [<4 days before the index date] and exposure to other high-risk drugs), and 
0% for tetracyclines (due to timing of exposure [>56 days before the index date] and re-
exposure after SJS/TEN; Figure 3.4-1). Results remained unchanged in a sensitivity 
analysis in which we shifted the index date by two weeks before the index date in the 
absence of recorded prodromal symptoms (Table 3.4-5). 
The absolute risk of SJS/TEN was 0.93 cases/100'000 users of trimethoprim alone or 
cotrimoxazole (accounting for the 11 cases with probable/very probable ALDEN), and 
between 0.28-0.95 cases/100’000 in users of quinolones, penicillins, cephalosporins, 
macrolides, and metronidazole (Table 3.4-2). 
Our results challenge the prevailing assumption that sulphonamide antibiotics are 
predominant triggers of SJS/TEN, and suggest that trimethoprim was at least partly 
responsible for the previously reported association between SJS/TEN and 
cotrimoxazole.88,89 Due to infrequent use, we were not able to evaluate the potential 
contribution of sulfamethoxazole or other sulphonamide antibiotics (e.g. sulfadiazine, 5 
of 13 cases in exposed to other sulphonamides in EuroSCAR). We further did not 
evaluate the non-antibiotic sulphonamide sulfasalazine, for which both previous case-
control studies reported an association with SJS/TEN.88,89 Despite the increased relative 
risk, the absolute risk of SJS/TEN in trimethoprim users was lower than for users of 
aromatic AEDs (20-45 cases/100’000 users) in the same study population.5  
Our results corroborate previously reported associations between SJS/TEN and 
penicillins, cephalosporins, quinolones, and macrolides,88,89 where the absolute risk for 
each antibiotic was comparable to the absolute risk in trimethoprim users. Conversely 
to the EuroSCAR study, which classified 6 of 7 cases exposed to tetracyclines with a 
probable/very probable ALDEN score,20,89 we observed no probable/very probable 
ALDEN scores in cases exposed to tetracyclines despite a large number of users 
(877’889).  
We observed an increased but non-significant OR for SJS/TEN in metronidazole users, 
and a low absolute risk (0.18 cases/100’000 users). Unlike in our study, all 40 cases 
exposed to metronidazole were concomitantly exposed to mebendazole in the previous 
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Taiwanese case-control study.134 Other case-control studies did not report results for 
metronidazole. 
Despite extensive case validation, we cannot rule out that other cutaneous reactions were 
incorrectly diagnosed as SJS/TEN in some cases. However, previously assessed 
associations were consistent with results from hospital-based observational studies with 
less potential for misclassification.88,89,217 Furthermore, given that the CPRD is a 
primary care database, we were not able to evaluate antibiotics that are used in inpatient 
settings. Finally, protopathic bias or confounding by indication may play a role because 
antibiotics may be used to treat prodromal symptoms of SJS/TEN or as infection 
prophylaxis during the treatment of acute disease. To minimize the risk of protopathic 
bias, we defined the index date as the date of the first recorded symptom of SJS/TEN 
wherever possible and assessed ALDEN scores to quantify the likelihood of causality 
of observed associations.20 Results from a sensitivity analysis in which we shifted the 
index date by two weeks before the date of the first recorded SJS/TEN diagnosis in all 
cases without recorded prodromal symptoms were virtually unchanged (Table 3.4-5). 
Further strengths and limitations of our study population and data source have been 
discussed elsewhere.196,217 
In summary, our results suggest that the previously reported association between 
cotrimoxazole and SJS/TEN is at least partly attributable to the non-sulphonamide 
antibiotic trimethoprim, which is frequently given in combination with 
sulfamethoxazole. Our study further corroborates previously reported associations 
between SJS/TEN and penicillins, quinolones, cephalosporins, and macrolides.  
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Table 3.4-1: Relative risk for SJS/TEN in patients with new antibiotic drug treatment. 
Drug exposure 
Number of cases (%)  
(n=480) 
Number of controls (%) 
(n=1920) 
OR crude (95% CI) 
Sulphonamide antibiotics:    
Cotrimoxazol˥ ≤84 days prior to 
the index date 
0 (0.0) 0 (0.0) N/A  
Sulfamethoxazole ≤84 days prior 
to the index date 
0 (0.0) 0 (0.0) N/A  
Non-sulphonamide antibiotics       
Trimethoprim only ≤84 days 
prior to the index date 
15 (3.1) 7 (0.4) 9.44 (3.83-23.25) 
Penicillins* ≤84 days prior to the 
index date 
33 (6.9) 51 (2.7) 3.63 (2.22-5.94) 
Quinolones+ ≤84 days prior to 
the index date 
6 (1.2) 6 (0.3) 4.34 (1.40-13.50) 
Cephalosporins‡ ≤84 days prior 
to the index date 
9 (1.9) 12 (0.6) 3.73 (1.53-9.10) 
Tetracyclines♦ ≤84 days prior to 
the index date 
<5 (<1.0) 10 (0.5) 0.87 (0.19-3.95) 
Macrolides□ ≤84 days prior to the 
index date 
18 (3.8) 18 (0.9) 4.83 (2.47-9.47) 
Metronidazole ≤84 days prior to 
the index date 
<5 (<1.0) <5 (<0.2) 2.98 (0.50-17.93) 
OR=Odds ratio, CI=confidence interval. 
Due to confidentiality regulations, we were not able to report the exact number of patients for categories that 
included <5 patients. 
˥ Sulfamethoxazole + trimethoprim. 
* 16x floxacillin, 9x phenoxymethylpenicillin, 8x amoxicillin. 
+ <5x ciprofloxacin, <5x norfloxacin. 
‡ 7x cephalexin, <5x cephradine, <5x cefadroxil. 
♦ <5x doxycycline, <5x lymecycline. 
□ 12x erythromycin, 6x clarithromycin. 
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Figure 3.4-1: ALDEN score for cases newly exposed to trimethoprim, penicillins, quinolones, cephalosporins, 
tetracyclines, macrolides, and metronidazole. 
<0, very unlikely; 0-1, unlikely; 2-3, possible; 4-5 probable; >5, very probable. 
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Table 3.4-2: Cumulative incidences of SJS/TEN among new users of suspected antibiotic culprit drugs. 
Antibiotic drug 
Number 
of new 
users 
Total number 
of SJS/TEN 
cases 
Risk per 
100'000 new 
users (95% CI) 
Nr. of SJS/TEN 
cases with very 
probable or 
probable causality 
Risk per 100'000 
new users (95% CI) 
All sulphonamide antibiotics 
without trimethoprim 
1’655 0 0 (NA) 0 0 (NA) 
Sulfamethoxazole 0 0 0 (NA) 0 0 (NA) 
All trimethoprim 1’134’395 15 1.32 (0.80-2.19) 11 0.97 (0.54-1.75) 
Cotrimoxazole 11’337 0 0 (NA) 0 0 (NA) 
Trimethoprim only 1’123’041 15 1.34 (0.81-2.22) 11 0.98 (0.54-1.77) 
Penicillins 2’519’811 33 1.31 (0.93-1.84) 24 0.95 (0.64-1.42) 
Quinolones 521’707 6 1.15 (0.52-2.56) 5 0.96 (0.40-2.30) 
Tetracyclines 877’889 <5 0.23 (0.06-0.91) 0 0 (NA) 
Cephalosporins 923’648 9 0.97 (0.51-1.87) <5 0.43 (0.16-1.15) 
Macrolides 1’438’087 18 1.25 (0.79-1.99) <5 0.28 (0.10-0.74) 
Metronidazole 556’422 <5 0.36 (0.09-1.44) <5 0.18 (0.03-1.28) 
CI=Confidence interval. 
Due to confidentiality regulations, we were not able to report the exact number of patients for categories that 
included <5 patients. 
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Table 3.4-3: Brief description of the Clinical Practice Research Datalink. 
Clinical Practice Research Datalink 
The Clinical Practice Research Datalink (CPRD) is an anonymised longitudinal 
primary care database. The data from the CPRD consists of medical patient records 
which are compiled by general practitioners, and covers approximately 13 million 
patients from more than 600 practices in the UK. With more than 4 million active 
patients, approximately 7% of the UK population are included and patients are 
representative of the UK general population in terms of age, sex and ethnicity. The 
CPRD primary care database is a valuable source of health data for research, including 
data on demographics, symptoms, tests, diagnoses, therapies (virtually complete 
outpatient drug prescription history), health-related behaviours and referrals to 
secondary care. For more than 50% of patients, linkage with datasets from secondary 
care, disease-specific cohorts and mortality records are available. The data in the 
CPRD has been repeatedly demonstrated to be of high quality, and has been used for 
numerous epidemiological studies published in peer-reviewed journals. 
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Table 3.4-4: ALDEN score adapted to the information available in the CPRD. 
Criterion Values Rules to apply Point range 
    
Delay from initial drug component 
intake to onset of SJS/TEN (index 
date) 
Suggestive +3 5-28 days -3 to +3 
 Compatible +2 29-56 days  
 Likely +1 1-4 days  
 Unlikely -1 >56 days  
 Excluded -3 Drug started on or after the onset of 
SJS/TEN 
 
    
    
Drug present in the body on date 
of onset of SJS/TEN (index date)* 
Likely 0 Number of prescribed tablets and dose 
instructions suggest intake of drug up 
until the date of onset of SJS/TEN 
-3 to 0 
 Doubtful -1 Number of prescribed tablets and dose 
instructions suggest intake of drug until 1-
5 days prior the date of onset of SJS/TEN 
 
 Excluded -3 Number of prescribed tablets and dose 
instructions suggest intake of drug until 
>5 days prior the date of onset of 
SJS/TEN 
 
    
    
Rechallenge┼  Positive specific for disease and drug +4 SJS/TEN after use of same drug -2 to +4 
 Positive specific for disease and drug +2 SJS/TEN after use of similar drug╪ or 
other reaction with same drug 
 
 Positive unspecific +1 Other reaction after use of similar drug╪  
 Negative -2 Re-exposure to same drug without any 
reaction 
 
    
    
Dechallenge Neutral 0 Drug stopped -2 to 0 
 Negative -2 Drug continued without harm  
    
    
Type of drug (notoriety)˥ Strongly associated +3 Drug of high-risk according to previous 
case-control studies 
-1 to +3 
 Associated +2 Drug with definite but lower risk 
according to previous case-control studies 
 
 Suspected +1 Previous case reports, ambiguous 
epidemiologic results 
 
 Unknown 0 Drugs with no reports or data from 
epidemiologic studies 
 
 Not suspected -1 No evidence of an association in previous 
epidemiologic studies with sufficient 
number of exposed patients 
 
    
    
Other cause Possible -1 Rank all drugs from highest to lowest 
intermediate score 
If at least one has an intermediate score of 
>3, subtract 1 point from the score of each 
of the other drugs taken by the patient 
(another cause is more likely) 
≤0 
    
ALDEN=Algorithm of drug causality for epidermal necrosis. 
* In the original ALDEN score, this criterion is assessed by taking into account the elimination half-life of each 
drug. Because the CPRD data does not allow determining the exact date that a patient was exposed to a tablet 
and because dose instructions are not available for all prescriptions we had to adjust this criterion.  
┼ In the original ALDEN score, potential prechallenge to the suspected drug was also determined. Because we 
only included first-time prescriptions recorded ≤84 days prior to the index to assess potential culprit drugs, we 
did not need to assess potential prechallenge. 
╪ Same ATC code up to the forth level. 
˥ Based on the EuroSCAR study, the case-control study by Roujeau et al., and previously published case reports. 
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Table 3.4-5: Relative risk for SJS/TEN in patients with new antibiotic drug treatment with adjusted index date*. 
Drug exposure 
Number of cases (%)  
(n=480) 
Number of controls (%)  
(n=1920) 
OR crude (95% CI) 
Sulphonamide antibiotics:    
Cotrimoxazol ≤84 days prior to 
the index date 
0 (0.0) 0 (0.0) N/A  
Sulfamethoxazole ≤84 days 
prior to the index date 
0 (0.0) 0 (0.0) N/A  
Non-sulphonamide antibiotics       
Trimethoprim only ≤84 days 
prior to the index date 
11 (2.3) 6 (0.3) 7.94 (2.93-21.53) 
Penicillins ≤84 days prior to the 
index date 
24 (5.00) 48 (2.5) 2.70 (1.57-4.63) 
Quinolones ≤84 days prior to 
the index date 
6 (1.2) 6 (0.3) 4.76 (1.43-15.80) 
Cephalosporins ≤84 days prior 
to the index date 
9 (1.9) 11 (0.6) 4.05 (1.63-10.09) 
Tetracyclines ≤84 days prior to 
the index date 
<5 (<1.0) 10 (0.5) 1.73 (0.54-5.51) 
Macrolides ≤84 days prior to 
the index date 
14 (2.9) 15 (0.8) 4.36 (2.09-9.09) 
Metronidazole ≤84 days prior to 
the index date 
<5 (<1.0) <5 (<0.2) 2.20 (0.40-12.03) 
*The index date was moved to two weeks before the date of the first recorded SJS/TEN diagnosis in all cases without a clear 
indication for disease onset. 
OR=Odds ratio, CI=confidence interval. 
Due to confidentiality regulations, we were not able to report the exact number of patients for categories that included <5 
patients. 
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3.5.1 Abstract 
Background: SJS/TEN have been associated with use of various drugs, but evidence is 
scarce. We studied the association between new use of drugs other than AEDs and 
antibiotics and SJS/TEN. 
Methods: We conducted a matched (1:4) case-control analysis in 480 previously 
validated SJS/TEN cases (1995-2013). We calculated ORs with 95% CI for SJS/TEN in 
new users of drugs compared to non-users. For cases of SJS/TEN diagnosed ≤84 days 
after first use of a drug we assessed causality between drug exposure and SJS/TEN using 
ALDEN. We calculated absolute risks by dividing the number of SJS/TEN cases ≤84 
days after new drug exposure by the total number of new users of the drug. 
Results: There was an association between SJS/TEN and use of allopurinol (OR 24.51, 
95% CI 2.94-204.04) and coxibs (OR 24.19, 95% CI 2.91-200.92). Proton pump 
inhibitors (PPIs), fluoxetine, mirtazapine, and 5-aminosalicylates (sulfasalazine and 
mesalamine) were also associated with an increased risk of SJS/TEN, though with lower 
ORs. Causality was probable in most exposed cases according to ALDEN. Absolute 
risks of SJS/TEN were 1.9-6.0/100'000 users for allopurinol, coxibs, and 5-
aminosalicylates, and 0.2-1.6/100’000 users for the remaining drugs. We found no 
association between SJS/TEN and oxicam analgesics, benzodiazepines, citalopram, 
sertraline, paroxetine, venlafaxine, and phosphodiesterase-5 inhibitors despite >100’000 
new users. 
Conclusions: In this observational study we observed likely associations between 
SJS/TEN and use of allopurinol, coxibs, and 5-aminosalicylates, and potential 
associations for PPIs, fluoxetine, and mirtazapine. 
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3.5.2 Introduction 
SJS/TEN are rare muco-cutaneous ADRs with a previously reported mortality of 1-9% 
for SJS and 30-50% for TEN. In the absence of effective pharmacotherapy, 
identification and early discontinuation of the culprit drug is crucial.83,86,194 Various 
AEDs, sulphonamide antibiotics, allopurinol, antiretroviral drugs, and oxicam 
analgesics have repeatedly been identified as key triggers of SJS/TEN.88,89 Reports of 
potential associations between SJS/TEN and a variety of other drugs are abundant, albeit 
based on little evidence. Hospital-based case-control studies reported an association 
between SJS/TEN and new exposure to the SSRI sertraline and to the proton pump 
inhibitor (PPI) pantoprazole.88,89 Case reports further anecdotally linked numerous other 
drugs to SJS/TEN, such as other SSRIs and PPIs, atypical antidepressants, 
benzodiazepines, and coxibs.91,93,96–102,104,109–112,114–116,133 Additionally, official drug 
product labels and national formularies (e.g. British National Formulary) list SJS/TEN 
as a potential adverse reaction to a variety of other drugs such as sildenafil 
(phosphodiesterase-5 [PDE5] inhibitor), duloxetine, atorvastatin, or ACE-
inhibitors.87,221  
We conducted a case-control study using data from the CPRD to analyse the association 
between SJS/TEN and a variety of allegedly associated drugs as well as a selection of 
not previously associated but commonly used drugs. The association between AEDs or 
anti-infective drugs and SJS/TEN has been evaluated in separate studies.5,222  
 
3.5.3 Patients and Methods 
Data source 
The CPRD is a large (13.3 million patients) anonymized primary care database that is 
representative of the UK population in terms of age and sex. Since 1987 participating 
GPs have recorded patient demographics and characteristics, symptoms, diagnoses, 
laboratory test results, and referrals to secondary or tertiary care. Drug prescriptions by 
the GP are issued electronically; thus, the CPRD holds a virtually complete outpatient 
drug prescription history.28 High quality of CPRD data has been repeatedly 
demonstrated, and the database has been used for numerous epidemiological studies 
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published in peer-reviewed journals.29 This study (including the use of HES data for the 
validation of the case population) was approved by the ISAC for MHRA database 
research (ISAC protocol 14_009R). 
 
Study population 
Case patients 
We previously validated all SJS/TEN diagnoses recorded in the CPRD that led to 
secondary care referral between 1995 and 2013.196 In short, two specialised clinicians 
classified all potential SJS/TEN cases with a recorded secondary care referral based on 
all available clinical information into probable/possible or unlikely cases of SJS/TEN. 
Patients without or little available clinical information were classified according to pre-
specified criteria. We then compared our classification against a representative sub-
group of patients for whom we had unequivocal diagnoses from secondary care 
extracted from hospital discharge letters and HES data. We established a case population 
of 551 validated SJS/TEN cases with a PPV of 0.87. The validation of our case 
population is described in detail elsewhere.196  
Of those 551 patients, we included 480 patients with ≥180 days of recorded active 
history in the CPRD prior to the ‘index date’. We defined the index date as the date of 
the first recorded SJS/TEN diagnosis (n=238), or the date of the first recorded SJS/TEN-
related symptom, wherever available (e.g. sore throat, painful eyes) prior to the first 
recorded SJS/TEN diagnosis (n=242). 
Control patients 
For each case, we randomly identified four control patients with no recorded diagnosis 
of SJS/TEN at any time. We matched control patients to cases on age, sex, general 
practice and years of recorded history prior to the index date. The index date for each 
control patient was the date of the first recorded SJS/TEN diagnosis of the matched case. 
Control patients were required to have a recorded GP visit ≤30 days prior to or after the 
index date to ensure active patient status. 
 
Exposure 
SJS/TEN project  Study 3.5 
112 
 
We defined drug exposure as a first-time recorded prescription of a drug listed in Table 
3.5-4 ≤84 days prior to the index date. The CPRD only rarely captures over the counter 
(OTC) drugs, and drugs prescribed in an inpatient setting or secondary care. Thus we 
did not assess potential associations for acetaminophen, ibuprofen, or diclofenac (typical 
OTC drugs), or various antineoplastic agents and intravenous corticosteroids (only 
administered in secondary care) despite previous reports of potential associations with 
SJS/TEN.89,135–137 We chose to evaluate drugs  prescribed ≤84 days prior to the recording 
of a SJS/TEN event rather than ≤56 days (EuroSCAR study),89 because the recoding of 
the SJS/TEN diagnoses may have been delayed if patients initially presented for 
emergency secondary care.  
 
Statistical analysis 
Case-control study 
We conducted conditional logistic regression analyses using SAS 9.4 (SAS Institute, 
Cary, NC, USA), to calculate ORs with 95% CIs to assess the association between 
various drugs and SJS/TEN. Where there was no exposed case or no exposed control 
for a given exposure, we used exact methods to estimate the ORs and 95% CIs. 
Given the small number of exposed patients per drug, we were not able to adjust our 
models for concomitant drug use. Instead, we reported the percentage of exposed cases 
who started therapy with another high risk drug ≤84 days before the index date for each 
drug (Table 3.5-1, anti-infective sulphonamides, carbamazepine, allopurinol, phenytoin, 
lamotrigine, phenobarbital, nevirapine, and oxicam analgesics). Due to confidentiality 
regulations, we were not able to report the exact number of patients for cells with <5 
patients.  
ALDEN 
A score to assess drug causality for epidermal necrolysis (ALDEN) was developed in 
2009,20 to systematically grade potential causality between drug exposure and SJS/TEN. 
The ALDEN score was developed for an inpatient setting where a lot of clinical 
information is available, rather than for studying data in electronic databases. We thus 
used an adapted version of ALDEN, excluding information that is not available in the 
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CPRD (Table 3.5-5) for each case who was considered exposed to a study drug. We 
plotted the proportion of cases by their likelihood of causality for each drug (Figure 3.5-
1).  
Cohorts to calculate absolute risk of SJS/TEN in new drug users 
We established 32 cohorts of new study drug users listed in Table 3.5-4. Patients with a 
first prescription for a drug of interest between January 1995 and December 2013 were 
eligible if they had ≥180 days of prior active history in the CPRD and ≥84 days of 
completed follow up after the recorded first prescription to ensure complete follow-up. 
We excluded patients with a previous diagnosis of SJS/TEN (with or without secondary 
care referral). We quantified the absolute risk of SJS/TEN as the number of incident 
diagnoses during follow up (only cases with a very probable/probable ALDEN), divided 
by the total number of patients who initiated therapy with the drug of interest. In a 
sensitivity analysis, we quantified absolute risks of SJS/TEN in all cases irrespective of 
ALDEN. 
 
3.5.4 Results 
Study population 
Among 480 SJS/TEN cases and 1,920 controls, 51.7% were women, and the mean age 
at the index date was 38.5 years (±25.2).  
Highly suspected drugs 
We observed 6 cases (1.3%) and <5 controls who were newly exposed to allopurinol, 
which resulted in an OR of 24.51 (95% CI 2.94-204.04). The ALDEN-based causality 
was probable in 66.7% of cases. We further observed an increased OR of SJS/TEN in 
association with new use of the sulphonamide sulfasalazine (OR 4.00, 95% CI 0.21-∞), 
based on <5 newly exposed cases, all of whom had a probable ALDEN score. Use of 
oxicam analgesics yielded an OR of 4.00 (95% CI 0.25-63.95; <5 exposed cases Table 
3.5-1), although all cases had very unlikely ALDEN scores (Figure 3.5-1). 
 
Coxibs 
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Use of coxibs yielded an OR of 24.19 (95% CI 2.91-200.92; Table 3.5-1) based on <5 
exposed cases of whom 80% had probable/very probable ALDEN scores. Cases were 
exposed to rofecoxib, celecoxib, or etoricoxib (Figure 3.5-1).  
 
Proton pump inhibitors 
We observed increased ORs for omeprazole (OR 5.85, 95% CI 2.07-16.56; 9 cases), 
lansoprazole (OR 3.66, 95% CI 0.98-13.72; <5 cases), and rabeprazole (OR 9.66, 95% 
CI 0.21-∞; <5 cases; Table 3.5-1), with probable ALDEN scores in 20%, 50%, and 
100% of cases, respectively (Figure 3.5-1). Due to small sample size, we were not able 
to assess the association between SJS/TEN and new use of pantoprazole (Table 3.5-6).  
 
Antidepressants and benzodiazepines 
Fluoxetine showed a slight association with SJS/TEN; OR of 1.36 (95% CI 0.28-6.75; 
<5 cases; Table 3.5-1) where 50% had a probable ALDEN score (Figure 3.5-1). There 
were fewer users of other antidepressants and thus few exposed cases. There were no 
very probable/probable ALDEN scored cases among citalopram exposed patients (<5 
unlikely cases; mainly due to timing of use), and no cases exposed to sertraline, 
paroxetine, or duloxetine. Among other antidepressants, we observed <5 mirtazapine 
exposed cases (OR 4.00, 95% CI 0.56-28.40; 100% probable ALDEN score), and <5 
venlafaxine exposed cases, all with ALDEN scores of unlikely or very unlikely. Finally 
there were <5 cases exposed to a benzodiazepines all of whom were concomitantly 
exposed to a high-risk drug; Table 3.5-6, Figure 3.5-2). 
 
Other previously associated drugs 
We identified <5 cases newly exposed to mesalamine (OR 4.00, 95% CI 0.25-63.95), 
all of whom had a probable ALDEN score. Alendronate was associated with an 
increased OR of 15.39 (95% CI 2.33-∞) based on <5 cases, with a probable ALDEN 
score in only 33.3% of the exposed cases. We observed some cases who were newly 
exposed to dipyridamole and tranexamic acid, but ALDEN suggested no causal 
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association in all cases (mainly concomitant exposure to other high-risk drugs; Table 
3.5-6, Figure 3.5-2).  
 
Commonly used drugs 
We did not observe an association between SJS/TEN and new use of statins, beta 
blockers, calcium channel blockers (dihydropyridines, phenylalkylamines, and 
benzothiazepines separately), ACE inhibitors, angiotensin receptor blockers, 
metformin, sulfonylurea, or oral contraceptives (Table 2). Different diuretics yielded 
statistically significantly increased ORs but ALDEN suggested unlikely or very unlikely 
causality for all associations, mainly due to concomitant exposure to other high-risk 
drugs or treatment start <4 days or >56 days prior to SJS/TEN; furosemide (OR 5.46, 
95% CI 1.46-20.43, n=5 cases), bendroflumethiazide (OR 8.00, 95% CI 1.46-43.70, n<5 
cases), and spironolactone (OR 6.21, 95% CI 1.04-37.22, n<5 cases; Figure 3.5-2 and 
Table 3.5-2).  
 
Absolute risks 
Allopurinol yielded the highest absolute risk of SJS/TEN, with 6.0 cases/100'000 new 
users (n=5 cases [only including cases with very probable/probable ALDEN scores]), 
followed by sulfasalazine (4.3 cases/100’000 new users; n=<5 cases) and mesalamine 
(3.8 cases/100’000 new users; n=<5 cases). All other drugs with ≥1 exposed case with 
a very probable/probable ALDEN score conferred lower absolute risks between 0.2-
1.9/100’000 new users (Table 3.5-3). We observed no cases or unlikely/very unlikely 
ALDEN scores among 153’172 new users of oxicam analgesics, 197’911 new users of 
sertraline, 181’962 new users of paroxetine, 113’977 new users of venlafaxine, 560’777 
new users of citalopram, 934’941 new users of benzodiazepines, 149’344 new users of 
tranexamic acid, and 200’523 new users of PDE5 inhibitors. We identified <100’000 
new users and no cases among users of all other evaluated drugs (Table 3.5-7). 
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3.5.5 Discussion 
The results of this study corroborate the previously established association between 
allopurinol and SJS/TEN, with an absolute risk of 6 cases/100’000 new users.88,89 
Among all other evaluated drugs, mesalamine and sulfasalazine conferred the highest 
absolute risks of SJS/TEN, with approximately 4 cases/100’000 new users, whereas 
oxicam analgesics (mainly meloxicam and piroxicam) were not associated with 
SJS/TEN. 
Several previous studies reported a strong association between new allopurinol use and 
SJS/TEN but provided no information on absolute risks. We estimated an absolute risk 
of 6 cases/100’000 new allopurinol users, which is higher than for most other culprit 
drugs of SJS/TEN (e.g.: 1 case/100’000 trimethoprim users),222 but much lower than for 
aromatic AEDs (20-46 cases/100’000 new users).5 In our study population, 1.3% of 
SJS/TEN cases were newly exposed to allopurinol, whereas previous hospital-based 
case-control studies reported allopurinol as alleged trigger of SJS/TEN in 15-20% of 
cases.89,223 Bias by unrecorded allopurinol use in gout patients does not explain the low 
exposure in our study, since gout diagnoses were not associated with SJS/TEN in the 
absence of a new prescription for allopurinol in our study population.217 However, 
allopurinol is frequently used at higher doses in cancer therapy, and is usually applied 
at specialized outpatient oncology-facilities in the UK, and these exposures are not 
captured by the CPRD.210 It is thus possible that a large proportion of previously 
observed cases were treated with allopurinol for other indications and at doses higher 
than those used for gout-attack prevention. However, none of the previous studies 
reported the underlying indication of allopurinol treatment.88,89  
Previous hospital-based case-control studies identified strong associations between new 
use of oxicam analgesics (meloxicam, piroxicam and tenoxicam) and SJS/TEN.88,89 We 
observed <5 cases (all exposed to meloxicam) who were diagnosed with SJS/TEN 
among >150’000 oxicam initiators (piroxicam, meloxicam, and tenoxicam), all of whom 
had a very unlikely ALDEN score which, by definition, rules out a causal association 
with 99% probability. It is possible that use of oxicam analgesics is not captured 
completely in the CPRD, since these drugs are mainly used for the treatment of 
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rheumatic diseases and may be prescribed in secondary care. However, even if previous 
associations were causal, our results suggest that the absolute risk of SJS/TEN for 
oxicam analgesics is low.  
Interestingly, both 5-aminosalicylates (sulfasalazine and mesalamine) were associated 
with a relatively high absolute risk (4 SJS/TEN cases/100’000 new users). Previous 
evidence on these drugs is scarce; sulfasalazine was evaluated in a case-control study, 
albeit in one drug class together with sulphonamide antibiotics, whereas mesalamine 
was only associated with SJS/TEN in a case report.88,89 However, given the relatively 
small number of new users (23’195 for sulfasalazine, 26’496 for mesalamine), our 
results will have to be followed up in further research.  
We observed a 24-fold increased risk of SJS/TEN in association with new exposure to 
coxibs (rofecoxib, celecoxib, and etoricoxib). The first coxibs (celecoxib and rofecoxib) 
were introduced to the European market in 2001, after the previous observational studies 
on SJS/TEN were initiated.88,89 However, a US-based case series reported 63 cases of 
SJS/TEN after exposure to valdecoxib, celecoxib, and rofecoxib in 2005.91 The absolute 
risk of SJS/TEN in new users of coxibs (1.9 cases/100’000 new users) is similar to the 
risk observed for trimethoprim,222 but much lower than the absolute risk for SJS/TEN in 
association with aromatic AEDs or allopurinol.5  
Unlike the EuroSCAR study,20,89 we did not observe an association between sertraline 
and SJS/TEN. Despite high numbers of new users of SSRIs (n=197’911 for sertraline, 
n=560’777 for citalopram, n=181’962 for paroxetine), we only observed likely-causal 
SJS/TEN cases for new exposure with fluoxetine (0.24 cases/100’000 new users, 
n=425’732 new users). On the other hand, we report for the first time a slightly increased 
absolute risk of SJS/TEN of 1.5 cases/100’000 new users of mirtazapine, an association 
which has not been evaluated before and which will have to be followed up.  
The EuroSCAR study reported a substantially increased risk of SJS/TEN among new 
users of pantoprazole.89 We observed associations between omeprazole, lansoprazole, 
and rabeprazole and SJS/TEN, but found no cases exposed to pantoprazole. It should be 
noted however, that there were only 59’431 new pantoprazole users in these data, fewer 
than other PPIs (n=78’621-925’125). PPIs are associated with polypharmacy,224 and 
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confounding by indication may also have played a role since PPIs may be used during 
acute SJS/TEN patients to prevent stress ulcers.172 Absolute risks of SJS/TEN were 
similar for all PPIs and ranged between 0.60-1.27 cases/100’000 new users. 
Although case reports suggested an association between benzodiazepines and 
SJS/TEN,96,121,225 we did not see such an association, which is consistent with previously 
reported null-results from large hospital-based case-control studies.88,89  
Despite high numbers of new users (>100’000) and case reports hypothesizing an 
association with SJS/TEN,101,115,221 we did not observe any likely causal SJS/TEN cases 
among new users of venlafaxine, tranexamic acid, or PDE5 inhibitors. 
Finally, we did not find evidence for an association between new use of metformin, 
sulfonylurea, statins, ACE inhibitors, angiotensin receptor blockers, beta-blockers, 
calcium-channel blockers, or contraceptives and SJS /TEN. There is a suggestion of an 
increased risk of SJS/TEN in users of diuretics (i.e. furosemide, bendroflumethiazide, 
and potassium-sparing diuretics) but all potential cases were considered unlikely 
according to ALDEN. Chronic kidney disease has been associated with SJS/TEN in 
previous studies,42,217 which could explain the finding with diuretics and could be biased 
by polypharmacy and polymorbidity in these patients.  
Despite the strengths of this study, some limitations need to be considered. First, we had 
less clinical information available to validate SJS/TEN diagnoses than previous 
hospital-based case-control studies such as the EuroSCAR.89 Thus, despite extensive 
outcome validation, misclassification might have led to some diminished risk estimates. 
Second, physicians might be more likely to diagnose SJS/TEN if patients are exposed 
to drugs which have previously been associated with SJS/TEN; this may have led to 
some overestimation of relative risks. Furthermore, we were not able to assess the 
association between nevirapine and SJS/TEN, because HIV patients are treated in 
specialized clinics in the UK; the same holds true for other drugs administered in 
secondary care or in specialised clinics (e.g. chemotherapy drugs) or typical OTC drugs 
(e.g. ibuprofen). This likely explains why we were only able to identify a likely culprit 
drug in approximately 25% of SJS/TEN cases, whereas previous hospital-based 
observational studies were able to identify a likely drug cause in 65% of SJS/TEN 
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patients.226 Use of unrecorded OTC-NSAIDs might be more likely in patients using 
coxibs, which could have led to biased risk estimates in these patients. Third, because 
ALDEN automatically grades causality higher for drugs with previous evidence for an 
association with SJS/TEN, the assessed likelihood for a causal association could 
potentially be underestimated for drugs that have not previously been associated with 
SJS/TEN.20  
Despite these limitations, this retrospective study found an increased risk of SJS/TEN 
in new allopurinol users. The absolute risk was lower than those of high-risk AEDs.88,89 
5-aminosalicylates (sulfasalazine and mesalamine) and coxibs further conferred 
increased risks of SJS/TEN. On the other hand, previously associated oxicam analgesics 
were not associated with an increased risk of SJS/TEN, and neither were commonly 
used drugs such as non-insulin antidiabetics, various antihypertensive drugs, statins, and 
contraceptives.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.5-1: Relative risk for SJS/TEN in association with suspected culprit drugs. 
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Drug exposure 
Number of cases  
(%) (n=480) 
Number of controls  
(%) (n=1920) 
OR crude (95% CI) 
Cases (%) 
exposed 
to HSD 
Highly suspected drugs:     
Allopurinol        
≤84 days prior to the index date 6 (1.3) <5 (<0.2) 24.51 (2.94-204.04) 0 
>84 days prior to the index date 11 (2.3) 28 (1.5) 1.61 (0.78-3.28)  
Oxicam derivatives        
≤84 days prior to the index date <5 (<1.0) <5 (<0.2) 4.00 (0.25-63.95) 100% 
>84 days prior to the index date 12 (2.5) 51 (2.7) 0.95 (0.48-1.90)  
Sulfasalazine        
≤84 days prior to the index date <5 (<1.0) 0 (0.0) 4.00 (0.21-∞) 0 
>84 days prior to the index date 6 (1.2) 16 (0.8) 1.55 (0.58-4.15)  
Drugs with some evidence for an association previous observational studies:    
SSRI        
Sertraline        
≤84 days prior to the index date 0 (0.0) <5 (<0.2) 4.00 (0.00-76.00) N/A 
>84 days prior to the index date 17 (3.5) 49 (2.6) 1.42 (0.80-2.51)  
Association suggested in case reports:       
COX-2 inhibitors        
All        
≤84 days prior to the index date †6 (1.3) <5 (<0.2) 24.19 (2.91-200.92) 16.7% 
>84 days prior to the index date 21 (4.4) 72 (3.8) 1.22 (0.72-2.07)  
SSRI        
Fluoxetine        
≤84 days prior to the index date <5 (<1.0) 6 (0.3) 1.36 (0.28-6.75) 0 
>84 days prior to the index date 41 (8.5) 103 (5.4) 1.78 (1.18-2.67)  
Other antidepressants        
Mirtazapine        
≤84 days prior to the index date <5 (<1.0) <5 (<0.2) 4.00 (0.56-28.40) 0 
>84 days prior to the index date 6 (1.3) 14 (0.7) 1.74 (0.66-4.61)  
PPI        
All        
≤84 days prior to the index date ♦14 (2.9) 13 (0.7) 5.07 (2.32-11.04) 7.1% 
>84 days prior to the index date 91 (19.0) 263 (13.7) 1.70 (1.26-2.30)  
Other        
Mesalamine/Mesalazine        
≤84 days prior to the index date <5 (<1.0) <5 (<0.2) 4.00 (0.25-63.95) 0 
>84 days prior to the index date <5 (<1.0) 17 (0.9) 0.47 (0.11-2.04)  
Alendronate        
≤84 days prior to the index date <5 (<1.0) 0 (0.0) 15.39 (2.33-∞) 0 
>84 days prior to the index date 5 (1.0) 27 (1.4) 0.71 (0.26-1.96)  
OR=Odds ratio, CI=confidence interval, HSD=high suspected drugs. 
†Rofecoxib (2x), Celecoxib (3x), Etoricoxib (1x) 
♦Omeprazole (9x), Lansoprazole (4x), Rabeprazole (1x) 
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Figure 3.5-1: ALDEN score for SJS/TEN cases newly exposed to suspected culprit drugs. 
<0, very unlikely; 0-1, unlikely; 2-3, possible; 4-5 probable; >5, very probable. 
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Table 3.5-2: Relative risk for SJS/TEN in association with drugs of common use. 
Drug exposure 
Number of 
cases  
(%) (n=480) 
Number of controls  
(%) (n=1920) 
OR crude (95% CI) 
Cases (%) 
exposed to 
HSD 
Drugs of common use:        
Antidiabetics        
Metformin        
≤84 days prior to the index date 0 (0.0) <5 (<0.2) <1.82 (0.00-15.26) 0 
>84 days prior to the index date 20 (4.2) 45 (2.3) 1.89 (1.08-3.31)  
Sulfonylurea        
≤84 days prior to the index date 0 (0.0) 0 (0.0) NA  0 
>84 days prior to the index date 21 (4.4) 44 (2.3) 1.97 (1.15-3.37)  
Oral contraceptives        
All        
≤84 days prior to the index date <5 (<1.0) <5 (<0.2) 1.08 (0.12-9.75) 0 
>84 days prior to the index date 66 (13.8) 244 (12.7) 1.24 (0.79-1.96)  
Calcium-channel blockers        
Dihydropyridine        
≤84 days prior to the index date <5 (<1.0) <5 (<0.2) 1.31 (0.14-12.64) 0 
>84 days prior to the index date 34 (7.1) 145 (7.6) 0.92 (0.60-1.41)  
Benzothiazepine        
≤84 days prior to the index date <5 (<1.0) <5 (<0.2) 4.00 (0.25-63.95) 0 
>84 days prior to the index date 10 (2.1) 29 (1.5) 1.43 (0.67-3.06)  
Phenalkylamine        
≤84 days prior to the index date <5 (<1.0) 0 (0.0) >3.73 (0.20-∞) 0 
>84 days prior to the index date <5 (0.4) 11 (0.6) 0.80 (0.18-3.65)  
ACE inhibitors        
All        
≤84 days prior to the index date <5 (<1.0) <5 (<0.2) 2.70 (0.45-16.18) 1 (50.0%) 
>84 days prior to the index date 55 (11.5) 187 (9.7) 1.28 (0.88-1.86)  
B-blockers        
All        
≤84 days prior to the index date <5 (<1.0) 6 (0.3) 2.16 (0.50-9.24) 0 
>84 days prior to the index date 65 (13.5) 249 (13.0) 1.07 (0.78-1.48)  
ARBs        
All        
≤84 days prior to the index date <5 (0.2) 0 (0.0) >4.00 (0.21-∞) 0 
>84 days prior to the index date 17 (3.5) 44 (2.1) 1.64 (0.90-2.99)  
Loop diuretics        
Furosemide        
≤84 days prior to the index date 5 (1.0) <5 (<0.2) 5.46 (1.46-20.43) 0 
>84 days prior to the index date 36 (7.5) 100 (5.2) 1.69 (1.07-2.65)  
Thiazide diuretics        
Bendroflumethiazide        
≤84 days prior to the index date <5 (<1.0) <5 (<0.2) 8.00 (1.46-43.70) 2 (50.0%) 
>84 days prior to the index date 41 (8.5) 166 (8.7) 1.00 (0.67-1.49)  
Other thiazides        
≤84 days prior to the index date 0 (0.0) <5 (<0.2) <4.00 (0.00-76.00) 0 
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>84 days prior to the index date 7 (1.5) 20 (1.0) 1.44 (0.59-3.56)  
Potassium sparing diuretics        
Spironolactone        
≤84 days prior to the index date <5 (<1.0) <5 (<0.2) 6.21 (1.04-37.22) 0 
>84 days prior to the index date 22 (4.6) 70 (3.7) 1.36 (0.79-2.33)  
Statins        
All        
≤84 days prior to the index date <5 (<1.0) <5 (<0.2) 1.75 (0.18-17.09) 0 
>84 days prior to the index date 50 (10.4) 157 (8.2) 1.57 (0.99-2.28)  
OR=Odds ratio, CI=confidence interval, HSD=high suspected drugs. 
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Table 3.5-3: Absolute risks of SJS/TEN among new users of suspected culprit drugs. 
Antiepileptic drug 
Number of 
new users 
Nr. of SJS/TEN 
cases with very 
probable or 
probable 
causality 
Risk per 100'000 
new users (95% 
CI) 
Total number of 
SJS/TEN cases 
Risk per 100'000 
new users (95% 
CI) 
Allopurinol 66’527 <5 6.01 (2.26-16.02) 6 9.02 (4.05-20.08) 
Oxicam analgesics 153’172 0 0 (NA) <5 0.65 (0.92-4.64) 
Coxibs 263’216 5 1.90 (0.79-4.56) 6 2.28 (1.02-5.07) 
Omeprazole 925’125 <5 0.22 (0.06-0.88) 9 0.97 (0.51-1.86) 
Lansoprazole 667’272 <5 0.30 (0.08-1.20) <5 0.60 (0.23-1.60) 
Rabeprazole 78’621 <5 1.27 (0.18-9.03) <5 1.27 (0.18-9.03) 
Fluoxetine 425’732 <5 0.24 (0.03-1.67) <5 0.47 (0.12-1.88) 
Mirtazapine 128’432 <5 1.56 (0.39-6.23) <5 1.56 (0.39-6.23) 
Mesalamine/mesalazine 26‘496 <5 3.77 (0.53-26.79) <5 3.77 (0.53-26.79) 
Sulfasalazine 23‘195 <5 4.31 (0.61-30.61) <5 4.31 (0.61-30.61) 
Alendronate 146‘010 <5 0.69 (0.10-4.86) <5 2.06 (0.66-6.37) 
CI=Confidence interval. 
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Table 3.5-4: List of suspected culprit drugs for SJS/TEN and drugs of common use included in this study. 
*Celecoxib, etoricoxib, lumiracoxib, parecoxib, rofecoxib, valdecoxib. 
■Alprazolam, bromazepam, clobazam, clonazepam, clorazepam, lorazepam, medazepam, oxazepam. 
┼Avanafil, sildenafil, tadalafil, vardenafil. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Highly suspected culprit 
drugs  
for SJS/TEN 
Suspected culprit drugs for SJS/TEN Drugs of common use 
Allopurinol COX-2 inhibitors* Methotrexate Metformin 
Oxicam-analgesics Sertraline Methotrimeprazine Sulfonylurea 
Sulfasalazine Fluoxetine Metolazone Oral contraceptives 
 Citalopram Dipyridamole Calcium-channel blockers 
 Rabeprazole Paliperidone ACE inhibitors 
 Benzodiazepines■ Strontium ranelate Beta-blockers 
 Fluvoxamine Febuxostat 
Angiotensin receptor 
antagonists 
 Paroxetine Bupropione Loop diuretics 
 Mirtazapine Tranexamic acid Thiazide diuretics 
 Duloxetine Mesalamine Potassium-sparing diuretics 
 Venlafaxine Modafinil Statins 
 Omeprazole Alendronate  
 Esomeprazole 
Phosphodiesterease-5 
inhibitors┼ 
 
 Lansoprazole Bezafibrate  
 Pantoprazole   
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Table 3.5-5: ALDEN score adapted to the information available in the CPRD. 
Criterion Values Rules to apply Point range 
    
Delay from initial drug 
component intake to onset of 
SJS/TEN (index date) 
Suggestive +3 5-28 days -3 to +3 
Compatible +2 29-56 days  
Likely +1 1-4 days  
Unlikely -1 >56 days  
Excluded -3 Drug started on or after the onset of 
SJS/TEN 
 
    
    
Drug present in the body on 
date of onset of SJS/TEN 
(index date)* 
Likely 0 Number of prescribed tablets and 
dose instructions suggest intake of 
drug up until the date of onset of 
SJS/TEN 
-3 to 0 
 Doubtful -1 Number of prescribed tablets and 
dose instructions suggest intake of 
drug until 1-5 days prior the date of 
onset of SJS/TEN 
 
 Excluded -3 Number of prescribed tablets and 
dose instructions suggest intake of 
drug until >5 days prior the date of 
onset of SJS/TEN 
 
    
    
Rechallenge┼  Positive specific for disease and 
drug +4 
SJS/TEN after use of same drug -2 to +4 
 Positive specific for disease and 
drug +2 
SJS/TEN after use of similar drug╪ 
or other reaction with same drug 
 
 Positive unspecific +1 Other reaction after use of similar 
drug╪ 
 
 Negative -2 Re-exposure to same drug without 
any reaction 
 
    
    
Dechallenge Neutral 0 Drug stopped -2 to 0 
 Negative -2 Drug continued without harm  
    
    
Type of drug (notoriety)˥ Strongly associated +3 Drug of high-risk according to 
previous case-control studies 
-1 to +3 
 Associated +2 Drug with definite but lower risk 
according to previous case-control 
studies 
 
 Suspected +1 Previous case reports, ambiguous 
epidemiologic results 
 
 Unknown 0 Drugs with no reports or data from 
epidemiologic studies 
 
 Not suspected -1 No evidence of an association in 
previous epidemiologic studies with 
sufficient number of exposed patients 
 
    
    
Other cause Possible -1 Rank all drugs from highest to lowest 
intermediate score 
If at least one has an intermediate 
score of >3, subtract 1 point from the 
score of each of the other drugs taken 
by the patient (another cause is more 
likely) 
≤0 
    
ALDEN=Algorithm of drug causality for epidermal necrosis. 
* In the original ALDEN score, this criterion is assessed by taking into account the elimination half-life of each 
drug. Because the CPRD data does not allow determining the exact date that a patient was exposed to a tablet 
and because dose instructions are not available for all prescriptions we had to adjust this criterion.  
┼ In the original ALDEN score, potential prechallenge to the suspected drug was also determined. Because we 
only included first-time prescriptions recorded ≤84 days prior to the index to assess potential culprit drugs, we 
did not need to assess potential prechallenge. 
╪ Same ATC code up to the forth level. 
˥ Based on the EuroSCAR study, the case-control study by Roujeau et al., and previously published case reports. 
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Table 3.5-6: Relative risk for SJS/TEN in association with suspected culprit drugs (no newly exposed cases with 
very probable or probable ALDEN scores). 
Drug exposure 
Number of cases  
(%) (n=480) 
Number of controls  
(%) (n=1920) 
OR crude (95% CI) 
Cases (%) 
exposed to 
HSD 
SSRI        
Citalopram        
≤84 days prior to the index date <5 (<1.0) 11 (0.6) 0.38 (0.05-2.92) 0 
>84 days prior to the index date 29 (6.0) 74 (3.9) 1.66 (1.04-2.64)  
Fluvoxamine        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  N/A 
>84 days prior to the index date 0 (0.0) 4 (0.2) <0.76 (0.00-4.46)  
Paroxetine        
≤84 days prior to the index date 0 (0.0) <5 (<0.2) 1.66 (0.00-13.89) N/A 
>84 days prior to the index date 22 (4.6) 60 (3.1) 1.52 (0.91-2.54)  
Other antidepressants        
Venlafaxine        
≤84 days prior to the index date <5 (<1.0) <5 (<0.2) 2.00 (0.18-22.06) 0 
>84 days prior to the index date 13 (2.9) 20 (1.0) 2.93 (1.45-5.91)  
Duloxetine        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  N/A 
>84 days prior to the index date 0 (0.0) 1 (0.1) <4.00 (0.00-76.00)  
Benzodiazepines        
All        
≤84 days prior to the index date <5 (<1.0) <5 (<0.2) 1.33 (0.14-12.82) 100% 
>84 days prior to the index date 10 (2.1) 28 (1.5) 1.45 (0.69-3.11)  
Other        
Tranexamic acid        
≤84 days prior to the index date <5 (<1.0) <5 (<0.2) 2.12 (0.19-23.47) 100% 
>84 days prior to the index date 13 (2.7) 32 (1.7) 1.79 (0.88-3.63)  
Dipyridamole        
≤84 days prior to the index date <5 (<1.0) 0 (0.0) >9.66 (0.21-∞) 0 
>84 days prior to the index date 7 (1.5) 13 (0.7) 2.21 (0.87-5.64)  
Methotrimeprazine        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  N/A 
>84 days prior to the index date 0 (0.0) 0 (0.0) N/A   
Metolazone        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  N/A 
>84 days prior to the index date 0 (0.0) 1 (0.1) <4.00 (0.00-76.00)  
Paliperidone        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  N/A 
>84 days prior to the index date 0 (0.0) 0 (0.0) N/A   
Strontium ranelate        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  N/A 
>84 days prior to the index date 0 (0.0) 3 (0.7) <1.04 (0.00-6.86)  
Febuxostat        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  N/A 
>84 days prior to the index date 0 (0.0) 0 (0.0) N/A   
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Bupropione        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  N/A 
>84 days prior to the index date 4 (0.8) 7 (0.4) 2.41 (0.67-8.66)  
Leflunomide        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  N/A 
>84 days prior to the index date 0 (0.0) 0 (0.0) N/A   
Methotrexate        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  N/A 
>84 days prior to the index date 4 (0.8) 11 (0.6) 1.46 (0.46-4.57)  
Modafinil        
≤84 days prior to the index date 0 (0.0) 0 (0.0) N/A  N/A 
>84 days prior to the index date 0 (0.0) 2 (<0.2) 1.66 (0.00-13.89)  
Phosphodiesterase-5 inhibitors        
≤84 days prior to the index date 0 (0.0) 1 (<0.2) 4.00 (0.00-76.00) N/A 
>84 days prior to the index date 5 (1.0) 22 (1.15) 0.90 (0.33-2.47)  
Bezafibrate        
≤84 days prior to the index date 0 (0.0) 1 (<0.2) 4.00 (0.00-76.00) N/A 
>84 days prior to the index date 1 (<1.0) 10 (0.5) 0.39 (0.05-3.10)  
OR=Odds ratio, CI=confidence interval, HSD=high suspected drugs. 
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Figure 3.5-2: ALDEN score for SJS/TEN cases newly exposed to suspected culprit drugs. 
<0, very unlikely; 0-1, unlikely; 2-3, possible; 4-5 probable; >5, very probable. 
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Table 3.5-7: Absolute risks of SJS/TEN among new users of suspected culprit drugs (no newly exposed cases). 
Antiepileptic drug 
Number of 
new users 
Nr. of SJS/TEN 
cases with very 
probable or 
probable 
causality 
Risk per 100'000 
new users (95% 
CI) 
Total number of 
SJS/TEN cases 
Risk per 100'000 
new users (95% 
CI) 
Citalopram 560’777 0 0 (NA) <5 0.18 (0.03-1.27) 
Venlafaxine 113’977 0 0 (NA) <5 0.88 (0.12-6.23) 
Benzodiazepines 934’941 0 0 (NA) <5 0.11 (0.02-0.76) 
Dipyridamole 47‘488 0 0 (NA) <5 2.11 (0.30-14.95) 
Tranexamic acid 149‘344 0 0 (NA) <5 0.67 (0.09-4.75) 
Pantoprazole 59’431 0 0 (NA) 0 0 (NA) 
Esomeprazole 73’867 0 0 (NA) 0 0 (NA) 
Sertraline 197’911 0 0 (NA) 0 0 (NA) 
Fluvoxamine 2369 0 0 (NA) 0 0 (NA) 
Paroxetine 181’962 0 0 (NA) 0 0 (NA) 
Duloxetine 30’089 0 0 (NA) 0 0 (NA) 
Methotrimeprazine 3985 0 0 (NA) 0 0 (NA) 
Metolazone 6897 0 0 (NA) 0 0 (NA) 
Paliperidone 69 0 0 (NA) 0 0 (NA) 
Strontium ranelate 9679 0 0 (NA) 0 0 (NA) 
Febuxostat 769 0 0 (NA) 0 0 (NA) 
Bupropione 49‘129 0 0 (NA) 0 0 (NA) 
Methotrexate 30‘994 0 0 (NA) 0 0 (NA) 
Modafinil 1708 0 0 (NA) 0 0 (NA) 
Phosphodiesterase-5 
inhibitors 
200‘523 0 0 (NA) 0 0 (NA) 
Bezafibrate 20‘460 0 0 (NA) 0 0 (NA) 
CI=Confidence interval. 
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4 Discussion and Outlook 
4.1 Discussion 
Although the knowledge about SJS/TEN has substantially increased over the past years, 
many aspects of the disease, such as the exact pathophysiology, the main culprit drugs, 
long-term complications in survivors, and pharmacological treatment remain under-
investigated. As a consequence, the quality of SJS/TEN warnings in drug dictionaries 
have been shown to be of low accuracy and the current guidelines for the management 
of SJS/TEN patients are mainly based on a consensus of expert opinions rather than 
scientific evidence.87,172 Because of the rare nature of SJS/TEN, clinical trials are often 
too small to detect SJS/TEN as an ADR of the drug under study. Observational research 
therefore plays an important role for the future understanding of SJS/TEN. However, 
existing observational studies on SJS/TEN are scarce, mainly because large medical 
claims databases have been proven to be unsuitable for the study of SJS/TEN.35–38 
Consequently, the largest previously conducted observational studies on SJS/TEN have 
recruited case patients in hospitals via questionnaires.88,89 While this approach allowed 
assessing the validity of SJS/TEN elaborately and with high accuracy, it is also 
accompanied by some limitations. Recruiting patients in hospitals is time-consuming 
and often costly, assessing the exposure status of patients is prone to recall bias, the 
exact population-at-risk is often unknown, and following-up on patients after the acute 
phase of SJS/TEN is difficult. Therefore, this thesis aimed to determine in a first step 
whether the CPRD allows conducting observational studies on SJS/TEN, by 
comprehensively assessing the validity of SJS/TEN diagnoses recorded in CPRD data. 
In Study 3.1 we elaborately describe and discuss the methodology of the validation and 
composition of our SJS/TEN case population.  
In a further step, we aimed to contribute to the general understanding of SJS/TEN by 
conducting comprehensive observational studies in our SJS/TEN case population 
established from the CPRD. Pharmacoepidemiology is a multidisciplinary research that 
is applied in the assessment of disease burden, in the evaluation of undiscovered drug 
effects, in the analysis of drug utilization, and also in comparative effectiveness or cost-
effectiveness analyses. The different studies presented in this SJS/TEN project 
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exemplify this versatility of pharmacoepidemiologic research. Study 3.2 describes the 
burden of SJS/TEN by presenting IRs of SJS/TEN in the UK for the first time. In the 
same study, demographics and characteristics of patients with SJS/TEN are elaborately 
analysed and described. Studies 3.3, 3.4, and 3.5 assessed potential associations between 
SJS/TEN and drugs, which have previously been associated with SJS/TEN in 
observational studies or case reports. In these studies, we further presented absolute risks 
of SJS/TEN associated with each of these drugs, which might contribute to future 
considerations of preventive measures in patients starting therapy with drugs carrying a 
relatively high risk of SJS/TEN. Calculating the cumulative incidence of SJS/TEN in 
new drug users further allowed us to show that a number of drugs that have previously 
been suggested as culprit drugs of SJS/TEN (e.g. benzodiazepines, citalopram), appear 
to be at least relatively safe in terms of SJS/TEN. Table 4.1-1 outlines the objectives, 
main findings, research area, and the novelty of the results of each of the studies included 
in this project. A thorough discussion of the results and limitations of the individual 
studies is presented in the discussion section of the respective studies. The most 
important findings and implications of these studies are discussed in the following 
sections.  
A study assessing mortality and long term sequelae of SJS/TEN using our CPRD-based 
case population is planned in the future but is not included in this thesis. 
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Table 4.1-1: Overview and summary of the five observational studies presented within this thesis. 
Objectives Main findings Research area 
Novelty of findings 
New 
Little existing 
evidence 
Strong existing 
evidence 
Study 3.1: 
 To assess the validity of SJS/TEN diagnoses 
recorded in the CPRD 
 To establish a relatively large and validated 
SJS/TEN case population 
 The overall validity of SJS/TEN diagnoses recorded in the 
CPRD is rather low and requires comprehensive validation 
 We managed to establish a population of 551 SJS/TEN 
cases with a positive predictive value of 90% 
Validation study X   
Case selection X   
Study 3.2: 
 To calculate first-ever IRs of SJS/TEN in the 
UK 
 To describe demographics and characteristics 
of SJS/TEN patients 
 To assess associations between SJS/TEN and 
life-style factors as well as comorbidities 
 Overall IR of SJS/TEN in the UK: 5.76 cases/1’000’000 py 
 IR highest in children and elderly 
 Patients of non-Caucasian ethnicity were at increased risk 
of SJS/TEN 
 Patients with pre-existing depression, lupus erythematosus, 
chronic kidney disease, recent pneumonia, or active cancer 
were at increased risk of SJS/TEN 
Disease burden X   
Analysis of risk groups X   
Analysis of risk groups  X  
Associated disease  X  
Study 3.3: 
 To assess potential associations between 
SJS/TEN and antiepileptics 
 To calculate absolute risks of SJS/TEN 
associated with each antiepileptic 
 Strong association between SJS/TEN and new use of 
aromatic antiepileptics  
 Absolute risks of SJS/TEN between 20-46 cases/100’000 
new users for carbamazepine, phenytoin, lamotrigine 
 Valproate, gabapentin, and pregabalin appear to relatively 
safe regarding SJS/TEN 
Suspected drug effect   X 
Absolute risk 
assessment 
 X  
Suspected drug effect  X  
Study 3.4: 
 To assess potential associations between 
SJS/TEN and antibiotics 
 To calculate absolute risks of SJS/TEN 
associated with each antibiotic 
 Strong association between SJS/TEN and new use of 
trimethoprim 
 Likely association between SJS/TEN and new use of 
penicillins, quinolones, cephalosporins, and macrolides 
 Absolute risks of SJS/TEN between 0.3-1 cases/100’000 
new users of antibiotics 
Suspected drug effect X   
Suspected drug effect  X  
Absolute risk 
assessment 
X   
Study 3.5: 
 To assess potential associations between 
SJS/TEN and drugs other than antiepileptics 
and antibiotics 
 To calculate absolute risks of SJS/TEN 
associated with each drug included in the 
study 
 Association between SJS/TEN and new use of allopurinol 
 Potential association for new use of 5-aminosalicylates, 
coxibs, proton pump inhibitors, fluoxetine, and mirtazapine 
 Absolute risks of SJS/TEN between 0.2-6 cases/100’000 
new users for these dugs 
 No association between SJS/TEN and oxicams, 
benzodiazepines, citalopram, sertraline, paroxetine, 
venlafaxine, and phosphodiesterase-5 inhibitors 
Suspected drug effect   X 
Suspected drug effect  X  
Absolute risk 
assessment 
X   
Suspected drug effect  X  
CPRD=Clinical Practice Research Datalink, SJS/TEN=Stevens-Johnson syndrome and toxic epidermal necrolysis, IR=Incidence rate, py=person-years.
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4.1.1 Study 3.1 
Validation of Stevens-Johnson syndrome and toxic epidermal necrolysis in the Clinical 
Practice Research Datalink 
 Together with two specialised clinicians, we evaluated the validity of the first-
recorded SJS/TEN diagnosis in 1324 patients based on all information available 
in the CPRD (including additional notes made by GPs [free texts]). A total of 565 
patients were classified as very probable or probable SJS/TEN cases. 
 The validity of our classification of recorded SJS/TEN diagnoses was tested 
against our gold standard (i.e. available diagnoses from secondary care extracted 
from discharge letters, HES data, and free text). 
 We established a final case population of 551 SJS/TEN patients requiring 
secondary care with a PPV of 90%. 
Study 3.1 was pivotal for the feasibility of the further studies on SJS/TEN presented 
within this project. Observational studies are instrumental for the investigation of 
SJS/TEN, because this ADR is unlikely to be detected in controlled clinical trials due to 
its rare nature. Numerous early observational studies (conducted between 1980 and 
1995) have not been able to establish SJS/TEN case populations from health-care 
databases due to issues with multi-diagnostic within the ICD-9 coding system.35–38 Only 
recently, a few epidemiologic studies on SJS/TEN have successfully been conducted in 
medical claims databases.41,42 In the majority of the existing large observational studies 
on SJS/TEN, case patients were recruited in hospitals, which allowed a better evaluation 
of potential SJS/TEN diagnoses, but makes defining a population-at-risk, which is a key 
variable for the calculation of absolute risk measures, difficult.88,89 
The validation of our study population revealed that the CPRD is a valid resource to 
study SJS/TEN in a large longitudinal population-based study population. However, 
when composing our case population we excluded more than 50% of all patients with a 
recorded SJS/TEN diagnosis because they either have not reportedly been referred to 
secondary care or because the validity of the SJS/TEN diagnosis was deemed uncertain 
during expert review. This indicates that extensive validation of potential SJS/TEN 
patients in the CPRD is absolutely required.  
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Free texts have furthermore proven to be an invaluable tool for the evaluation and 
validation of potential SJS/TEN diagnoses by providing more detailed clinical 
information in addition to the codes recorded in the CPRD and diagnoses from 
secondary care which we used as our gold standard (n=39). From the year 2013 on, free 
texts are no longer collected by the CPRD, which will complicate the validation of 
SJS/TEN diagnoses recorded in the CPRD after 2013. Due to concerns about patient 
confidentiality, original discharge letters are also no longer available to researchers. 
While it is important to safeguard patient confidentiality in observational research, the 
increasing constraints on data availability may severely hamper the conduct of 
observational studies, especially of rare diseases that are difficult to diagnose correctly 
such as SJS/TEN, where clinical details are critical to the case validation process, and 
where there will always be relatively few cases. While this limitation did not apply to 
this study, it might be a major impediment for future research.  
 
4.1.2 Study 3.2 
The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the 
UK 
 The first ever calculated overall IR of SJS/TEN in the UK was 5.76 
cases/1’000’000 py. Incidence rates were highest in patients aged <10 or ≥80 
years and during the winter months, but did not significantly vary by sex or year 
of diagnosis. 
 We found that patients of black, Asian, or mixed ethnicity were at a 2-fold 
increased risk of SJS/TEN when compared to Caucasians. 
 We observed associations between SJS/TEN and pre-existing depression, lupus 
erythematosus, CKD, recent pneumonia, and active cancer, which may be caused 
by underlying drug therapy in most of these diseases. 
Study 3.2 describes the case population in detail in terms of demographics, and 
frequency of life-style factors and comorbidities. We calculated IRs of SJS/TEN in the 
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UK population and assessed potential associations between SJS/TEN and life-style 
factors, demographics, and various comorbidities. 
The calculated IRs (5.76 cases/1’000’000 py) and observed associations between 
SJS/TEN and non-white ethnicity, and various comorbidities were in line with 
previously reported results (1-12 cases/1’000’000 py) and further corroborate the 
validity of our case population.39–42 The results are discussed in detail in the discussion 
section of Study 3.2. This study is of great significance as it is the first study to describe 
the disease burden of SJS/TEN within the UK. Other observational studies have reported 
a lower overall IR of SJS/TEN in other European countries (1-3 cases/1’000’000 py),39 
a higher overall IR of SJS/TEN in the US (12.7 cases/1’000’000 py),42 and an overall 
IR of SJS/TEN comparable to the one we calculated for the UK in Korea (5.9 
cases/1’000’000 py).41 The IR of SJS/TEN is likely to vary across geographical regions, 
because the risk of SJS/TEN seems to depend on ethnicity (potentially associated with 
different HLA expression),157 and because drug usage might vary in different countries. 
The reported associations between SJS/TEN and pre-existing depression, lupus 
erythematosus, CKD, recent pneumonia, and active cancer as well as increased IRs of 
SJS/TEN in some categories contribute to the understanding of at-risk-patients and 
might thus be useful for preventive considerations regarding SJS/TEN. 
 
4.1.3 Study 3.3 
The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of 
antiepileptic drugs 
 We observed a strong association between SJS/TEN and new use of 
carbamazepine (OR 92.57, 95% CI 19.89–∞), phenytoin (OR 49.96, 95% CI 
10.13–∞), and lamotrigine (OR 26.90, 95% CI 4.88–∞). Causality, according to 
the ALDEN score, was very probable or probable for most exposed cases.  
 Absolute risks for SJS/ TEN were highest for phenytoin (45.86 cases/100,000 
exposed), lamotrigine (44.17 cases/100,000 exposed), and carbamazepine (20.38 
cases/100,000 exposed).  
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 Despite frequent use, no ALDEN-score confirmed cases were observed in new 
users of valproate (40,941 exposed), gabapentin (116,037 exposed), pregabalin 
(59,967 exposed), levetiracetam (9677 exposed), topiramate (11,307 exposed), 
or clonazepam (18,075 exposed). 
 The results of our study are consistent with those of previous studies of SJS/TEN, 
which found increased risks of SJS/TEN in new users of the aromatic AEDs, 
carbamazepine, phenytoin, and lamotrigine.  
 
Study 3.3 confirms the association between SJS/TEN and the aromatic AEDs 
carbamazepine, phenytoin, and lamotrigine, which have been reported in previous 
hospital-based observational studies.88,89 However, conversely to the hospital-based 
studies, the CPRD allowed assessing the total number of new users for each drug (i.e. 
the population-at-risk) and thus the calculation of absolute risks of SJS/TEN in 
association with each AED. Knowledge of these absolute risks is important regarding 
cost effectiveness considerations of suggested routine pre-treatment screenings for 
previously discovered HLA alleles, which appear to increase susceptibility to SJS/TEN 
upon exposure to certain culprit drugs of SJS/TEN. Knowledge of the population-at-risk 
further enabled us to systematically show that some AEDs which have been suggested 
to cause SJS/TEN in case reports appear to be at least relatively save regarding SJS/TEN 
and may thus be considered as potential alternative drugs in epilepsy patients who 
developed SJS/TEN under treatment with a high-risk antiepileptic.  
 
 
 
 
4.1.4 Study 3.4 
Antibiotic drug use and the risk of Stevens-Johnson Syndrome and Toxic Epidermal 
Necrolysis - A Population-Based Case-Control Study. 
 We observed a strong association between SJS/TEN and trimethoprim in the 
absence of sulfamethoxazole (OR=9.44, 95% CI 3.83-23.25; absolute risk: 0.98 
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SJS/TEN cases/100’000 users). This suggests that the previously reported 
association between cotrimoxazole and SJS/TEN is at least partly attributable to 
the non-sulphonamide antibiotic trimethoprim, which is frequently prescribed as 
a single agent in the UK, whereas trimethoprim is usually prescribed as a 
combined antibiotic with sulfamethoxazole (cotrimoxazole) in most other 
countries that have contributed data to SJS/TEN research.  
 Our study further corroborated previously reported associations between 
SJS/TEN and use of penicillins, quinolones, cephalosporins, and macrolides, for 
which absolute risks were between 0.28-0.96 SJS/TEN cases/100’000 users. 
 We further observed an association between SJS/TEN and metronidazole. 
However, more data on this association is required. 
While previous case-control studies reported a strong association between SJS/TEN and 
cotrimoxazole (sulfamethoxazole+trimethoprim),88,89 this study was the first to show an 
association between SJS/TEN and trimethoprim as a single agent. Although the 
synergistic effect of trimethoprim and sulfamethoxazole is in contestation,227–229 the use 
of trimethoprim as a single agent in the UK is exceptional because cotrimoxazole is still 
the first choice in many countries. Previous studies were therefore not able to separately 
assess associations for trimethoprim and sulfamethoxazole as single agents. 
Interestingly, the sulphonamide sulfamethoxazole rather than trimethoprim was 
generally considered to be the causative agent of SJS/TEN.89 Although previously 
reported associations between SJS/TEN and antibiotics other than sulphonamides are 
corroborated in Study 3.4,88,89 further evidence on these associations is required. The 
results of this study further suggest that the absolute risk of SJS/TEN in association with 
antibiotics (including trimethoprim) is significantly lower than for aromatic AEDs or 
allopurinol. 
4.1.5 Study 3.5  
Stevens-Johnson syndrome and toxic epidermal necrolysis in association with 
commonly used drugs other than antiepileptics and antibiotics - A population-based 
case-control study. 
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 The results of this study confirm an association between SJS/TEN and the use of 
allopurinol (OR 24.51, 95% CI 2.94-204.04). 
 Coxibs (OR 24.19, 95% CI 2.91-200.92), PPIs (OR 5.07, 95% CI 2.32-11.04), 
fluoxetine (OR 1.36, 95% CI 0.28-6.75), mirtazapine (OR 4.00, 95% CI 0.56-
28.40), sulfasalazine (OR 4.00, 95% CI 0.21-∞), and mesalamine (OR 4.00, 95% 
CI 0.25-63.95) were also associated with an increased risk of SJS/TEN. 
 Absolute risks of SJS/TEN were 6 cases/100’000 new users of allopurinol, 1.9 
cases/100’000 new users of coxibs, 4.3 cases/100’000 new users of sulfasalazine, 
3.8 cases/100’000 new users of mesalamine, 1.6 cases/100’000 new users of 
mirtazapine, 0.2 cases/100’000 new users of fluoxetine, and 0.2-1.3 
cases/100’000 new users of PPIs. 
 We found no association between SJS/TEN and previously associated oxicam 
analgesics, benzodiazepines, citalopram, sertraline, paroxetine, venlafaxine, and 
phosphodiesterase-5 inhibitors despite >100’000 new users of each drug in the 
CPRD. 
 
Study 3.5 confirms the previously reported association between SJS/TEN and 
allopurinol.88,89 However, the absolute risk of SJS/TEN in our study was significantly 
lower for allopurinol when compared to aromatic AEDs (6 cases/100’000 new users vs. 
20-46 cases/100’000 new users). However, it needs to be highlighted, that our absolute 
risks of SJS/TEN in allopurinol users pertain to gout patients only, since patients with 
chemotherapy and cancer (a frequent indication for allopurinol at higher dosages) are 
treated at specialized facilities and are not systematically captured in the CPRD. We 
further identified coxibs, PPIs, fluoxetine, mirtazapine, sulfasalazine, and mesalamine 
as likely culprit drugs of SJS/TEN, with absolute risks of SJS/TEN of 0.2-4.3 
cases/100’000 new users. Because there is only little previous evidence suggesting these 
associations, more data is needed to confirm these observations.  
Various other drugs have been suggested as culprit drugs of SJS/TEN in numerous case 
reports (Table 1.2-1). The great number of such reports as well as the lack of systematic 
observational research on such associations has led to much confusion regarding the risk 
of SJS/TEN and certain drugs.87 In Study 3.5 we did not find any exposed SJS/TEN 
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cases despite a high number of new users (>100’000) for a number of drugs which have 
repeatedly been linked to SJS/TEN (oxicam analgesics, benzodiazepines, citalopram, 
sertraline, paroxetine, venlafaxine, and phosphodiesterase-5 inhibitors). Our results 
suggest that these drugs appear to be at least relatively safe in terms of SJS/TEN. 
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4.2 Limitations of this project 
4.2.1 Case misclassification 
Despite the many strengths of this project and of database research in general, disease 
misclassification is a challenge when using health-care databases for observational 
studies (Table 1.1-5). The validity of SJS/TEN diagnoses in the CPRD has not been 
assessed prior to this project, which is why we elaborately validated our SJS/TEN case 
population based on a profound understanding of the CPRD and of the clinical 
presentation of SJS/TEN. Although the results of our validation study suggest a rather 
high validity of our final case population (PPV of 87%), the inclusion of some false 
positive cases other than the 13% indicated by the PPV is possible. Correctly diagnosing 
SJS/TEN is difficult due to the lack of specific tests, various differential diagnoses, and 
the rare encounter with this type of reaction. Aside from the SJS/TEN diagnoses 
recorded in the CPRD, we therefore also cannot guarantee the accuracy of all the 
diagnoses made in secondary care, which we defined as our gold standard for the 
validation of SJS/TEN cases. Such potential case misclassification may have resulted in 
somewhat overestimated IRs (although we adjusted IRs for type 1 error) and may have 
introduced a slight null bias when assessing potential risk factors for SJS/TEN. On the 
other hand, reported ORs could potentially be overestimated for assessed associations 
between SJS/TEN and well-known culprit drugs of SJS/TEN (e.g. AED or allopurinol) 
because physicians may over-diagnose SJS/TEN in users of these drugs. However, our 
results were similar to results from previous hospital-based studies in which researchers 
had access to more clinical patient records (e.g. EuroSCAR study89) and case validity 
could be addressed more sufficiently, which generally corroborates the validity of our 
case population. We were furthermore not able to assess false negative SJS/TEN patients 
in the CPRD. However, owing to the severity of SJS/TEN, it can be assumed that the 
number of patients for whom a SJS/TEN diagnosis was erroneously not recorded is 
rather low in any health-care database. 
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4.2.2 Stevens-Johnson syndrome vs. toxic epidermal necrolysis  
Although in the CPRD specific diagnostic codes to differentiate between SJS and TEN 
exist, we did not differentiate between SJS and TEN for any analyses of the presented 
project. Firstly, some clinical diagnoses from secondary care, which we used as gold 
standard for the validation of SJS/TEN diagnoses, did not allow validating SJS and TEN 
diagnoses separately, because they only consisted of e general code SJS/TEN. As a 
consequence we were not able to assess the accuracy of differentiation between SJS and 
TEN diagnoses in the CPRD. Second, neither Read codes nor HES data include a code 
for SJS/TEN overlap, which is why we assumed that separately calculated IRs would be 
somewhat overestimated for both SJS and TEN. Previous estimates of the ratio of SJS 
and TEN are sparse, but have been reported to be 3:1 and 5:1.86 In our study the ratio of 
SJS to TEN was approximately 7:1, which may indicate that some TEN cases were 
recorded as SJS. However, it is also possible that previous studies overestimated the 
proportion of TEN events relative to SJS. However, given that the pathophysiology and 
presumed culprit drugs do not differ between SJS, SJS/TEN overlap, and TEN our 
comparative analyses are not affected by this limitation. 
 
4.2.3 Missing information on drug exposures 
Missing information about certain drug exposures is a further limitation of the presented 
project. The proportion of cases who were recently exposed to well-known culprit drugs 
of SJS/TEN was lower in our studies than in the hospital-based EuroSCAR study (e.g. 
7.5% vs. 25% for AEDs, 1.3% vs. 14.8% for allopurinol).89 This might indicate that 
information about drug exposures was missing in some cases. Besides underestimated 
ORs, this limitation could also have affected the assessment of concomitant use of other 
high-risk drugs for ALDEN in some cases. The CPRD does furthermore not record over-
the-counter drugs (e.g. ibuprofen), inpatient drug use (e.g. chemotherapy or inpatient 
antibiotic use), or use of HIV drugs (e.g. nevirapine), which is why we were not able to 
assess associations between SJS/TEN and a number of drugs that have been suggested 
as culprit drugs of SJS/TEN. This potentially explains why we were only able to identify 
a likely culprit drug in approximately 25% of SJS/TEN cases, whereas previous 
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observational studies were able to identify drugs as likely etiologic factor in 65% of 
SJS/TEN patients.226 We furthermore cannot guarantee that a patient with a recorded 
prescription of a certain drug in the CPRD has actually taken this drug, and was therefore 
correctly considered to be exposed to the respective drug, which is a general limitation 
of the CPRD.  
 
4.2.4 ALDEN score 
The ALDEN score was an invaluable tool for the assessment of potential causality 
between SJS/TEN and drug exposure in our cases, but might underestimate the causal 
association for drugs that have not previously been associated with SJS/TEN because it 
systematically grades causality higher for drugs with previous evidence for an 
association with SJS/TEN.20 However, the criterion of causal attribution was not the 
decisive factor to classify probability of causality in almost all of the assessed cases in 
Studies 3.3, 3.4, and 3.5 (i.e. causality was likely or unlikely respectively regardless of 
this criterion in the majority of cases). Due to the available data in the CPRD we 
furthermore had to adapt some criteria from the original clinical ALDEN score. Among 
other criteria, the ALDEN score grades the likelihood for causality based on whether or 
not the drug is present in the patient’s body on the day of the onset of SJS/TEN. Because 
information on the number of prescribed tablets and dose instructions is sometimes 
missing in the CPRD, and because we do not have information about a patient’s 
adherence to the treatment instructions, we were not able to accurately assess this 
criterion. 
 
4.2.5 Further limitations 
First, although we were primarily interested in IRs and likely etiologic factors of the 
first recorded SJS/TEN diagnosis in each case patient, we cannot assure that none of the 
cases included in our studies had an episode of SJS/TEN prior to entering the CPRD. 
Second, given the rare occurrence of SJS/TEN, low statistical power is an inherent 
problem of studies analysing risk factors of SJS/TEN, even when using large data 
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sources such as the CPRD. Therefore, the results presented in our studies have to be 
interpreted carefully, within the context of previously published evidence and biologic 
plausibility, and conclusions should not be drawn from one single study. Third, 
protopathic bias or confounding by indication may play a role in a number of assessed 
associations between SJS/TEN and drugs. Antibiotics, for example, may be used to treat 
prodromal symptoms of SJS/TEN or as infection prophylaxis during the treatment of 
acute disease (although treatment guidelines advised against prophylactic antibiotics, as 
this might promote skin colonialization, particularly with Candida albicans).172 To 
minimize the risk of protopathic bias, we defined the index date as the date of the first 
recorded symptom of SJS/TEN wherever possible, assessed ALDEN scores to quantify 
the likelihood of causality of observed associations, and performed sensitivity analyses 
in which we shifted the index date by 2 weeks before the date of the first recorded 
SJS/TEN diagnosis in all cases without recorded prodromal symptoms wherever 
applicable. Finally, general limitations of observational research in health-care 
databases that might not be included in the discussion above are presented in Table 1.1-
5. 
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4.3 Outlook 
Although the body of existing research of SJS/TEN is growing rapidly, many aspects of 
this disease remain unclear and subjects of speculation. This comprehensive SJS/TEN 
project contributes to the general understanding of this under-investigated disease, by 
revealing previously unreported findings and by confirming previous hypotheses with 
little existing evidence regarding the epidemiology and culprit drugs of SJS/TEN. It 
further provides evidence that similar diseases, such as acute generalized exanthematous 
pustulosis, can be successfully studied in the CPRD through extensive validation of 
recorded diagnoses. We hope that the results of our studies as well as future 
improvements of recorded information within health-care databases will encourage 
researchers to consider future observational studies on SJS/TEN or similar diseases 
using data from the CPRD or other similar health-care databases. However, as discussed 
in Study 3.1, the successful validation of SJS/TEN diagnoses recorded in the CPRD 
considerably relied on information extracted from free texts and discharge letters. The 
acquisition of these additional data sources has over the past years been compromised 
due to patient confidentiality concerns, which might to some extent jeopardize similar 
research in the future. While working with sensitive patient data inevitably requires 
regulations on patient confidentiality, this project also highlights the importance of 
being able to obtain a wide range of health-related patient data in order to be able to 
conduct observational studies of high-quality. In the light of this project, we would 
therefore like to point out that patient confidentiality was not at danger of being 
compromised during our analysis of free texts and discharge letters in any way due to 
prior anonymization of the patient details and censoring of critical information. Whilst 
we understand that patient confidentiality is a growing concern particularly with the 
growing impact and popularity of big data, we are not entirely convinced that halting 
the collection and access to these additional data sources is the best solution to address 
these concerns due to the potentially weighty impact on some future observational 
studies using CPRD data. 
While we comprehensively studied the epidemiology of SJS/TEN as well as potential 
risk factors and culprit drugs of SJS/TEN in our case population, we have so far not 
studied the mortality and long-term complications in SJS/TEN patients. Analysing the 
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follow-up in SJS/TEN patients in hospital-based observational studies is challenging, as 
information about the time after the acute phase of SJS/TEN is difficult to collect. 
Therefore the various proposed long-term complications in SJS/TEN survivors have 
almost exclusively been described in case reports or case series.61 The longitudinal 
nature of CPRD data, and the fact that death is recorded at high validity, our case 
population would allow assessing the mortality of SJS/TEN, to analyse the influence of 
other variables on the risk of dying from SJS/TEN, and to study potential long-term 
complications in survivors of SJS/TEN. The list of reported long-term complications of 
SJS/TEN is extensive and diverse.61 Ocular complications are common in survivors of 
SJS/TEN but may not be recorded sufficiently in the CPRD, because ocular 
complications are likely treated by ophthalmologists rather than GPs. Similarly, 
urogenital/gynaecological complications (e.g. vaginal adenosis) might predominantly 
be treated in specialised clinics rather than by GPs and thus might not be eligible to be 
studied in the CPRD. On the other hand psychological complications (e.g. depression or 
anxiety disorders) and pulmonary complications (e.g. bronchiolitis obliterans) might be 
assessable via recorded diagnoses, or drug prescriptions and other therapeutic 
interventions used to manage these long-term complications. We therefore plan to 
analyse the mortality and, wherever possible, long-term complications of SJS/TEN in a 
propensity-score matched cohort study using the SJS/TEN case population established 
in Study 3.1 in the future. 
The understanding of genetic factors predisposing for SJS/TEN is growing rapidly, and 
associations between some culprit drugs of SJS/TEN and predisposing genetic factors 
(e.g. HLA-B*15:02 for carbamazepine-induced SJS/TEN) have been established with 
strong evidence.143 A previous study conducted by Chen et al. has already proven the 
effectiveness of screening patients for predisposing risk factors of SJS/TEN before 
initiating therapy with a known culprit drug of SJS/TEN.158 The absolute risks of 
SJS/TEN associated with each drug presented within this project might further be useful 
for future economic considerations regarding such screening, as costs associated with 
SJS/TEN have been reported previously.42 
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